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Abstract 
 
Breast cancer being multifaceted disease constitutes a wide spectrum of histological and 
molecular variability in tumors. Now, in the wake-up of the Human Genome Project 
(HGP) several evidences recommend a marked plasticity adopted by tumor cells in 
modulating the tissue invasion and progression during multiple stages of metastasis.  
However, the task for the identification of these casualties in a cancer genome is 
complicated by the interplay of inherited genetic and epigenetic aberrations. These 
aberrations are like two sides of the same coin. Therefore, in this thesis we provide an 
extrapolate outlook to the sinister partnership between genetic and epigenetic aberrations 
in relevance to breast cancer.  
 DNA methylation is a prototypical epigenetic parameter that lay ground in 
understanding the gene regulation and their intricate interactions in the normal and 
diseased state. However, when it is comprehended by the extensive study of the genomic 
and transcriptomic parameter, it leads to better understanding of complex trait 
architecture of disease aetiology. The key to our analysis holds in identification of 
effective model that enables in predicting the phenotypic traits and outcomes, elucidating 
the presence of diagnostic and prognostic biomarkers and generate an insight into genetic 
underpinnings of heritable complex traits. In view of this, we explored the emerging 
approaches based upon data integration and meta-dimensional analysis to deepen our 
understanding to the relationship between the genomic variations and human phenotypes. 
This integrated study comprised of Illumina 450 DNA methylation, Affymetrix SNP 
array and RNAseq dataset retrieved from the Cancer genome atlas (TCGA) portal which 
elaborated the biological and complex outlay in the diagnosis, prognosis and therapeutic 
implications of breast cancer. 
 Owing to the identification of diagnostic marker, the genetic determinants of 
DNA methylation pattern was extensively interrogated in tumor and matched normal 
samples. In lieu of this, an overall enrichment in significant CpG-SNP pairs were 
identified at 50 base pairs upstream and downstream of CpG site. The correlation between 
the genetic variant and the differential DNA methylation at specific loci was labelled as 
methylation quantitative trait loci (meQTLs). In a multistep approach to the identification 
of key drivers of the complex trait, the differentially methylated CpG sites were analysed 
for the association with the gene expression in unrevealing the differential expression of 
the tumor suppressor genes in tumor and matched normal sample. The integrated study of 
genetic variation characterised single nucleotide polymorphism, DNA methylation and 
gene expression led to the foundation for identification of novel biomarkers for diagnosis 
of breast cancer. This integrative analysis was further substantiated with the 
clinicopathological features to stratify the risk associated with the survival of the breast 
cancer patients. An intensive Cox proportional regression analysis established a 
significant association between differential methylation and the stratification of breast 
cancer patients into high and low risk, respectively. The innovative study interrogating 
the impact of differentially methylated CpGs and SNPs on the survival unwrapped a new 
horizon in the prognosis of breast cancer.       
x 
 
 In view of established study specifying DNA methylation works in concert 
with genetic variants, several modulators have been identified against the DNA 
methyltransferase (DNMTs) enzyme to revert malignancy. However, the inherited 
toxicity and the lack of specificity offer limitations. In the present study, we have 
identified a novel inhibitor that owes property to rejuvenate the expression of tumor 
suppressor genes and holds enhanced selectivity towards triple-negative breast cancer 
cells to normal cells. Thus, the recognition of DNA methylation as a significant 
contributor to normal and disease state has opened a new avenue for drug discovery and 
therapeutics in breast cancer.  
 
Keywords: DNA methylation; single nucleotide polymorphism; methylation quantitative 
trait loci; DNA methyltransferases; inhibitor; breast cancer 
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Chapter 1 
Introduction 
1.1 DNA methylation landscape in human genome 
DNA methylation is relishing a meteoric rise in the field of epigenetics from the euphoria 
surrounding the human genome project. This field of epigenetics holds a master key to 
unfold and unlock the mechanism concomitant with the profound alteration in gene 
expression in response to the environmental cues [1]. It provides a clue in understanding 
the tenacity and the genome plasticity associated with chromatin modifications and 
remodeling engines. Most of these epigenetic modulations known till date is characterized 
by the covalent and non-covalent modulation of DNA and histone proteins [2]. Of all the 
modulations, DNA methylation is a core molecular actor that play significant role upon 
the epigenetic stage influencing the epigenetic stability and heritability and subsequently 
retaining the integrity of the DNA [3].  
In the mammalian genome the primary target for methylation is the cytosine 
residue; the enzymatic attachment of the methyl to the 5̍ carbon of the pyrimidine ring 
creates 5-methylcytosine (5-MeC) [4-6]. This forgotten 5
th
 base being a cognate to 
cytosine undergoes complementary base pairing with guanine. Usually in mammalian 
genome, the targeted cytosine residue of methylation machinery resides within the 
palindromic sequence of the 5̍-C-p-G-3̍ dinucleotide. Nearly 70% of all CpG dinucleotide 
are methylated; however, the spatial distribution is non-random across the genome. 
Besides the irrational distribution, there is a small genomic region bearing the higher 
frequency of CpG dinucleotide at the closer proximity with an average of 1-2 kilobases 
forming CpG islands [6]. There are about 45,000 CpG islands. Most of the chromosome 
harbours 5-15 islands per MB being predominant at the promoter region of the genes or 
lie within the first exon of the genes [7]. These sporadic sequences associated with the 
epigenetic pattern have the maximal impression on growth and development. 
1.2 Significance of DNA methylation 
The functionality DNA methylation is integrated to regulate the gene expression in terms 
of positive correlation between the extent of methylation, transcriptional and 
recombinational quiescence. This correlation is most conspicuous in transposable 
elements prevalent across the mammalian genome. It maintains the host defense system 
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through the transcriptional silencing of these parasitic elements which is a threat to the 
structural integrity of the genome [8, 9].   
 The hypermethylation of bulk DNA holds the functional standpoint in the 
assembly of repetitive DNA into a heterochromatin which maintains the functional 
compartmentalization of genome into its active and inactive state [10]. While the 
primordial germ cells and the embryonic stem cells progress with the mitotic division 
without detectable DNA methylation, the cellular differentiation initiates with DNA 
methylation [11, 12]. Much of these cellular differentiations are established during the 
gastrulation stage of embryonic development.  
 DNA methylation has significant application in the somatic lineage of genes in 
genomic imprinting in-lieu of embryonic development and physical requirements [13]. 
The genomic imprinting is characterized by monoallelic or the uniparental expression of 
genes in the somatic cells [14]. These imprints are transmitted as unique methylation 
pattern of imprinted genes to the gonads during gametogenesis and after fertilization 
persists in the somatic cell. The acquisition and propagation of imprinted genes carrying 
differential methylation pattern play an intrinsic role in mammalian development [15].  
Besides, the differential methylation also guides to the transcriptional silencing of the 
majority of genes on one of the two X-chromosome in each somatic cell of the female. 
During the early embryonic development, one of the two X-chromosome is randomly 
selected for inactivation; also an example of parental imprinting [16, 17]. 
1.3 Catalytic mechanism of DNA Methylation 
The chemistry associated with the cytosine methylation hovers around the activity of the 
enzyme DNA methyltransferases (DNMTs) and the cofactor S-adenosyl-L-methionine 
(AdoMet), the source for a methyl group [18-20]. This enzymatic reaction brought about 
by DNMTs implicates via covalent mechanism coupled with acid/base catalysis. In the 
presence of the nucleophilic addition to the enzyme, the methyl-sulphur bond of AdoMet 
is destabilized which in turn renders the methyl group to the C5 position of cytosine 
molecule via the SN2 mechanism [21]. The stepwise mechanism initiates with transient 
covalent bond formation between C6 of the target cytosine and thiol group of Cysteine 
residue (Cys) forming a 6-Cys-S-cytosine adduct [22]. This nucleophilic addition at C6 
carbon is expedited by transient protonation of glutamic acid residue at N3 of cytosine 
establishing 4-5 enamine structure [5]. Thus, the stable covalent bond elevates the 
electron density at C5-postion promoting the displacement of methyl moiety of AdoMet 
molecule to provide 5-CH3-6-Cys-S-5 forming 6-dihydrocytosine complex [23, 24]. 
Finally, the deprotonation at C-5 position departs the cysteine residue subsequently 
resolving the covalent intermediate into methylated cytosine and s-adenosyl-L-
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homocysteine (AdoHcy) as a by-product [25]. The detailed mechanism is elaborated in 
Figure 1.1.  
 
Figure 1.1 Mechanism of DNA methylation: Motif IV of the enzyme active site constitute Cys 
residue such that the thiol attacks at C-6 of cytosine molecular which results in electron cloud at 
5-C. Simultaneously, proton donation (H
+
) by Glu-COOH apparently stabilizes the transition 
state. In step 2, 5C carbanion of cytosine molecule attaches at –CH3 of SAM forms an 
intermediate complex. In step 3, the abstraction of the proton from the enzyme followed by the β-
elimination results in the formation of 5C=6C double bond. In step 4, the methylation group is 
attached to 5-̍C forming stable complex and the enzyme in released by proton addition.   
1.4 DNA methylation machinery 
The cellular DNA methylation is established and maintained by the complex interplay of  
family of dedicated enzymes, called DNA methyltransferases (DNMTs) [26, 27]. These 
DNMTs constitute four members being grouped into two families having discrete 
structure and function. DNMT1, being the maintenance methyltransferase duplicates the 
existing methylation mark on the daughter strand of hemimethylated DNA successfully 
propagating across the successive generation [28] while, DNMT3 family actively 
participates in de-novo methylation during embryonic development [29-31]. This 
DNMT3 family constitute two active members as DNMT3A and DNMT3B and a 
regulatory component as DNMT3L [29, 32]. The structural machinery of the active 
members is integrated into the regulatory domain (N-terminal) and the catalytic domain 
(C-terminal) exclusively dependent on each other. The catalytic domain establishes nine 
out of ten conserved motifs being crucial for its function. Topologically the catalytic 
domain is grouped into two sub-domain [33]. The first half of the domain constitute 
structurally conserved motifs I-III which enables in co-factor (AdoMet) binding while, 
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the conserved motifs IV-VIII along with the partner domain is predominantly responsible 
for the catalytic mechanism [34]. The target cytosine binding site is enclosed within the 
conserved motif IV (ProCysGln), VI (GluAsnVal) and VIII (GlnXArgXArg) [26, 35, 36].  
 The large N-terminal domain bearing two glycine-rich loops is implicated in 
sequence-specific DNA recognition by DNMTs and flipping of target cytosine [37]. This 
terminal is accreted with the multi-functional domains; the nuclear localization sequence 
(NLS) domain that escorts in translocation of DNMT1 into the nucleus, replication foci 
targeting (RFT) domain enriched in glycine residue that recruits DNMTs to replication 
foci of DNA, the cysteine-rich (CXXC) domain also referred as zinc binding domain that 
forms interface for binding of unmethylated DNA and the two bromo-homology domain 
(BAH1 and BAH2) actively involved in protein-protein interaction thus, regulating the 
chromatin structure [27, 38, 39]. While the catalytic domain is conserved across the 
DNMTs, the N-terminal domain of DNMT3A/B contains a PWWP (pro-trp-trp-pro) that 
is functionally significant in non-specific binding with DNA [Figure 1.2] [37, 40, 41].  
 The subsidiary DNMT3L shares homology with DNMT3A and DNMT3B in both 
N and C-terminal domains while, it is deficient in conserved amino acid sequence 
prerequisite to catalytic activity. It is specifically expressed in germ cell and is essential 
for the establishment of a subset of methylation pattern in both male and female germ 
cells [42]. DNMT2 exemplified by divergent evolution shares structural homology with 
known DNA Mtase and its functionality corresponds to cytosine methylation of the 
anticodon loop of tRNA [43]. Structure elucidation of DNMTs is of considerable interest 
as its inhibition results in subsequent restoration of aberrantly silenced tumor suppressor 
genes in cancer.  
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Figure 1.2 Architecture of DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L regulatory 
and the active site domain. Abbreviations: DMAP: DNMT1-associated protein, BAH1: Bromo 
adjacent homology domain, PWWP: Pro-Trp-Trp-Pro, ADD: ATRX-DNMT3-DNMT3L (related 
to the plant homology (PHD)-like domain of regulator ATRX); KG linker: Consists of Lys and 
Gly residues. 
1.5 DNA methylation profiling in cancer 
The mechanism of gene silencing induced by DNA methylation includes direct inhibition 
of transcriptional activity by blocking the binding of transcription factors to the 
methylated sites. In another method, methyl-CpG binding proteins (MBDs) recognizes 
the methylated DNA and recruits corepressors (HDAC) resulting into compact chromatin 
structure leading to gene silencing [44, 45]. Gene silencing is characterized by the unique 
profile of aberrant DNA methylation in different types of cancer. Hence, a myriad of 
biomarkers based on DNA methylation need to be identified for variable classes of 
neoplasia [46]. The variable methylation pattern in association with biomarkers is 
identified both in localized regions and across genome-wide offers platform in the 
diagnosis, prognosis, therapeutic implications and post-therapeutic monitoring. 
Aberration in DNA methylation is visualized in the early events of carcinogenesis, some 
being localized in precancerous lesions [47]. DNA methylation being active readout can 
be easily identified in tumors with low purity. Moreover, only small fraction of promoter 
regions of aberrantly methylated genes can be directly correlated with cancer initiation 
and progression [48, 49]. These epigenetically silenced domains carry a majority of 
methylated genes actively participating in cancerous stem cell progression [50-52]. In 
general, the aberration in DNA methylation occurs in higher percentage in tumors as 
compared to genetic variations, resulting in higher sensitivity.  
1.6 Techniques for DNA methylation profiling  
The variability in methylation pattern among the cell types and during development or 
diseases and sometimes in response to environmental cues offers considerable theoretical 
and technological challenges in comprehensive genome-wide mapping [53]. The standard 
molecular biology techniques such as cloning and polymerase chain reaction offer 
limitation as it wipes out the DNA methylation information. Moreover, the standard 
hybridization technique cannot detect the methyl group being located in the major groove 
of DNA. Thus, the methylcytosine pre-treatment method was developed to reveal its 
presence or absence both in the localized regions and genome-wide at cytosine residue. 
There are methods constituting methyl-sensitive restriction enzyme digestion, affinity 
enrichment and bisulphite conversion [54, 55]. These technologies based approaches are 
based upon their ability in discriminating the methylated to unmethylated cytosine. Once 
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the genomic DNA has undergone one of these methylation-dependent steps, molecular 
biology techniques, including sequencing and probe hybridization can be implemented to 
reveal methylated-cytosine loci. Finally, several computational methods and software 
tools applications can be applied for analysis and interpretation of DNA methylation 
profile [56]. Thus, in the plethora of techniques for determining DNA methylation and 
profiles is a consequence of the conjoint analysis of pre-treatment and analytical steps 
[57-59]. The following section details about the methods for DNA methylation profiling. 
1.6.1 Methylation-sensitive endonuclease digestion 
Methyl sensitive restriction endonuclease treatment is a powerful tool in the discovery of 
methylation marker associated with targeted candidate genes as well as systemic genome 
scanning [60]. There are sequence specific restriction enzyme having particular 
recognition for methylated CpG regions while, some of them are being inhibited from 
restriction digestion by 5meC. Some of these methylation-sensitive restriction enzymes 
for DNA methylation studies are HpaII and SmaI such that each of this constitute 
isoschizomer and neoschizomer that are not inhibited by CpG methylation  [61, 62]. 
Beside genome-wide studies, the method is also applicable for locus specific analysis 
having linkage with DNA methylation across multiple kilobases. This methyl-sensitive 
restriction digestion is followed by PCR, gel electrophoresis and hybridization on 
Southern Blotting [63, 64].  However, this method has some limitation as many a times 
the incomplete digestion results in a false-positive result.  
1.6.2 Affinity purification of methylated DNA 
Recent advancement in high-throughput technology constitutes protein affinity for the 
identification of methylated fraction of genomic DNA [65-67]. These methylated 
fragments are purified either through immunoprecipitation (MedIP26) by using an anti-
m5C antibody or by DNA binding domain specific to methyl-CpG-binding protein 
(MAP27) [68]. These methods are specific to high-density DNA methylation constituting 
enriched methylated CGIs. Recently, affinity purification using CXXC (CAP; X: any 
residue) have been introduced in specific to unmethylated DNA [69]. However, the 
uneven distribution of methylated cytosine or CpG sites offers limitation in terms of the 
composition of an array for hybridization as a consequence of which individual CpG sites 
cannot be identified [68].  
1.6.3 Bisulphite sequencing of methylated DNA 
The analysis of DNA methylation on treatment with sodium bisulphite spurred a 
revolution in the epigenome-wide associations study (EWAS) of the methylation pattern. 
The treatment with bisulphite differentially selects cytosine to 5-methylcytosine residues 
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that are deaminated to yield uracil and are amplified as thymine during PCR [70, 71]. 
This bisulphite treated DNA can be identified by methylation specific PCR [72], 
restriction digestion [73], or DNA sequencing [74]. In comparison to other methods, 
sequencing of subcloned bisulphite converted DNA is more reliable for the detailed study 
of methylation pattern associated with each CpG sites across the genome. Further ahead, 
it provides an explicit method for determination of methylation pattern for haplotypes in a 
qualitative and quantitative manner. Besides, the synergistic application of bisulphite 
conversion with sequencing aids in the genome-wide study of methylation pattern without 
being restricted by the presence of restriction enzyme or high CpG density. Genome-wide 
processing of bisulphite treated DNA follows several steps. 
 The bisulphite treated DNA results in the conversion of the majority of 
unmethylated Cs to Ts in the sequencing reads. The absolute DNA methylation level is 
calculated in terms of percentage of recurrence Cs and Ts frequency in the sequencing 
reads being aligned to the reference genome. Alignment of these reads is brought about 
by two alternative approaches. The wild card aligners BSMAP21 [75], RMAP25 [76], 
RRBSMAP26 [77], Methy-Pipe [78]) replaces Cs is the genomic DNA to wild letter Y 
which in turn matches to both Cs and Ts in the read sequence. In contrary, the three-letter 
aligners (Bismark28 [79], MethylCoder32 [80]) converts all Cs into Ts in the reads as 
well in the genomic DNA sequence. Once the alignment is done, the absolute methylation 
is determined in terms of frequency of alignment of Cs and Ts to each C in the genomic 
DNA sequence.  
 Once the data processing and normalization is accomplished, the next step 
constitutes visual inspection of methylated regions. The big-Bed format prompts in 
dynamic visualization of DNA methylation which is based on the colour coding of each 
CpG site [81]; while, big-Wig format represents methylation level of single CpG sites in 
terms of variable heights of interspersed vertical bars [82]. These binary files are then 
uploaded to the web-based genome browser mainly UCSC [83], Ensemble [84] or Human 
Epigenome [85]for visualization. These genome browser prompts in regions-specific 
visualization while, the global methylation pattern can be visualized through box plots, 
Hibert plot [86], scatter plots or tree-like diagrams. R/Bioconductor provides an interface 
for these plot constructions [87]. Mapping of genome-wide methylation pattern between 
the groups of samples helps in visualization of systemic differences between the tumor 
patients and healthy control group. Finally, statistical significance between differential 
methylation groups can be verified and validated through volcano plots, Q–Q plots or 
Manhattan plots [88]. 
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1.6.4 Array hybridization 
Array-based analysis of methylation pattern is coupled with enzymatic methods. The 
differential methylation sensitive and cutting of behavior of SmaI and XmaI is followed 
by methylated CpG island amplification (MCA) [89]. This method is further associated 
with representational difference analysis (RDA) or array hybridization [90]. However, the 
process based upon MCA is significant as it provides coverage of lower resolution. In an 
alternative approach, differential methylation hybridization (DMH) is based upon 
restriction digestion of pool of genomic DNA by methylation-sensitive restriction 
enzymes and mock digestion of another pool [91]. Consequently, the parallel pool of 
DNA is produced which is amplified and labeled with fluorescent dyes of cyan/red array 
hybridization [92]. The relative signal intensities of fluorescent dye are used to detect 
locus- specific DNA methylation. This method is referred as the microarray-based 
assessment of differential methylation pattern [93].   
1.6.5 Next Generation Sequencing 
Next-generation sequencing (NGS) offers a platform for harnessing massive-parallel 
short-read DNA sequences to digitally catechise genome-wide DNA methylation. Several 
NGS platforms developed so far constitute 1) 454 GS20 pyrosequencing (Roche Applied 
Science), 2) Solexa sequencing (Illumina) and 3) Supported Oligonucleotide Ligation and 
Detection: SOLiDTM (Applied Genes) [94-97]. These methods are based upon 
fundamental principle of immobilization of template DNA to solid surface and parallel 
sequencing of clonally amplified or single DNA template as a consequence of which 
thousand to billions of sequence reads are generated in single run [98, 99]. This 
technology has enhanced drastically thus, reducing the sequencing cost per base and 
enables genome-wide bisulphite sequencing of DNA methylation pattern in high 
throughput at a single base resolution in a very short span of time [100]. The large data 
generated are being co-ordinated by national and international consortia (The Cancer 
Genome Atlas, TCGA) for data analysis [101]. NGS is advantageous over microarray as 
it provides higher base resolution with relatively small artifacts such as noise in the form 
of cross hybridization without any limitation in the genome coverage. Moreover, larger 
dynamic range and high-coverage increases the efficiency of resultant data [102]. Thus, 
high throughput analysis based on NGS can be successfully implemented in identification 
of methylation signatures for diagnosis and prognosis of cancer.  
 The quantitative based analysis based upon above-mentioned approaches 
supersedes over the non-quantitative method for detection of aberrant methylation pattern 
in the clinical settings [96, 103]. These methodologies are even compatible with degraded 
DNA. Many types of cancer display variability among the patients with similar 
histopathology and disease stage. Technology based on the high-throughput analysis can 
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be implemented in molecular characterization of variable grades of a tumor. The digital- 
based approach in NGS will promote in early detection with minimal methylated residues 
in biomarker discovery. Finally, with the recent advancement in the technology, DNA 
methylation has undergone a revolution in the diagnosis, prognosis, therapeutic and post-
therapeutic implications of cancer. 
1.7 DNA methylation as therapeutic target in cancer 
There are plethora of genes and pathways being regulated by DNA methylation. It serves 
as the biomarker in the restoration of aberrantly silenced genes in cancers [104, 105]. 
These methylation patterns can be monitored by the introduction of several 
chemotherapeutic agents or epi-drugs. Epi-drugs can be defined as the modulators that 
can inhibit or activate epigenetic proteins associated with amelioration, cure or prevention 
of diseases [106, 107]. The expression of these epigenetic proteins is altered in many 
human diseases primarily in cancer. These alterations in protein expression are visualized 
in an early stage of cell transformation; thus, they can be considered as drivers rather than 
passengers in cancer [108, 109].  
Multiple inhibitors targeting DNMTs are deemed to be the most putative 
anticancer agent having the ability to revert the aberrant methylation pattern at the 
promoter region of tumor suppressor genes. These DNMTs co-ordinates in mRNA 
expression in normal tissue and are overexpressed in tumors [110]. The elevated 
expression has been reported in cancers of the liver, colon, prostate, breast cancer and 
leukemia. Thus, inhibitors against DNMTs promise anticancer agents as they restore the 
expression of epigenetically silenced tumor suppressor genes in these cancers. Two such 
FDA approved nucleoside DNMT inhibitors, 5-azacytidine (Vidaza) [111] and 5-aza-2̍-
deoxycytidine (Dacogen) [112] had been reported to be effective in the treatment of bone 
marrow disorder in myelodysplastic syndrome. These inhibitors get incorporated into 
DNA in place of cytosine. 5-aza-2̍-deoxycytidine (decitabine) when, co-administered with 
carboplatin reverses the platinum resistance in ovarian cancer-promoting in prolonged 
progression-free survival [113]. These inhibitors have been identified in activating the 
dormant gene expression of the p16 gene subsequently, decreasing the growth of cancer 
cells [114]. Besides regulation of gene expression through DNMTs, these nucleoside 
inhibitors also get incorporated into RNA thus, inducing ribosomal disassembly and 
preventing the expression of oncogenic proteins at the translation level. However, these 
nucleoside inhibitors offer some limitations [115, 116]. The ability of these inhibitors to 
get incorporated into DNA and RNA arrests the cell cycle forming DNA/RNA covalent 
protein-adduct is toxic [117]. Moreover, in aqueous solution these inhibitors are readily 
hydrolysed by cytidine deaminase. Thus, toxicity and instability of these inhibitors 
inevitably presents a challenge to their applications clinically. 
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1.8 DNA methylation in breast cancer 
Most of the epigenetic studies unravels the hypothesis behind the disease predisposition is 
a consequence of the mismatch between prenatal and postnatal environment [118]. This 
epigenetic mismatch because of DNA methylation is widely associated with the 
developmental origin of health and diseases mainly the non-communicable diseases such 
as diabetes, cardiovascular and neuro-developmental disorders [119]. Of all the diseases 
known till date, cancer remains elusive, and it is widely accepted that the co-ordinated 
effect of genetic and epigenetic disorders leads to cancerous state [120, 121]. 
 DNA methylation characterized by genome-wide hypomethylation of sparsely 
populated CpG sites in intergenic and repetitive sequences and hypermethylation of 
densely packed CpG islands at promoter regions leads to cancer [122]. Hypomethylation 
of the repetitive sequences primarily in the transposons causes genomic instability and 
DNA breakage, and the intergenic region of chromatin undergoes de-condensation [123]. 
In many cases, hypomethylation also results in loss of imprinting or demethylation of 
retrotransposon leading to cancer [124-127]. On the contrary, the hypermethylation of 
tumor suppressor genes at the promoter region leads to somatic aberrations in cancer 
[128]. The driving force associated with cancer is mainly focused on promoter 
hypermethylation of CpG islands as it clearly demonstrates the permanent gene silencing 
both physiologically and pathologically. This anomaly in gene silencing compels in the 
aberrant clonal expansion of cells subsequently fostering to tumor progression [Figure 
1.3] [129].  
 
 
Figure 1.3 DNA methylation-mediated gene silencing in cancer. 
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 Of all the cancers were known till date, breast cancer occupies the top most slot in 
morbidity and mortality of women in developed countries while, the developing countries 
are on a rise. In 2014, the invasive nature of breast cancer accounted for 232,670 newly-
diagnosed cancer cases and 40,000 cancer death in women in USA[130]. This high 
mortality rate is explicated by the histological and morphological heterogeneity of the 
disease. According to World Health Organization (WHO), the standard classification of 
breast cancer defines 18 different histological types [Table 1.1] [131, 132]. This 
histological variability contributes to the differences in prognosis and target-specific 
response in chemotherapy. Many a times these tumors offer resistance to drug treatment, 
as a consequence of which the disease relapse.  
 Subsequent studies have classified this heterogeneous group of disease into a 
spectrum of subtypes having distinct genotype and phenotype. This classification system 
is based upon presence of estrogen receptor (ER+), progesterone receptor (PR+) and 
human epidermal growth factor receptor 2 (HER2+); however, their mere absence results 
in triple negative breast cancers (ER/PR/HER2-) [133, 134]. Based on the presence of 
these receptors, patients are grouped into four major sub-groups of Luminal A (ER+ 
and/or PR+, HER2-), Luminal B (ER+ and/or PR+ , HER2+), HER2 (ER-, PR-, and 
HER2+) and triple-negative (ER-, PR-, HER2-) [135, 136]. Over last decade, several 
efforts have been sought to improve this stratification of breast cancer; however, there are 
still in the subject of controversy. Increasing shreds of evidences have substantiated the 
critical role of epigenetic deregulation in the early event of carcinogenesis and 
subsequently prompts to assess the epigenetic cause of breast cancer [108, 137]. More 
significantly, methylation signatures are regularly employed in the stratification of breast 
cancer patients in diagnosis and prognosis [138]. With recent advancement in technology 
like microarray and next generation sequencing associated with genome-wide DNA 
methylation profiling will guide new pavement in better understanding of breast cancer 
etiology [139].  
Table 1.1 Histopathological types of invasive breast carcinoma (Adapted from Weigelt et.al, 
2005) 
Histological types of invasive  
breast Carcinoma 
Frequency 10-year survival  
Rate 
Invasive ductal carcinoma 50-80% 35-50% 
Invasive lobular carcinoma 5–15% 35–50% 
Mixed type, lobular and ductal  features 4–5% 35–50% 
Tubular/invasive cribriform carcinoma 1–6% 90–100% 
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Mucinous carcinoma <5% 80–100% 
Medullary carcinoma 1–7% 50–90% 
Invasive papillary carcinoma <1–2% Unknown 
Invasive micropapillary carcinoma <3% Unknown 
Metaplastic carcinoma <5% Unknown 
Adenoid cystic carcinoma 0.1% Unknown 
Invasive apocrine carcinoma 0.3–4% Unknown 
Neuroendocrine carcinoma 2–5% Unknown 
Secretory carcinoma 0.01–0.15% Unknown 
Lipid-rich carcinoma <1–6% Unknown 
Acinic cell carcinoma 7 cases Unknown 
Glycogen-rich, clear-cell carcinoma 1–3% Unknown 
Sebaceous carcinoma 4 cases Unknown 
 
1.9 Work done so far in diagnosis of breast cancer 
The statistics of breast cancer is startling and calls for early diagnosis. Multifactorial 
etiology is characterized by constellations of risk factors. These risk factors are 
concomitant with genetic and epigenetic predispositions, loss of host immunological 
defense, viruses as well as other carcinogens. Hormonal imbalance in estrogen is 
considered to be one of the most significant promoters of carcinogenesis [140]. Despite 
the ongoing research in finding the cause of breast cancer, this avenue does not hold great 
promise in the scenario of combating this deadly disease. Besides, finding the cause, the 
most important aspect is the early diagnosis of the disease such that the prognosis for a 
cure will guide into appropriate therapeutic interventions.   
1.9.1 Methods for early diagnosis of breast cancer 
The association between survival and stage of disease diagnosis are two concomitant 
aspects in disease cure. If a patient is diagnosed in its early stage of tumor proliferation; 
an appropriate therapy and medication will lead to the long-term survival. As per the 
instruction of physician, the art of periodic breast examination preferentially in the 
patients with an increased risk (family history of breast cancer) will be judicious in early 
diagnosis and very often highly curable [141]. This early diagnosis can be associated with 
factors such as the common type of breast lesions, recurrence of such lesions, 
characteristic symptoms and family history. The most common lesions in women are 
characterized by fibrocyst, fibroadenoma, intraductal papilloma and duct ectasia while, in 
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men gynecomastia is more predominant [142]. While monthly breast examination is of 
great importance in early diagnosis, it can only identify palpable lesions. However, 
techniques based upon X-rays such as mammography or xerography can detect in the 
preclinical stage before lesions enter into the clinically palpable size. Thus, breast X-rays 
are implemented for identification of clinical lesions benign or malignant state. However, 
a great deal of concern is associated with exposure to radiation by X-rays. Moreover, 
women with high breast density are sensitive to mammography, resulting in only 24-46% 
of the detection of malignancies [143]. Similarly, Magnetic Resonance Imaging (MRI) 
has been useful in detecting aberrations associated with benign and malignant lesions but, 
its poor specificity results in unusual breast biopsies and associated uncertainties [144-
146]. Thus, the methods for early detection need to be fortified by the advent of molecular 
technologies related to cellular changes in genome or proteome. Since last decade, there 
had been a substantial advancement in biomarkers discoveries, having a decisive role in 
understanding the cellular and molecular mechanism oftransformation of the normal cell 
to a malignant state. 
1.9.2 Diagnosis based upon biological marker 
Biological markers offer a way around to the hurdles in this era of genomic medicine. 
These markers are characterized by an indicator that can measure normal biological 
process, pathogenic or pharmacological process in response to therapeutic interventions. 
It can be instigated at any stage of disease diagnosis, prognosis or predictive outcome. 
These biomarkers can also be associated with changes in the environment and are referred 
as exposure biomarkers [147]. Thus, biomarkers antecedent to the disease are influenced 
by both genetic and epigenetic variations. Further ahead, these markers can be 
implemented in the stratification of individual based upon associated risk or prognosis 
and can be a surrogate endpoint in clinical trials [148, 149]. An ideal biomarker must 
compliment with clinically relevant information ideally across multiple individuals and 
populations. Typically, a molecular marker in breast cancer are obtained from breast 
epithelial cells which include primarily ductal lavage, periareolar fine-needle aspiration, 
fine needle biopsies or core-needle biopsies [150]. Herein we elaborate about the genetic 
and epigenetic biomarker primarily DNA methyl markers known till date in breast cancer.  
1.9.3 Diagnosis based upon genetic markers 
The autosomal inheritance of dominant allele exemplifies significant predisposing factor 
in 10% of women with breast cancer. BRCA1 and BRCA2 are identified to be the most 
susceptible genes linked to germline mutation and hereditary cause in most of the women. 
Women having mutation in either of these genes are associated with cumulative lifetime 
risk of 60-80% in development of breast cancer [151]. Understanding the normal 
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biological function and regulations of these two genes will lead to the study of molecular 
basis of heredity and will provide new driving force in disease diagnosis and therapeutic 
strategy. The functional characterization of these genes constitutes the maintenance of 
genome integrity by compromising unusual loss, duplication or chromosomal 
rearrangement of DNA. The developments of breast rely upon estrogen and progesterone 
for growth, differentiation, and homeostasis [152]. The inactivation or mutation of these 
genes results in estrogen-induced DNA damage. Thus, DNA damage results in error- 
prone DNA repair leading to global genomic instability and concomitant accrual 
functionality leading to tumorigenesis. Mutation in BRCA1 and BRCA2 causes repression 
of transcriptional activity of estrogen and progesterone receptors leading to the unusual 
proliferation of the epithelial cell and altered the hormonal response. Thus, the study of 
mutations associated with BRCA1 and BRCA2 is identified to be beneficial in diagnosis 
and treatment of breast cancer patients [153, 154]. Being a caretaker of genome integrity, 
it has been recognized as a prime target for therapeutic interventions. These genes also 
unfold the risk associated with the genetic context in different populations and historical 
groups. However, the inconsistency in mutation prevalence and penetrance brings about 
controversies in understanding the risk associated with each patient [155, 156]. 
Penetrance is defined as the percentage of individuals carrying particular variant of a gene 
may be associated with risk for cancer predisposition [157, 158]. Some of these genes 
having high penetrant include the following.    
 TP53 being tumor suppressor gene plays significant role in the regulation of cell 
growth. Germline mutation associated with this gene results in a spectrum of 
malignancies including sarcoma, adrenocortical, sarcoma and leukemias. Females 
carrying TP53 have a higher frequency of malignancy and susceptibility to Li Fraumeni 
syndrome [159]. Besides, Phosphate tensin (PTEN) homologs have been identified to be 
actively participating in phosphatidylinositol-3-kinase (PI3K) phosphatase activity [160] 
[161]. However, the dysfunction associated of this gene leads to cell cycle arrest, 
apoptosis, and anomalous cell survival. Germline mutation in PTEN results in Cowden 
syndrome (CS) and is characterized by multiple hamartomas and elevated malignant 
transformation [162]. In breast cancer, 50% women at an average age of 36-46 years are 
diagnosed with CS. Frequency of this multifocal and bilateral disease has been identified 
to be elevated in patient with ductal adenocarcinoma. More than 67% of women bearing 
CS are also associated with benign breast diseases, such as adenosis, adenosis, 
fibroadenomas and apocrine metaplasia [163]. Besides genes having high penetrant, there 
are some genes associated with moderate penetrance and the risk associated varies from 
1.5 to 5. Some of these genes and the associated risk are described in the following 
section.  
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Checkpoint kinase 2 (CHEK2) encoding for serine-threonine kinase are activated 
in response to damage caused by double-stranded DNA breaks (DSBs) and transmits 
signal for the repair of the proteins and the processors in the downstream [164]. It also 
phosphorylates BRCA1, expediting its role in DNA repair. However, female carrying 
CHEK2 mutations in the homozygous state have six-fold increase in bilateral or recurrent 
breast cancer [165]. Similarly, BRCA1-associated RING domain 1 (BARD1) encodes for 
a protein having structural and functional homology with BRCA1 [166]. Mutations in 
these genes are deleterious and results in aberration in DSB repair and arrest of apoptosis. 
However, the mutation in PALB2 gene conjointly with BRCA2 interrupts in DNA repair 
mechanism, leading to tumor suppression [167]. Some of the moderate penetrate genes 
having frequent mutation includes, ATM, RAD51C, MRN complex and others [168-170].   
In short, the mutation associated with the genes mentioned above results in 
successful screening and detection of malignancy, however, the complexity associated 
with its outcome, requires clarification as to whether these mutations act as driver or 
accelerator. Thus, the selection of the appropriate biomarker for particular settings and 
cohorts is very essential. Finally we would like to say that the selection of the most 
promising biomarker for specific settings and cohorts will lead to enhanced diagnosis.  
1.9.4 Single nucleotide polymorphism in breast cancer predisposition 
Identification of genetic risk associated with the allelic polymorphism, either at a single 
locus or epistatic effect will promote in screening and stratification of breast cancer. 
Several studies have revealed the presence of SNPs in association with DNA repair genes 
(PALB2, BRIP1, CHEK2, ATM, and RAD50) which can be implemented in screening and 
stratification of breast cancer. Genome-wide studies reveals the presence of SNPs 
associated with genes and loci (LSP1, TOX3, FGFR2, TGFB1, MAP3K1, 2q35, and 8q 
loci) in Ashkenazi Jewish ancestry accounting 80-90% of hereditary breast cancer [171]. 
Similarly, studies conducted by Johnson et al. in 437 patients bearing primary breast 
cancer disclosed the presence of 25 SNPs in association with BRCA1, BRCA2, ATM, 
TP53 and CHEK2 genes. Some of these SNPs associated with high risk include; 
(rs1799950, rs4986850, rs22279945, rs16942, and rs1799966) of BRCA1 gene, 
(rs766173, rs144848, rs4987117, rs1799954, rs11571746, rs11571747, rs4987047, 
rs11571833 and rs1801426) of BRCA2 gene, (rs3218707, rs4987945, rs4986761, 
rs3218695, rs1800056, rs1800057, rs3092856, rs1800058 and rs1801673) of ATM gene, 
rs1787991 of CHEK2 gene and rs1042522 of TP53 gene [172]. Similarly, Cox et al. 
genotyped 9 SNPs and found evidence for association of rs1045485 with CASP8-D302H 
in breast cancer [173]. Stacey et al. studied approximately 300,000 SNPs in 1,600 
individuals from Iceland and reported the presence of rs13387042 and rs3803662 on 
chromosome 2q35 and 16q12 respectively [174]. 
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 Zhang et al. studied the regulatory regions of ER-α gene in Chinese population 
and identified rs379857 to be predominant in 300 breast cancer patients [175]. Similarly, 
Abbasi et al. studied 150 Iranian patients and identified 3 SNPs associated with codon 10, 
235 and 594 in ER-α gene and other being associated with codon 392 of ER- β gene 
having additive effect in development of breast cancer [176]. Hosseini et al. also reported 
the elevated expression of ERα gene and down-regulation of ERβ gene in cancer tissues, 
having a significant role in breast cancer development. Thus, SNPs regulating the 
expression of genes in breast cancer can be a potential tool for diagnosis and therapeutic 
implications. Although the success of GWAS endorses the identification of genetic 
variants asociated with diseases, however, it requires complementary approaches for 
answering the unidentified variants.  
1.9.5 DNA Methylation: An epigenetic biomarker in diagnosis of breast 
 cancer  
Several studies conducted so far elucidate the gradual transformation of methylation 
pattern in normal, pre-malignant and malignant breast tissue. This gradation in 
methylation pattern promotes in early detection and classification of breast cancer 
subtypes. Hypermethylation in the promoters region of tumor suppressor genes primarily 
in APC, CCND2, CDKN2A (p16
ink4a
), HIN-1 (SCGD3A1), NES1 and RARB are best-
described methylation in breast cancer [177-182]. Several studies disclose that aberrant 
promoter methylation is largely associated with gene silencing and dysregulation of the 
cell cycle. Recent studies have also revealed that hypermethylation in developmental and 
differentiating genes mainly HOXB13, HOXA1, and HOXA9 and PAX6 are concomitant 
with breast carcinogenesis [183, 184]. Aberrant methylation pattern in polycomb-
regulated genes is implemented in identification of basal-like cancers. Significant CpG 
hypermethylation have been reported to be associated with genes ESR1, E-cadherin, 
CCND2, 14-3-3-σ, RASSF1A andSFRP1 in both ductal carcinoma in-situ (DCIS) and 
invasive ductal carcinoma (IDC) [185-187]. Cancer-specific methylations markers in 
conjunction with methylation-specific PCR (MSP) can be successfully implemented in 
the detection of breast cancer. Evron et al. identified three-gene panel of Cyclin D2, RARβ 
and TWIST for detection of malignancy by extracting ductal fluid and lavage [180, 188, 
189]. However, Fackler et al. improvised three-panel to nine-panel of gene RASSF1A, 
TWIST, HIN1, Cyclin D2, RARβ, APC, BRCA1, BRCA2 and p16 being associated with the 
detection of malignant cells in breast cancer [190].  
 According to Knudson's two-hit model theory, complete inactivation of tumor 
suppressor gene is characterized by loss-of-function of both the copies of the gene. 
Genetic mutation and epigenetic gene silencing characterized by hypermethylation, 
synergistically leads to the deactivation of tumor suppressor genes. Some of these genes 
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under the conjoint effect are p16INK4a, APC and BRCA1 [191]. Hypermethylation of 
p16INK4A promoter results in loss of function required for human mammary epithelial 
cell growth successfully bypassing cell senescence leading to malignancy. Similarly, 
genes such as, BRCA1 and MGMT associated with DNA repair undergoes DNA 
methylation mediated inactivation fostering the malignant transformation of the 
mammary gland. More recently, genes SFRP1 and WIF1 associated with WNT oncogenic 
pathway have been also identified to be hypermethylated in primary breast tumors [192].  
 Thus, from the above study it is apparent that cells in response to carcinogenic 
stimuli aggregate anomalous methylation pattern across the promoter region of tumor 
suppressor genes and are prone to be transformed into malignant cells. Once the patient 
have been diagnosed with breast cancer, the next question arises is the survival 
probability and recurrence of this deadly diseases. These two factors can be explained in 
terms of prognosis in breast cancer.  
1.10 Work done so far in prognosis of breast cancer 
If a woman is diagnosed with breast cancer at a younger stage of fewer than 50 years, the 
chemotherapy increases their 15-years of survival rate by 10% while, in older women the 
increase is only 3%. However, the chemotherapy substantially affects the patient leading 
to a wide range of acute and long-term side effects. Many a times it is not possible to 
accurately predict the risk associated with metastasis development and progression, as a 
consequence of which adjuvant therapy leads to relapse in 40% of patients and ultimately 
that die [193]. Thus, new prognostic markers are required to assess the patients who are at 
high risk of developing metastasis.  
1.10.1  Established and recent prognostic markers 
In oncology, prognostic markers are a clinical measure that enables to elicit patient’s risk 
associated with recurrence of disease after primary treatment. These markers play a vital 
role in distinguishing patients into different risk groups for which specific treatment 
strategies can be advised during patient counseling. They also have application in 
defining the strata in clinical trials in order to ensure comparability of treatment groups. 
In breast cancer, the risk of metastasis development is characterized by the presence of 
lymph node metastasis and the loss of histopathological differentiation. The vessel 
invasion in the patients with tumour-negative axillary lymph nodes results in distant 
recurrence [194]. However, many a time’s women bearing breast tumor without holding 
the spread in lymph node develop metastasis while, those having tumour spread to the 
lymph nodes do not develop distant metastases in 10 years after local therapy. Thus, 
markers to predict the metastasis loci are in scarcity. It has also been predicted that ER+ 
breast tumors metastasize to the bone while, the invasive lobular carcinomas recur with 
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increased frequency in ovaries and gastrointestinal tract [195, 196]. These traditional 
prognostic markers can identify the risk associated with approximately 30% of patients, 
while, the remaining 70% of patients require a new set of prognostic marker to classify 
patients into high and low risk.  In order to identify the potential novel marker, it should 
be tested retrospectively in large patient cohorts along with long follow-up period. The 
conjoint multivariate analysis of established and novel marker should be done in order to 
assess its significance. Some of these metastatic prognostic markers are enlisted in Table 
1.2. Among the enlisted markers, ERBB2 (epidermal growth factor receptor 2) has raised 
attention as a plausible prognostic marker. ERBB2, proto-oncogene codes for a 
transmembrane receptor with constitutive tyrosine kinase activity. This gene is 
overexpressed in 15-30% of breast cancer patients [197]. The prognostic potential was 
evaluated by Ros and colleagues in recently published literature, including 81 studies and 
27,161 patients. Most of the studies done so far has reported that the amplification of 
ERBB2 gene is associated with prognosis of patients with axillary lymph metastasis [198]. 
The increasing evidence based upon its response to adjuvant chemotherapy and endocrine 
therapy substantiate to its finding of the potential prognostic marker. However, its weak 
prognostic determinant in lymph-node-positive breast cancer, as declared by WHO, offers 
limitations and requires adequate studies to validate its prognostic significance.  
Table 1.2.  Metastatic prognostic marker in breast cancer 
Established 
Marker 
Clinical Study Metastatic Determinant Details 
Histological 
grade 
Established Grade 1 tumor: low metastasis 
risk; grade 2: intermediate 
risk; grade 3: high-risk 
metastasis 
Grading depends 
ontumor size [199] 
Tumour size Established Tumour size < 2 cm diameter: 
low risk metastasis; Tumour 
size 2-5 cm diameter: 
Intermediate risk; Tumour size 
> 5 cm diameter: High risk 
Independent 
prognostic marker 
[200] 
Axillary lymph 
node 
Established Absence of lymph-node 
metastases: low-risk 
metastasis; Presence of lymph-
node metastases: high-risk 
metastasis 
Depends upon tumor 
size [201] 
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Angio-invasion 
 
 
Established in 
patients having 
lymph-node-
negative tumor 
Tumour gets associated with 3 
blood vessels to undergo 
metastasis 
Localized in patients 
with lymph node-
negative tumors[202] 
Steroid receptor 
expression 
Established with 
adjuvant therapy 
decision 
Low steroid level is associated 
with metastasis 
Related to 
histological grade: 
short term metastasis 
[200] 
PAI1/uPA 
protein level 
Newly 
established 
High level of uPA and PAI1 
protein: high-risk metastasis 
Independent marker 
[203] 
ERBB2 genes Established ERBB2 amplification is 
associated with metastasis 
Patients with lymph 
node + tumor[204] 
1.10.2  Gene expression pattern based prognostic markers 
 The heterogeneity was taken into consideration, and the prediction of metastatic potential 
requires concurrent analysis of wide range of markers. The introduction of microarray 
technology and next generation sequencing has enabled in genome-wide analysis of gene 
expression and the associated mutations. Unsupervised analysis of gene expression 
pattern leads to the classification of breast tumors into four distinct subgroups as Luminal 
A, Luminal B, HER2 and Triple negative (TN). The basal-like subgroups (HER2 and TN) 
bearing estrogen-negative-receptor shows high expression of cytokeratin-5 and 
cytokeratin-17 [134]. However, estrogen-positive receptor subgroup Luminal A exhibits 
high-level expression of cytokeratin-8 and cytokeratin-18 while, luminal B has low 
expression of these genes. These findings reveal that the differential gene expression 
associated with subtypes holds characteristic clinical significance and are a potential 
prognostic target for therapeutic implications [205].   
In another approach, the supervised classification of gene-expression pattern can 
predict the clinical behavior of tumors. This classification method was based on the 
expression profile of 70 genes to predict the likelihood of distant metastasis in young 
patients (< 55 years of age) having lymph-node-negative tumors [206]. The primary 
breast tumors were classified as poor prognosis and good prognosis signatures based on 
the expression profile. Poor prognosis signature comprised of the genes that convoluted 
cell cycle, invasion, metastasis, angiogenesis and signal transduction. It also included the 
genes that are exclusively expressed in the stromal cells surrounding the epithelial cells in 
the tumor. Some of these genes constituting of MMP1 and MMP9 promotes in 
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extracellular matrix (ECM) degradation and tumor invasion. The upregulation of these 
genes in stromal cells offers significant prognostic signature for breast cancer metastasis. 
Thus, multivariate analysis of gene-expression signatures holds strong prediction for 
metastasis-free survival and overall survival. During the analysis of 151 patients having 
lymph-node-negative tumors, 60% of the patients were in high metastatic risk (poor-
prognosis) while, 40% of the patients were in low metastatic risk (good prognosis). 
However, after 10 years of the follow-up period, 56% of the patients had poor-prognosis, 
and only 13% were with good prognosis [207]. Recently, studies based upon RT-PCR 
analysis of 21 genes exhibited the metastatic potential to be associated with an expression 
ratio of HIXB13 and IL17BL genes [208]. Thus, gene-expression profiling defines the 
prognostic classification of breast cancer, however, many a times the presence of 
mutations and polymorphism in the proximity of gene expression offers limitations to its 
potential prognostic significance. 
1.10.3  Analysis of mutations including single nucleotide polymorphisms 
for identification of prognostic biomarkers 
Identification of numerous breast cancer predisposition factors associated with single-
locus or epistatic effects can be largely used for breast cancer risk assessment [209]. The 
conjoint effect of multiple genetic risk loci increases the risk prediction accuracy and 
eventually upholds in developing population-based risk screening and stratification 
programs [210]. These genetic loci are associated with germline DNA variations mainly 
the SNPs and copy number variations. Several studies have demonstrated that a germline 
mutation in BRCA1 and BRCA2 genes results in a translational shift and aberrantly 
spliced site leading to premature truncation of encoded proteins [211]. However, the 
germline mutation associated with BRCA1 and BRCA2 genes are very rare, and the 
predisposition of these 2 genes could explain only 15-20% of the genetic risk in overall 
populations [212, 213]. Similarly, germline mutations associated with TP53 and PTEN 
genes exhibit moderate penetrance for breast cancer predisposition [214-216]. 
With the advancement in genotype technologies and completion of Human 
Genome, Hap Map and 1000 Genomes projects, the paradigm shift of genetic association 
with limited candidate genes has expanded to the genome-wide investigation of genetic 
variants. Thus, GWAS investigation have identified >4,500 low-penetrance SNPs 
associated with >700 different diseases or traits [217]. Studies conducted by Easton et al. 
evaluating breast cancer cases in United Kingdom have identified 4 SNPs associated with 
the genetic loci of FGFR2, TNRC9, MAP3K, and LSP1 [218]. Furthermore, Ghoussaini et 
al. conducted a large-scale replication study in European women based upon multiple 
independent breast cancer GWAS and identified 3 novel loci susceptible to breast cancer 
on chromosome 12p11, 12q24 and 21q21.While, SNPs on 12q24 and 21q21 loci were 
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strongly linked to ER+ breast cancer, SNPs located on 12p11 chromosome offered risk 
for both ER+ and ER- breast cancer [219]. More recently, the Collaborative Oncological 
Gene- Environment Study (COGS) conducted by Michailidou et al on the largest GWAS 
study constituting > 100,000 breast cancer individuals of European ancestry, identified 41 
novel loci susceptible to breast cancer susceptible located on chromosomes 1-14, 16, 18, 
19 and 22. These variants were associated with high, moderate and low penetrance genes 
and explained about 50% of the familial risk of breast cancer. Thus, the genetic loci 
harboring the risk variants included MDM4, TET2, TERT, KLF4, POU5F1B, RAD51B, 
and BABM1 genes [220]. Importantly, these results shared genetic susceptibility for 
breast, ovarian and prostate cancer, providing evidence that the development and 
progression of these hormone-related cancers share common genetic etiology. Besides, 
the identification of prognostic marker based upon genetic variants, the epigenetic 
modulation does hold large significance in the detection of the risk associated loci across 
the genome.  
1.10.4 Risk associated with DNA methylation in prognosis of breast   
 cancer  
Aberrant epigenetic regulations in breast cancer are emphasized on the molecular 
mechanism of cancer development, prediction of aggressiveness and potential epigenetic 
therapeutic implications. The investigation carried out so far is propounded on the 
identification of novel biomarkers to predict the risk associated with survival of breast 
cancer patients. There are many pieces of evidence that the hypermethylation of tumor 
suppressor genes in breast cancer plays a decisive role in cell-cycle regulation, tissue 
invasion, apoptosis, metastasis, and angiogenesis [221-224]. Thus, the aberrant 
methylation profiles of these genes are highly associated with cancer staging and 
prognosis.  
            Esteller et al., identified the significant role of BRCA1, p16, GSTP1 and CHD1 in 
tissue invasion and metastasis. In addition, ADAM23 gene responsible for cell adhesion 
process exhibited increased promoter hypermethylation [225]. Similarly, Fang et al. 
analyzed 39 primary breast tumor specimen using Infinium 27K platform identified DNA 
methylation signatures concomitant with breast cancer metastasis. The methylation 
signature of three genes, primarily, rho guanine nucleotide exchange factor (ARHGEF7), 
ALX homeobox 4 (ALX4) and RAS-protein-specific guanine nucleotide releasing factor 2 
(RASGRF2), holds strong determinant for metastasis-free survival and overall survival. In 
particular, these signatures shared common prognostic space in gliomas, colon, and breast 
cancer [226]. In another study carried by Dedeurwaerder et al., profiling 248 breast 
cancer samples recognized immune genes holding significant prognostic value. In 
particular, the promoter hypermethylation of lymphocyte transmembrane adaptor1 
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(LAX1) and CD3D genes strongly determined the survival in breast cancer subtypes 
[227]. In recent study, Conway et al. evaluated 935 CpG sites in 517 invasive breast 
tumors from Carolina Breast Cancer study. Array-based DNA methylation profiling led to 
the identification of 266 differentially methylated CpG loci associated with hormone 
receptor (HR+ and HR-), luminal A and p53 wild-type and mutant breast cancer. 
Hypermethylation of FABP3, FGF2, FZD9, GAS7, HDAC9, HOXA11, MME, PAX6, 
POMC, PTGS2, RASSF1, RBP1, and SCGB3A1 genes were associated with the CpG loci 
of HR+, luminal A and p53 wild-type breast cancer. Similarly, highly methylated loci in 
HR-, basal-like and p53 mutant tumors comprised of BCR, C4B, DAB2IP, MEST, RARA, 
SEPT5, TFF1, THY1, and SERPINA5 genes. Hypermethylated luminal-tumours were also 
enriched for homeobox and developmental genes (ASCL2, DLK1, EYA4, GAS7, HOXA5, 
HOXA9, HOXB13, IHH, IPF1, ISL1, PAX6, TBX1, SOX1, and SOX17) [228]. These 
differentially methylated genes had a substantial role in establishing and maintaining 
tumor phenotypes and clinical outcomes. Methylome sequencing in triple-negative breast 
cancer carried out by Stirzaker et al. identified distinct methylation cluster associated with 
17 differentially methylated regions holding a strong association with overall survival. 
Notably, these DMRs predominantly overlapped with conserved transcription factor 
binding regions and DNAase 1 hypersensitive regions. Of the genes enlisted, many were 
associated with WT1 (Wilson Tumour 1), WT1-AS (Antisense WT1), DMRTA1 (DMRT-
like family A1) and HOXB13 (Homeobox gene family) [229].   
 Besides, the exclusive analysis of genetic and epigenetic aberration, the integrated 
study will embark on a contextual framework for unraveling the cryptic details of 
recurrence and overall survival. Once the diagnosis and prognostic markers have been 
identified the next step follows is to identify suitable inhibitor which can minimise the 
load of this deadly disease. Herein we enlist the inhibitors that have been implemented 
against breast cancer. 
1.11 Molecular targets and inhibitors known till date for 
treatment of breast cancer 
Our therapeutic armamentarium presents several chemotherapeutic agents against breast 
cancer. However, the vast majority of patients develop resistance and eventually 
capitulate to the disease. Inhibitors targeting specific molecular target in breast cancer 
holds promise for improving clinical outcomes. The large success of lapatinib and 
trastuzumab is treating HER2-overexpression in combination with endocrine therapy 
against positive hormone receptor exemplify this [230, 231]. 
 
 
23 
 
1.11.1  Targeting genetic regulators 
Basic research concerned with the better understanding of the biology underlying the 
malignant progression of breast cancer has motivated us to identify promising molecular 
targets in breast cancer. Advancement in the modern oncology has expanded the spectrum 
of potential molecular targets. However, the intra-tumour heterogeneity in the 
microenvironment presents a biased assessment to the complete spectrum of genomic 
alterations of the corresponding cancers. The complete spectrum of targets can be 
visualised according to the cellular component targeted, namely, breast cancer cells 
[Table 1.3], breast cancer stem cells [Table 1.4] and the breast cancer tissue 
microenvironment [Table 1.5]. Most of these genetically regulated targets and the 
therapeutic agents are specific to malignant cells and possess higher therapeutic index 
than the conventional chemotherapeutics. However, toxicity is the major concern. 
Table 1.3 Targeted genetic agents against breast cancer cells 
Cellular Target Therapeutic 
Agents 
Application on Patients Clinical Study 
mTORC1/2  INK128  
 
AZD2014  
Advanced or metastatic solid 
tumors 
ER+ or advanced MBC 
Phase I  [232] 
 
Phase I    [233] 
Dual PI3K–mTOR 
 
XL765  
 
BEZ235  
 
GDC-0980  
GSK2126458  
HR+, HER2– recurrent or 
MBC 
HR+ MBC,  HER2+ locally 
advanced MBC  HER2+ MBC 
ER+ locally advanced or MBC 
Solid tumors or lymphoma 
Phase I–II   [234] 
 
Phase I        [235] 
 
Phase II      [236] 
Phase I        [235] 
Pan-PI3K  XL147  
BKM120 
GDC-0941 
HER2+, MBC, HR+, HER2 
HER2–, HR+, MBC 
ER+ locally advanced or MBC 
Phase I-II    [237] 
Phase II       [238] 
Phase II       [236] 
PI3Kα  BYL719 
GDC-0032 
Advanced solid malignancies 
Locally advanced or metastatic 
solid tumors 
Phase I        [239] 
 
Phase II       [240] 
PI3Kβ  GSK2636771 Advanced solid tumors with 
PTEN deficiency 
Phase I-II a [241] 
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AKT  MK-2206 
 
 
AZD5363 
ER+, MBC, Advanced BC 
with a PIK3CA mutation 
and/or PTEN loss 
Advanced ER+ BC 
Phase I        [242] 
 
 
Phase I       [243] 
IGF-1R  Cixutumumab 
 
Dalotuzumab 
Locally recurrent or MBC 
HER2+ previously treated BC 
ER+ BC 
Phase I-II    [244] 
 
Phase II       [241] 
Multitargeted 
FGFR  
Dovitinib 
 
E-3810 (EOS) 
HR+, HER2– BC 
Locally advanced or metastatic 
solid tumors 
Phase I-II   [245] 
 
Phase I       [246] 
MET pathway  Onartuzumab 
Foretinib 
Cabozantinib 
TNBC  
HER2+ MBC, TNBC 
HR+, HER2– BC 
Phase II     [247] 
Phase I-II  [248] 
Phase II     [249] 
Cyclin-
dependentkinase 
PD0332991 
Dinaciclib 
Seliciclib 
MBC,  HR+ advanced BC  
Metastatic TNBC 
Advanced solid tumors 
Phase I        [248] 
Phase I        [250] 
Phase I        [250] 
MAPK pathway  AZD6244 
 
GSK1120212 
TAK-733 
Locally advanced or metastatic 
solid tumors 
Advanced solid tumors 
Advanced solid tumors 
Phase I        [251] 
 
Phase I        [252] 
Phase I        [253] 
EGFR–HER3  MEHD7945A Locally advanced, or 
metastatic epithelial 
malignancies 
Phase I        [254] 
Aurora kinases  ENMD-2076 Locally advanced or metastatic 
TNBC 
Phase II       [255] 
Androgen receptor Bicalutamide 
 
Abiraterone 
 
Androgen receptor-positive, 
HR– MBC 
ER+ MBC progressing after 
letrozole or anastrozole 
Phase II       [256] 
 
Phase II       [257] 
Prolactin receptor  LFA102 Metastatic Breast Cancer  Phase I        [258] 
Table 1.4 Target agents against breast cancer stem cells 
Cellular Target Therapeutic 
Agents 
Application on Patients Clinical Study 
 γ- secretase  MK-0752 Metastatic or locally advanced Phase I      [233] 
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RO4929097 
BMS-906024 
solid tumor 
HER2– unresectable or MBC 
Advanced or metastatic solid 
tumors 
 
Phase I      [259] 
Phase I      [260] 
Delta-like ligand 4  MEDI0639 Advanced solid tumors Phase I      [261] 
Smoothened 
receptor  
XL139 
Vismodegib 
PF-04449913 
LDE225 
TAK-441 
LEQ506 
Solid tumors, Advanced or 
metastatic solid tumors 
HER2– unresectable or MBC 
Advanced or metastatic solid 
tumors 
Advanced tumours 
Advanced solid tumors 
Advanced solid tumors 
Phase I   [262] 
Phase I    [263] 
Phase I    [264] 
Phase I    [265] 
Phase I    [266] 
Phase I    [267] 
Frizzled receptor  OMP-18R5 
OMP-54F28 
Advanced or metastatic solid 
tumors 
Advanced or metastatic solid 
tumors 
Phase I    [268] 
Phase I    [245] 
β-catenin  PRI-724 Advanced solid tumors Phase I    [269] 
Porcupine  LGK974 Melanoma (except uveal), 
lobular or triple-negative BC, or 
pancreatic adenocarcinoma  
Phase I    [270] 
 
Table 1.5 Targeted Agents against breast cancer microenvironment 
Cellular  
Target 
Therapeutic 
Agents 
Application on Patients Clinical Study 
PD-1  Nivolumab 
 
AMP-224 
Locally advanced or 
metastatic solid tumors 
Advanced cancer 
Phase I   [271] 
 
Phase I   [258] 
PD-L1  BMS-936559 
MPDL3280A 
Relapsed breast cancer 
Advanced solid tumors 
Phase I   [272] 
Phase I   [244] 
Lysyl oxidase  Simtuzumab Advanced solid tumors Phase I     [273] 
Chemokine 
receptor  
PLX3397 Advanced solid tumors Phase I    [231] 
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Integrin  Cilengitide 
 
PF-04605412 
 
IMGN388 
Unresectable solid tumors, 
excluding lymphoma 
Advanced or metastatic solid 
tumors 
Advanced solid tumors 
Phase I    [274] 
 
Phase I    [246] 
 
Phase I     [225] 
Hypoxia  EZN-2968 
TH-302 
Advanced solid tumors 
Advanced solid tumors 
Phase I    [275] 
Phase I   [276] 
1.11.2 Targeting epigenetic regulators for breast cancer therapy 
Epigenetic aberrations characterized by DNA methylation, histone modifications, miRNA 
downregulation and chromatin remodeling offer new therapeutic targets in breast cancer 
[277, 278]. HDAC inhibitors have shown the reactivation of ESR1 and PGR gene 
expression in ER-negative breast cancer cells [279]. Some of these inhibitors primarily 
vorinostat, entinostat, and panobinostat have already passed through the clinical trials. 
Triple-negative breast cancer cells, when targeted with HDAC inhibitors in combination 
with aurora kinase inhibitors, enhances the antitumor activity [280, 281]. HDAC 
inhibitors also restore the sensitivity to trastuzumab through small molecule acting as 
EGFR/HER2 inhibitor [282].  Phase II trial assessing the inhibitory effect of entinostat in 
combination with exemestane in ER+ breast cancer shows reduced risk of progression of 
breast cancer [283, 284]. DNA methyltransferases inhibitors, specifically 5-azacytidine 
and decitabine have been successfully implemented in the treatment of hematological 
malignancies have also shown efficiency in treating metastatic breast cancer [285-287]. 
Transient low doses have exhibited antitumor efficacy in the in-vivo condition in a breast 
cancer xenograft model and restoration of expression of hypermethylated genes. 
Moreover, the hypermethylation of tumor suppressor genes including BRCA-1, E-
cadherin, and MASPIN are also restored in breast cancer [288]. DNMT inhibitors also 
sensitize breast cancer lines to chemotherapeutic agent doxorubicin by inducing tumor 
necrosis factor related apoptosis inducing ligand (TRAIL) [289]. Moreover, the conjoint 
effect of HDAC and DNMT inhibitors induces enhanced expression of ESR1 gene [290]. 
The ongoing research elucidates the novel combination strategies of epigenetic modifiers 
with tamoxifen, aromatase inhibitors, trastuzumab and other cytotoxic agents in breast 
cancer treatment. A number of early phase ongoing or completed clinical trials for early 
phase solid tumor diagnosis are included in table 1.6. 
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Table 1.6 Epigenetic modifiers in breast cancer 
Cellular  
Target 
Agent Application on patients Clinical Trials 
HDACs  Vorinostat 
 
Vorinostat + tamoxifen 
 
 
Vorinostat + aromatase 
 
Entinostat + exemestane 
 
 
Entinostat + Anastrozole 
 
Vorinostat + paclitaxel + 
bevacizumab  
 
Vorinostat/placebo + 
nabpaclitaxel 
+ carboplatin 
Vorinostat + ixabepilone 
 
Vorinostat + trastuzumab 
 
Vorinostat + lapatinib 
 
Advanced breast cancer, median prior chemotherapy cycles 
 
Advanced ER-positive breast cancer 
hormone-resistant 
 
Advanced ER-positive breast cancer 
 
Advanced ER-positive breast cancer, progression on prior non-
steroidal AI 
 
Primary operable triple-negative breast cancer 
 
Primary operable triple-negative breast cancer 
 
 
Advanced breast cancer 
 
 
Primary operable breast cancer, triple-negative or high-grade ER-
positive 
Advanced breast cancer 
 
Advanced HER2-positive breast cancer 
 
Phase II [291] 
 
Phase II  [292] 
 
 
Phase II   [283] 
 
Phase II   [293] 
 
 
Phase II    [294] 
 
Phase I-II  [283] 
 
 
Phase II  [295] 
 
 
Phase I  [296] 
 
Phase I-II [297] 
 
Phase I-II [298] 
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Entinostat + lapatinib 
 
Advanced solid tumors and advanced HER2-positive breast 
cancer 
Phase I-II [299] 
DNMTs  AZA single agent 
 
 
AZA + entinostat 
 
Decitabine + panobinostat 
+/− tamoxifen 
 
AZA + nab-paclitaxel 
Primary operable breast cancer “window trial”, 
a triple-negative breast cancer 
 
Advanced breast cancer: triple-negative and hormone-resistant 
 
Advanced triple-negative 
breast cancer 
 
Advanced solid tumors and breast cancer 
 
Phase II   [300] 
 
 
Phase I-II  [266] 
 
Phase II    [301] 
 
Phase I-II  [302] 
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1.11.3 Other molecular targets 
There are numerous other molecular target agents also being under clinical trial. These 
include the compounds targeting SRC complex, a tyrosine kinase regulating numerous 
oncogenic targets, primarily cell proliferation, survival, induction of angiogenesis and 
promoting cell migration or invasive phenotype (dasatinib, bosutinib, and saracatinib) 
[303-305]. Interestingly preclinical studies substantiate the conjoint effect of anti-SRC 
agents and trastuzumab. SRC complex are activated in cells despite acquired and de-novo 
trastuzumab resistance, and acts in the downstream of trastuzumab resistance which in 
turn can be pharmaceutically reversed. Similarly, HER3 has emerged as potential drug 
target candidate against U3‑1287 and MM‑121 inhibitors have been identified [306, 
307]. Targeting HER3 is of greater significance in HER2+ metastasis breast cancer, as the 
data have disclosed that the formation of HER2-HER3 dimer promotes the malignant 
progression of HER2+ breast cancer cells [308]. Another group of targeting agents 
corresponds to the androgen receptor or prolactin receptor. The inhibitors targeting these 
receptors are bicalutamide, enzalutamide and abiraterone [256]. Molecular 
characterization of triple negative breast cancer spectacles the presence of luminal 
androgen receptor subtypes. Targeting these receptors is of greater significance as it 
simulates the growth of tumor cells in context with the stimulation of WNT and HER2 
oncogenic pathway.  
Identification of genetic and epigenetic aberrations described so far has led to the 
development of targeted therapeutics in breast cancer. However, the clinical results 
obtained so far do not meet the requirement for treatment of intra-tumor heterogeneity in 
breast cancer. With the advent of next-generation sequencing techniques, the 
interrogation of large-scale genomic alterations regulating DNA methylation will 
significantly expand to the new therapeutic arsenal. On targeting the DNA 
methyltransferase enzyme (DNMTs) will cause the reversal of the differential 
methylation (hypermethylation) opening a new window to the therapeutic intervention in 
breast cancer.  
1.12 Lacuna in the understanding of the problem 
With the advent of whole genome sequencing program, several human cancers have come 
up with an explicated results that the mutated genes associated with epigenome can 
remodel the complete cellular programming leading to cancerous state. The presence of 
these associated mutations was unknown and overlooked, however the analysis of 1,000 
of cell lines by whole exome sequencing disclosed the presence of large number of 
potential mutations regulating epigenetic modifications, preferentially DNA methylation 
[309]. Genome-wide association studies (GWAS) have identified the presence of these 
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mutations in the form single nucleotide polymorphism (SNPs) holding an increased risk 
in several diseases including cancer [310]. Surprisingly, cancer associated SNPs are 
highly enriched in  the defined region of functional enhancers and alter the chromatin 
landscape [311]. Moreover, several genome-wide expression quantitative trait loci are 
linked to genetic variations and changes in gene regulations [312]. More recently, these 
genetic variants have been identified to be strongly associated with transcription factor 
binding site, there-by leading to differential gene expression. Although many studies have 
revealed allele-specific DNA methylation and gene expression related to genome 
imprinting and X-chromosome inactivation, recent studies have shown that these allele-
specific phenomena are involved in other cellular activities [313]. Notably, most of the 
allele-specific DNA methylation are strongly correlated with SNP genotypes affecting the 
binding of transcription factors and long-range chromosome structure. Conversely, the 
presence of SNPs in the vicinity of CpG site can create or delete the loci, subsequently 
influencing the binding of transcription factor and methyl-binding proteins (MBDs) [314].  
Further studies need to be associated with epigenetic variation (epigenotype), genetic 
variation (genotype) and trait or disease (phenotype) to explain the functional causality of 
diseases [Figure 1.4] [315]. Moreover, there are increasing the number of nucleosides, 
and non-nucleoside analogs being studied as anti-cancer drugs. Inhibition of DNA 
methyltransferase (DNMTs) by 5-azacytidine (Vidaza; azacitidine) and 5-Aza-2̍-
deoxycytidine (Dacogen; decitabine) have been approved by FDA for cancer treatment 
[316]. However, owing to their genotoxic effect in high dose offers limitation for further 
implementation in clinical settings. 
Ever growing evidence of epigenetic alterations characterized by DNA 
methylation in cancer, offers a chance to enhance the increased sensitivity and specificity 
in its diagnosis and therapy. Several genome-wide consortia such as 1000 Genome 
Project, IHEC, and Roadmap projects are blueprints for methylome mapping [317-319]. 
These databases constitute massive data for reference in research and clinical trial. 
Integration and management of these data from several “omics” approach mainly 
genomics, transcriptomics, and epigenomics will lead to the production of predictive 
models for identification of novel epigenetic biomarkers and signatures [Figure 1.4]. 
Moreover, combinations of hypermethylated biomarkers in breast cancer will enhance the 
sensitivity of detection and prediction of tumor progression. Implementing high-
throughput study of next generation sequencing and statistical analysis will increase in the 
characterization of cancer subtypes. Owing to the lacunae in the analysis based upon 
exclusive genetic and epigenetic aberrations, our present work elaborates the conjoint 
study of genetic and epigenetic anomalies that will be effective in diagnosis, prognosis 
and therapeutic implication in breast cancer. 
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Figure 1.4: Epigenetic and genetic aberrations synergistically regulate the cellular function 
leading   to carcinogenesis. 
1.13 Objectives 
In many instances genetic and epigenetic aberrations have been thought to be an 
independent entity relishing an active participation in carcinogenesis. However, with the 
recent outcome of complete genome sequencing of thousands of human cancer have 
resulted in an unexpected findings of many mutations that control the epigenome. Of all 
the epigenetic process, the imbalance in DNA methylation conspires with the mutation to 
drive the process of cancer development and progression. Thus, it offers a daunting 
challenge to identify a stochastic change in genome-wide DNA methylation and 
associated mutations in revealing the anomalies in breast cancer. Moreover, the active 
participation of DNA methyltransferases in differential methylation needs to be targeted 
to slow down its hyperactivity leading to therapeutic interventions. Keeping these views 
in mind, we have designed objectives as follows:  
 
1. To understand how differential allelic distribution regulates CpG methylation in 
 tumor and normal samples leading to the diagnosis of breast cancer.  
2. To decipher how single nucleotide polymorphisms affect DNA methylation at 
 nearby CpGs and impact breast cancer prognosis among individuals. 
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3. To identify novel inhibitor(s) targeting DNA methyltransferases for therapeutic  
  intervention in breast cancer. 
 The success of genome-wide association studies has been successfully 
comprehended with the epigenome-wide association studies in identification in capturing 
the disease association epigenetic variant primarily differential DNA methylation in the 
diagnosis, prognosis and therapeutic implications of breast cancer. 
1.14 Overview of this thesis 
Integration of genetic and epigenetic marks holds the key to the understanding the 
underlying biology of the complex interaction of inherited trait and environmental cues in 
the catastrophe of the deadly disease like cancer. This interplay between the two layers of 
information reveals correlation between single nucleotide polymorphism (SNPs) and the 
DNA methylation at a particular site leading to the identification of methylation 
quantitative trait loci (meQTL). In chapter 2, we begin with genotype-epitype interactions 
and the associated phenotypes in identification of diagnostic marker in breast invasive 
carcinoma (BRCA) samples obtained from TCGA database. Realizing the fact that the 
large section of cancer-related SNPs resides in the noncoding region and holds incredible 
functional impact, we look forward to identify novel diagnostic biomarkers with respect 
to the presence of these meQTLs. Once we have established a platform for diagnosis, we 
also need to analyze the longevity related to breast cancer patient survival. Chapter 3 
details about the epigenome-wide association analysis (EWAS) of the myriad of meQTLs 
in association with the risk to the survival of breast cancer patients. In our study, we 
mainly reveal the complex interplay of genetic and epigenetic variants in predisposing the 
diagnosed BRCA patients to a lethal stage. Comprehensive assessment of these risk 
variants at different stages will lead to the identification novel biomarkers in breast cancer 
prognosis. Once we have identified the biomarkers in association with diagnosis and 
prognosis, the next step follows therapeutic implications. In chapter 4, we describe the 
pharmacological manipulation of key epigenetic enzyme DNA methyltransferase in breast 
cancer reprogramming. In light of emerging concept of chemoinformatics, molecular 
docking, and simulation studies have been employed to accelerate the development of 
novel DNMT inhibitors having medicinally relevant space. The in-silico analysis has 
been comprehended by an in-vitro study to visualize the effect of the novel inhibitor 
inhibiting DNMT activity and the ability to restore the expression of silenced tumor-
suppressor gene devoid of being toxic to normal cells.  
The strategy for the effective treatment can be based upon the combinatorial 
analysis. If we can integrate candidate-altered genetic and epigenetic profile into a 
predictive model in conjunction with novel therapeutic implications, it will lead to the 
low-dose and customized high-impact treatment we seek. 
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Chapter 2 
 
To understand how differential allelic distribution 
regulates CpG methylation in tumor and normal 
samples leading to the diagnosis of breast cancer 
 
2.1 Introduction 
The susceptibility to inherit breast cancer is estimated to be 25-50% however, only 5-10% 
of cases are explained by the genetic variant in association with BRCA1, BRCA2, and 
TP53 genes [320]. In some instances, it is characterized by the conjoint effect of multiple 
genetic variant loci [321]. Thus, heredity is not the only cause for genesis in most of the 
breast cancer. It is a consequence of a gradual accumulation of mutational load, telomere 
dysfunction, and epigenetic gene silencing with developing age [322]. Exposure to 
estrogen hormone causes an anomalous change in breast epithelial stem cell subsequently 
propagating cell to divide. Besides the direct stimulation of epithelial cells development, 
growth hormone also influences stromal microenvironment for tumor cell development 
leading to profound tumor progression. During metastasis, this microenvironment is 
regulated largely by paracrine signaling between epithelial and neighboring stromal 
fibroblast [323]. This eccentricity in breast development leading to the cancerous ailment 
is affected by variability in environmental cues associated with epigenetic aberrations. 
Thus, it can be inferred that genetic variations in conjunction with epigenetic anomalies 
regulate the aberrant division of epithelial and stromal cells leading to breast cancer.   
 Elucidating the genetic and non-genetic determinants in the diagnosis of breast 
cancer is one of the principal challenges in the field of biomedical research. Despite 
GWAS discloses > 800 SNPs in several diseases, still a substantial portion of the 
causality remains enigmatic [324]. The epigenomic equivalent of GWAS characterized by 
epigenome-wide association studies (EWAS) presents novel opportunities in confounding 
the factors and follow-up influencing the disease etiology. DNA methylation is a 
significant epigenomic marker that represents a molecular phenotype that links to the 
genotype in resolving disease complexity. This variation in the genotype is characterized 
by the presence of SNPs in the vicinity of CpG sites which in turn disrupts methylation 
status at each CpG sites. These SNPs form major class of methylation quantitative trait 
loci (meQTLs) [325, 326]. It has also been reported that these SNPs are associated with 
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CpG sites within consensus sequence of methyl-CpG binding proteins; thus, it can be 
hypothesised that strategies focusing on the identification of SNPs for genotyping will 
contribute in elucidating the genetic epidemiology of breast cancer. 
 The dynamic characterization of DNA methylation facilitates the determination of 
diagnostic biomarker by considering inter and intra-individual variations. The SNPs 
associated with each CpG sites influences the methylation pattern leading to differentially 
methylated regions (DMRs) [327]. These DMRs across the healthy individual and the 
cancerous tissue helps in estimating the variance across particular CpG site located in the 
intergenic or intragenic regions. However, the loci constituting unstable methylation 
pattern are precluded as false positive hits. Nowadays reference data set consortia such as 
1000 Genome Project has been created based on the epigenomic profiles of stem cells and 
developmental somatic tissue profile from healthy individuals [138]. Systemic screening 
of these reference data set obtained from different individuals enables in identification 
and exclusion of variable CpG sites and regions facilitating in biomarker selection. 
 Methylation at any CpG site is quantified in terms of beta value that is defined as 
the ratio of intensities between methylated (M) and unmethylated (U) allele. Thus, beta 
value is given by the equation 1:  
                                           𝑏𝑒𝑡𝑎 =
max (M,0)
max(M,0)+max(U,0)+100
                               (Equation 1) 
Where, M and U codes for signal A and B produced by two different beads in Illumina 
methylation assays. Here the constant 100 has been used to normalize the beta value 
provided the value with respect to M and U are comparatively small [328]. The beta value 
of any locus range from 0 (unmethylated) to 1 (completely methylated). While, Illumina 
platform corroborates with the genome-wide association of beta values at each CpG site, 
the genotypic information with respect to allele frequency distribution can be excavated 
from Affymetrix high-throughput SNP array database. For each SNP,  the intensities of 
two alleles denoted as A and B are measured as four sets of perfect match probe from 
sense and antisense strands, denoted as +/-. The intensities are normalized by excluding 
background noise as mismatch probes (MM) [329, 330]. TCGA database repository 
supports the platform for Illumina DNA methylation 27/450 and Affymetrix genome-
wide human SNP array 6.0 data covering 33 cancer types [331]. Thus, beta value and 
genotypic details across the breast cancer and matched normal patients can be assembled 
in the identification of meQTLs as the diagnostic marker.  
 The present study unravels the combinatorial effect of meQTLs and gene 
expression in tumor growth and development. The contribution of genetic variants (SNPs) 
in regulating DNA methylation and gene expression illuminate their potential function in 
unfolding the complexity of deadly disease like cancer. Many studies conducted till date 
already discloses the significance of SNPs in the disease phenotype. Besides, targeting the 
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CpG sites in protein-coding regions, SNPs were also identified to influence the non-
coding regions mainly the promoters, introns, alternates spliced regions and the intergenic 
regions. The complete analysis is based on recently developed statistical methodology at 
R-interface, overarching the confounding paradigm of differential methylation, single 
nucleotide polymorphism and gene expression in the diagnosis of breast cancer. In 
summary, we have demonstrated the systematic assessment of methylation and expression 
data being influenced by genetic variations in breast cancer and the analysis were based 
on enriched publically accessible TCGA cohort. Thus, the combinatorial effect of 
differential methylation and gene expression will be a gateway towards the understanding 
of the underlying mechanism behind breast cancer pathogenesis. 
2.2 Materials and Methods 
2.2.1 Dataset retrieval from TCGA repository  
The Cancer Genome Atlas (TCGA) in a national research consortium spearheaded by 
National Cancer Institute (NCI) in collaboration with National Human Genome Research 
Institute (NHGRI). The database offers comprehensive profiles of cancer genomes 
through the application of high-throughput technologies, primarily microarrays and next 
generation sequencing. It is affluent with more than 6000 patients’ tumor and matched 
normal samples profiles, extending up to 37 types of genotypic and phenotypic data 
across 33 cancer types. The data generated are categorized based on data type and data 
level. This categorised data include level 1 (Raw, non-normalized), level 2 (processed 
data), level 3 (segmented/normalised) and level IV (summarised) data. These data 
integrate samples details as “TCGA barcode describing the participants and biospecimens 
(blood, tissue) [332]. We downloaded the Level-III DNA methylation and RNA seq and 
Level-1 SNP array data of breast invasive carcinoma (BRCA).  
2.2.2 Illumina 450 k DNA methylation data 
Illumina has established Infinium-based Human Methylation microarray assay for 
quantitative analysis of methylation across the genome. This high-throughput assay 
Human Methylation450 (450K) Bead Chip consists of 485,577 probes that cover 482 421 
CpG sites, 3091 non-CpG sites and 65 random SNP. The level 3 methylation normalized 
dataset for BRCA encompasses the detail for 746 tumors and 96 matched normal 
samples. Of the total, 740 tumor samples were obtained from the primary tumor, while 
remaining 6 samples pertaining to metastatic class were filtered out. Each of these 
normalized data sheets incorporated the details for genomic coordinates and beta-values 
for each CpG sites, while the associated gene information was optional. 65 non-random 
SNPs were excluded and 485,512 CpG sites were processed for further studies. These 
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methylation files were processed to interrogate the SNPs associated with each CpG loci. 
The entire set of SNPs information was based upon the Affymetrix Genome-Wide Human 
SNP Array 6.0 genotypic platform.   
2.2.3 Affymetrix SNP arrays dataset preparation  
Affymetrix system offers series of microarray platform feasible for exploring biological 
mechanisms such as genotyping, copy number variations and the differential expression, 
on the whole genomic scale. In our present study, we mainly focus on SNP based 
microarrays for high-throughput genotyping in genome-wide association studies. Level 1, 
raw SNP array data for 1076 for BRCA tumor, 137 matched normal and 975 blood 
samples were downloaded from TCGA Data Portal. Data normalization and genotype call 
for each sample were performed by “Corrected Robust Linear Model with Maximum 
likelihood distance” algorithm [333]. CRLMM algorithm estimates the genotype based 
upon two-stage hierarchical model (M) for log ratio of IA and IB (M = log2 (IA/ IB). The 
model follows the empirical Bayes approach in which the mean conditioned on genotype 
has multivariate normal distribution while the variance has an inverse gamma 
distribution. Based upon the information for mean and variance, CRLMM computes the 
posterior probabilities for each genotype given the observed log ratio M. The algorithm 
estimates the genotype using linear mixture model and for each SNP-genotype 
combination, the uncertainty parameter is corrected using HapMap samples. In order to 
process the large data set, the crlmm-package was substantiated with ff package to reduce 
memory footprint (http://cran.at.r-project.org/web/packages/ff/index.html). The algorithm 
was implemented to decode the genotype calls for SNPs as 1 (AA/Reference allele), 2 
(AB/Heterozygous allele) and 3 (BB/Alternate allele). The genotype calls at the threshold 
of 0.05 were filtered while, those having more than 25% low confidence calls was 
excluded. The complete process of data normalization and data filtering resulted in 
905,422 SNPs for further analysis.  
2.2.4 RNAseq dataset preparation 
Direct sequencing of the transcriptome by RNA-sequencing (RNA-seq) method is now 
possible with the advent of next generation technology. Sequence data from RNA-seq 
method can be used to identify (de-novo assembly of transcripts) and quantify the 
expressed transcripts. RNA-seq data also facilitates detection of transcript fusion and 
alternate splicing of isoforms. TCGA Data Portal offers enormous resource for 
identification of differentially expressed genes between different tissue types (for 
example, cancer vs. normal or different cancer types) [334]. Methodology for RNAseq 
data development involves the alignment of the fragmented transcript (short reads) to the 
reference genome. RNASeqV2 level 3 released gene expression for RNAseq were 
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downloaded from TCGA. The dataset constitutes the details for 1056 tumor and 112 
matched normal samples. The data processing and quality control was done by Broad 
Institute TCGA workgroup [http://gdac.broadinstitute.org/]. The reference for gene 
transcript was based upon HG19 UCSC track 
(http://hgdownload.cse.ucsc.edu/downloads.html). The Map-Splice was used to do the 
alignment and the quantification was carried by RSEM [335, 336]. We downloaded the 
upper quantile normalized RSEM count estimates.  
2.2.5 R statistical programming software 
The complete statistical analysis detailed in the study was carried out at R-interface 
[http://www.R-project.org/]. R is acquainted with the substantial collection of the 
statistical algorithms for easy handling of data and well-designed extension system and 
excellent visualization platform. It constitutes several integrated modules and packages 
while, new modules can be submitted to the central repository of the Comprehensive R 
Archive Network (CRAN) or to, the Bioconductor [337].  
2.2.6 Procedure for the identification of regulatory CpG-SNP candidates 
associated with breast cancer diagnosis 
Figure 2.1 is a detailedoutline of the procedure for identification of regulatory Cp-SNP 
candidates involved in thediagnosis of breast cancer. We describe the details in the 
following steps. 
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Figure 2.1 Detailed outline for identification of CpG-SNP pair candidates in the diagnosis of 
breast cancer. Complete study is based upon DNA methylation, SNP-array and RNAseq dataset.  
Step 1. The “BED” format file of DNA methylation and SNP array data constituting 
485,512 CpG sites and 905,422 SNPs, respectively were prepared as an input to the 
OverlapSelect program from UCSC Kent source library. This data integration is based on 
genomic positions that find all the SNPs lying in the vicinity of the CpG sites. The 
program was used to search the neighboring SNPs of the chosen CpG site using the 
following command:  
overlapSelect -selectFmt=bed -selectRange -inRange -mergeOutput CpG.bed, SNP.bed 
output.bed. 
Note: Only unique CpG-SNP pairs were analyzed for further studies.  
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Step 2. For each of the CpG-SNP pair obtained in step 2, we extracted the corresponding 
beta value for each CpG site and the genotype with respect to each SNP genotype from 
the common patient samples (731 samples in breast cancer). We applied the Analysis of 
Variance (ANOVA) to assess the statistical significance between the beta-values and the 
neighboring genotype [338]. 
Step 3. For each of the significant CpG site obtained from Step 2 was evaluated for 
differential methylation in tumor and matched normal samples in breast cancer. The beta 
value associated with CpG site in the tumor and matched normal samples sharing 
common space (86) were assembled. The significant difference in beta-values associated 
with respect to CpG site was computed based on paired t-test. The mean beta value 
associated with each significant CpG site across the sample was calculated. All the 
significant CpG site having mean beta value across the tumor sample greater than normal 
were retained, and the remaining were filtered out.  
Step 4: For each significant SNP obtained in step 2, the frequency associated with major 
and minor allele in tumor sample were calculated using Hardy-Weinberg equation as 
follow [339]. 
𝑝2 + 2𝑝𝑞 + 𝑞2 = 1                               Equation 1 
𝑝 + 𝑞 = 1     Equation 2 
Here in the above equation  𝑝 and 𝑞 corresponds to major and minor allele, respectively. 
The respective allele frequency for each SNP in normal sample was obtained from “1000 
genome population” database (http://www.1000genomes.org/). Moreover, the differential 
allelic distribution in tumor was compared with respect to normal in order to identify the 
percentage of germline and somatic mutation associated with each SNP. 
Step 5.  Finally, the differentially methylated sites obtained from step 3 were studied for 
their effect on gene expression. Spearman correlation test was implemented to study the 
significant association between DNA methylation and gene expression in tumor and 
normal sample, respectively. The complete analysis was carried at threshold p-value of 
0.05 and correlation coefficient was computed. Moreover, the average value of expression 
of the gene associated with DNA methylation was calculated in tumor and normal 
sample. 
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2.3 Results 
2.3.1 Interpretation of genotype, methylation and gene expression dataset 
in breast cancer 
To study the correlation between the genetic and epigenetic codes in breast cancer 
comprehensively, Affymetrix genome-wide SNP array and Illumina Methylation450 
dataset were merged for analysis. Prior to the processing of conjoint methylation and 
genotypic data, an intermediate step of pre-processing was carried out to filter non-
significant CpG site across the genome. One dimensional matrix was constructed to 
compare the overall methylation pattern associated with 485, 5512 CpG sites across 740 
tumors and 90 normal samples, respectively [Figure 2.2 a]. All the statistical parameters 
were set to compute the variance across these samples at the provided R-interface. Of the 
total 485, 5512 CpG sites, 448, 2886 CpG sites bearing zero variance across the samples 
were filtered out, and the remaining 37,2626 methylated CpG loci were processed for 
subsequent analysis. Illumina file, level 3 data substantiates β-value for given CpG site. 
Beta-value was then converted to M-value based on equation 2. M-value imparts better 
Detection and True Positive Rate (TPR) for both methylated and unmethylated CpG 
probes. Moreover, minimal threshold difference imposition enhances the performance of 
M-value in comparison to beta-value application.  
                                                              𝑀𝑖 =  𝑙𝑜𝑔2(
𝛽𝑖
1−𝛽𝑖
)                                  (Equation 2) 
The heterogeneity in methylation was processed for CpG sites positioned on each 
chromosome, and it was evident that the variation expanded profoundly in tumor samples 
to normal samples [Figure 2.3]. This hypervariability in the methylation pattern is 
characterized by the quantitative difference in aberrant methylation associated with CpG 
islands in different individual tumors. This increased variability across tumor sample was 
striking feature as it largely distinguished cancer from the normal cells. Polymorphism in 
allele distribution surrounding the CpG site may define the cause for the variation in 
methylation pattern. Thus, an integrative analysis based upon the identification of 
significant CpG-SNP pair was carried out for 731 tumor samples sharing a common 
interface for methylation and SNP array data [Figure 2.2b]. Finally, differentially 
methylated regions (DMRs) were correlated with the differential gene expression for 86 
samples constituting both methylation and RNAseq data as obtained from TCGA [Figure 
2.2a].  
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Figure 2.2 Venn diagram details about the BRCA dataset. (a) DNA methylation holds 
information for 740 tumors (T) and 90 matched normal (N) sample. RNAseq dataset constitutes 
details for 1156 tumor and 112 matched normal samples. There are 86 samples which share 
common space in both tumors and normal samples for DNA methylation and RNAseq dataset. (b) 
DNA methylation and SNP array datasetshare 731 tumor samples in the overlapping zone. 
 
Figure 2.3 Genome-wide variation in methylation pattern associated with each chromosome in (a) 
Tumor samples b) Matched normal samples. Variation in methylation level has been identified to 
be comparatively high in tumor in comparison to normal population.  
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2.3.2 Mapping of significant CpG-SNP pairs in the identification of 
meQTLs 
Screening of epigenomic modification at high resolution has disclosed a direct correlation 
between the underlying genetic variation and differential methylation pattern, 
subsequently defining the presence of meQTLs. In an attempt to identify SNPs 
genetically influencing methylation pattern, we integrated 905,422 SNPs and 372,626 
CpG sites using ucsc tool-overlapSelect. Distribution of CpG-SNP pairs around the CpG 
site were identified within a base interval of 100-bases and the sliding window of 50-
bases extending to the maximum boundary of 5000-bases in the upstream and 
downstream region. Beta value and the genotype associated with each CpG-SNP pairs 
were mapped across 731 samples sharing a common interface for SNP array and 
methylation data. An integrated two-dimensional matrix was generated for each CpG-
SNP across the samples, and statistically significant CpG-SNP pairs were mapped based 
upon non-parametric one-way analysis of variance “ANOVA” [340]. There were a few 
instances in which multiple SNPs were mapped to a single CpG site. Figure 2.4 shows a 
bell-shaped distribution of CpG-SNP pairs by applying a sliding window. From the 
figure, it is evident that CpG-SNP density is high across 50-bps upstream and 
downstream of CpG-site. The overlapselect file constituting 7970 CpG-SNP pairs at 50-
bps interval were evaluated for further analysis. The rationale for selecting the loci 
starting with 50-bases is to minimize the probe effect [341]. Illumina 450K methylation 
chip is identified to have a “probe effect” i.e SNP within 10bp of the CpG probe may be 
enriched in methylation quantitative loci (meQTLs). Moreover, DNA methylation locus 
are primarily associated with promoter regions (besides, inter/intra-genic regions), thus 
localization of SNP/SNPs may interfere the interaction of DNA methyltransferases 
enzyme (DNMTs) with CpG loci leading to anomalous DNA methylation [342].   
Now considering the presence cis-acting elements mainly the enhancers mostly 
localized as far 5000bp. Presence of SNPs on enhancer may deregulate its functional 
property as well as its interaction with the promoter region. Moreover, the presence SNPs 
in the vicinity of histone marks (H3K4me3, H3K9-14Ac and H3K36me3) associated with 
active promoters, enhancer and transcriptionally active regions, interferes with the DNA 
methylation distribution leading to aberrant pattern.  
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Figure 2.4 Significant distribution of CpG-SNP pairs around a given CpG site. The CpG-SNP 
density is identified to be high at 50 bases upstream and the downstream region. 
2.3.3 Identification of differentially methylated regions in tumor and 
matched normal samples 
Identification of DNA differential methylation distribution between the tumors and the 
normal cells is a landmark in understanding the processes underlying tumorigenesis. 
Studying of such differentially methylated region upholds in identification of diagnostic 
and prognostic marker. Specifically, the aberration in methylation pattern of a particular 
gene (or group of genes) is beneficial for the early detection of breast cancer and or 
stratification of tumors into subtypes. Extensive studies have been invested in identifying 
aberrantly methylated regions and correlating with tumor development or phenotype. 
However, studies done so far have focused on small sets of loci. Here, we have 
investigated the genome-wide pattern of differential methylation distribution based on a 
comprehensive study in breast cancer tissue and matched normal dataset. Localisation of 
differentially methylated regions (DMRs) have been investigated with respect to the 
polymorphism (SNPs) associated with each CpG sites. Influence of this local genetic 
variation in DNA methylation is called as cis-meQTLs. In order to examine the difference 
in methylation level in tumor with respect to normal, beta values associated with each 
7970 significant CpG sites across was analyzed based upon student t-test. The statistical 
significance was set at threshold p-value < 0.05. The significant difference in methylation 
level across 86 tumor and matched normal sample led to the identification of 997 CpG 
sites of potential interest. These regions were distributed across all 
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chromosomes. Significant distribution of 997 differentially methylated CpG sites in order 
of their chromosomal location and –log 10 p-values have been depicted in Manhattan plot 
[Figure 2.5]. The mounting p-value in the plot beyond the threshold led to the 
identification of those CpG loci holding marked difference in methylation pattern in 
tumor with respect to normal. This differential methylation pattern was a consequence of 
the variation in allelic distribution. The quantile-quantile (Q-Q) plot in terms of –log10 (p-
values) clearly depicts the association between the variable allelic distribution and 
differential methylation   [Figure 2.6]. The major and the minor allelic frequency for each 
SNP was computed in tumor and normal samples by following HWE and 1000 genome 
project of population genetics, respectively. We enlisted the top 3 CpG-SNP pairs 
strongly associated with differential methylation as; cg02058408:rs9891975, 
cg05388880:rs4421026 and cg25198340:rs17235834 [Table 2.1]. Differential 
methylation pattern in tumor with respect to normal was a consequence of difference in 
major and minor allele frequency. While the minor allele frequency associated with SNP 
rs9891975 and rs4421026 was high, elevation in major allele frequency was seen with 
respect to SNP rs17235834.  In the upcoming section, we elaborate the detailed study of 
the correlation between differential methylation, allelic distribution and the gene 
expression. 
Figure 2.5: Manhattan plot presents the association with -log10 (P-values) for each differentially 
methylated CpG sites (y-axis) in the tumor in comparison to normal samples in the order of 
chromosomal position. The red and the blue line indicates the threshold -log10 (1 × 10
–4
) and –
log10 (0.2), respectively, for genome-wide statistical significance. 
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Figure 2.6:  Quantile-Quantile (Q-Q) plot with respect to observed versus expected p-values. Q-Q 
plot of –log10 (p-values) depicts the association between differential methylation (DMRs) and the 
allelic variation associated with SNPs. The observed quantile is higher than the expected value, 
disobeying the null hypothesis. 
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Table 2.1 Allelic distribution with respect to top 3-SNPs and its effect on methylation in tumor and normal sample 
S.No. CpG ID SNP ID P-value Mean-
value 
Tumor 
Mean-
value 
Normal 
Difference Gene Allele 
Frequency 
Normal 
Allele Frequency 
Breast Cancer 
Major Minor Major Minor 
 
1 cg02058408 rs9891975 1.29E-31 0.57997 0.16217 0.41865 
 
Intergenic 
A  
 92% 
G  
 8% 
A  
4 % 
G  
96% 
 
2 cg05388880 rs4421026 1.18E-25 0.81975 0.51601 0.30373 
 
DCTD 
C 
99% 
T 
1% 
C 
0.6% 
T 
99.4% 
 
3 cg25198340 rs17235834 2.25E-45 0.84669 0.54799 0.29870 IL17RD 
G 
98% 
A 
2% 
G 
4% 
A 
96% 
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2.3.4 Establishing the correlation between allelic distribution, differential 
methylation and gene expression in the diagnosis of breast cancer 
Finally, the significant association between genetic variations and DNA methylation was 
extended to gene expression by incorporating the RNA-seq dataset. The association 
between differential methylation and gene expression was measured by Spearmen 
correlation coefficient [343]. A complete analysis was carried out for 86 samples 
overlapping with methylation and RNA-seq data set. All data were quantile normalized 
prior to analysis.  Of the total 997 significant CpG-SNP pairs influencing differential 
methylation, 713 had associated gene information while, the remaining were localized in 
the intergenic regions. The relationship between DNA methylation and gene expression 
were analysed in terms of beta values and log2-transformed fold change in gene 
expression for both tumor and normal samples.  
 From the conjoint analysis, 16 of total 713 CpG-SNP pairs showed a significant 
nominal correlation between differential methylation and gene expression. Interestingly, 3 
CpG-SNP pairs; cg08710564:rs4929917, cg08306955:rs16890134 and 
cg14482998:rs9387025 holds high negative correlation with gene expression of ST5, 
CMAH and FYN genes, respectively. Further ahead, we disintegrated the above analysis 
in order to have a clear vision of the individual factors (SNP, methylation and gene 
expression) being correlated. The variable pattern in the allelic frequency distribution is a 
remarkable feature in understanding the disease etiology. For example; major allele T of 
SNP rs4929917 was associated with increased methylation level of CpG site cg08710564. 
Major and the minor allele frequency associated with SNP rs4929917 in normal 
population was identified to be 5% and 95%, respectively while, in breast cancer the 
allelic frequency flipped to 96% and 4%, respectively [Figure 2.7a]. The difference in the 
allelic distribution led to variation in methylation pattern in tumor and normal samples. 
Methylation distribution with respect to the CpG loci cg08710564 in tumor ranged from 
65-85% and was higher than the normal sample [Figure 2.7b]. This differential 
methylation in tumor led to downregulation of ST5 gene. Based upon the spearman 
correlation analysis, we found a significant inverse correlation between differential 
methylation and fold change in mRNA expression of ST5 gene in breast cancer 
(coefficient r = -0.42, p < 0.0001) [Figure 2.8a]. An average fold change in gene 
expression in tumor with respect to normal is shown Figure 2.8b. In another example, 
very high frequency of minor allele T associated with SNP rs16890134 led to the 
differential methylation of the CpG site cg08306955. The frequency of allele “T” is 
identified to be as high as 99% in the breast cancer patients however, the frequency was 
low (1%) in the normal population [Figure 2.9a, b]. This differentially methylated CpG 
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site located at 5̍ UTR region was responsible for downregulation of CMAH gene, and the 
correlation coefficient was identified to be -0.44 at p-value < 0.0001 in tumor sample 
[Figure 2.10a]. Figure 2.10b shows the mean fold change in gene expression of CMAH 
gene in tumor and normal sample. Finally, we also identified that nearly equal distribution 
of major and minor allele can also affect methylation as well as gene expression. The 
frequency allele A and G associated with the SNP rs9387025 in breast cancer was found 
to be 57% and 43%, respectively [Figure 2.11a]. This allelic distribution in breast cancer 
was linked to the hypermethylation of CpG site cg14482998 associated with the intron 
variant of FYN gene [Figure 2.11b]. Integrated analysis of DNA methylation and FYN 
transcriptome revealed a reverse correlation between differential methylation and mRNA 
expression (r = - 033, p-value < 0.01) in tumor sample [Figure 2.12a]. Average fold 
change in gene expression in the tumor and matched normal sample is shown in Figure 
2.12b. Moreover, the genotypic distribution of these SNPs (rs4929917, rs16890134, 
rs9387025) in tumor and matched normal revealed that most of these mutations are 
germline while, only smaller percentage fall under somatic mutations [Figure 2.13]. 
 
Figure 2.7 (a) Major and minor allele frequency distribution of “C” and “T” associated with SNP 
rs4929917 in breast cancer and normal population. Major allele frequency is comparatively high 
in tumor as compared to normal sample. (b) The methylation associated with CpG site 
cg08710564 in tumor ranges from 65%-82%, while, in normal the distribution ranges from 48-
52%.  
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Figure 2.8 Spearmen correlation with respect to fold change in gene expression and DNA 
methylation in breast cancer in comparison to a normal cell. (a) Fold change in gene expression of 
ST5 gene has a negative correlation with respect to DNA methylation (cg08710564) in a breast 
cancer while, it is positive in normal sample. The correlation coefficients were identified to be -
0.42 (p < 0.0001) and 0.49 (p < 0.001), respectively. (b) Average fold change in gene expression 
of ST5 gene in tumor and normal was 6.9 and 7.4, respectively.  
 
Figure 2.9 Major and minor allele frequency distribution of “A” and “T” associated with SNP 
rs16890134 in breast cancer and normal population. Minor allele frequency is comparatively high 
in tumor in comparison to the normal samples. (b) The methylation associated with CpG site 
cg08306955 in tumor ranges from 55%-80%, while, in normal the distribution ranges from 55-
65%. 
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Figure 2.10 Spearman Correlation with respect to fold change in gene expression and DNA 
methylation in breast cancer in comparison to a normal cell. (a) Fold change in gene expression of 
CMAH gene has a negative correlation with respect to DNA methylation (cg08306955) in a breast 
cancer while, it is positive correlation in normal sample. The correlation coefficients were 
identified to be -0.44 (p < 0.0001) and 0.13 (p < 0.1), respectively. (b) Average fold change in 
gene expression of CMAH gene in tumor and normal is 5.3 and 5.7, respectively. 
 
Figure 2.11: Major and minor allele frequency distribution of “A” and “G” associated with SNP 
rs9387025 in breast cancer and normal population. Both Major allele and Minor allele holds 
nearly equal frequency in breast cancer and in the normal population. (b) The methylation 
associated with CpG site cg14482998 in tumor ranges from 78%-88%, while, in normal the 
distribution ranges from 65-75%.  
Tumor
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Figure 2.12 Spearman correlation with respect to fold change in gene expression and DNA 
methylation in breast cancer in comparison to normal cells. (a) Fold change in gene expression of 
FYN gene has a negative correlation with respect to DNA methylation (cg14482998) in breast 
cancer while, it is positive correlation in normal sample. The correlation coefficients were 
identified to be -0.33 (p < 0.01) and 0.46 (p < 0.0001), respectively. (b) Average fold change in 
gene expression of FYN gene in tumor and normal is 6.2 and 6.8, respectively. 
 
Figure 2.13 Somatic and Germline Mutation: Differential genotypic analysis (Tumor with respect 
to Normal) of the SNPs (rs4929917, rs9387025, rs16890134) identified from the above studies 
shows that the mutations are inheritable (germline) in comparison to the somatic.  
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2.4 Discussion 
The inter/intra-tumor heterogeneity in breast cancer possess an important impediment to 
the targeted therapy [344-346]. Fuelled by Darwinian Theory of evolution regulating the 
disease, these variability leads to the emergence of resistance in breast cancer cells when 
being subjected to the selective pressure [347-349]. Indeed, the analysis of a cohort of 
candidate genes in population-based and in the pedigree analysis would allow in tracing 
possible clause in the pathway analysis of the specific type of cancer [350, 351]. 
Identification of common pathway associated with genetic heterogeneity would lead to 
the identification of novel targets for the early diagnosis of cancer [352-354]. 
 Comprehensive mapping of a genetic variant of the genome between individuals 
discordant for certain phenotype has revealed a plethora of SNPs having a significant 
association with the diverse phenotype, including cancer [355, 356]. Despite the success 
of GWAS in identification of variable loci in disease diagnosis, a substantial proportion 
of the causality remains inexplicable. On a similar account, epigenetics studies 
characterized by DNA methylation also provides novel insight into low-frequency drivers 
of breast cancer [357-359]. DNA methylation reflects phenotypically significant 
difference in gene transcription making the profile based diagnostic test to be more 
substantial and reproducing. However, several studies reflect that the diagnostic analyses 
based on methylations were interrupted by mutations.  
 Till date, the presence of these mutations were overlooked while, it is surprising in 
view that more than 1,000 of cell lines recently being analysed reveal the presence of 
numerous mutations being associated with epigenetic modifiers (DNA methylation) 
[309]. The fact that pinnacle of the hierarchy of genes is being regulated by the 
epigenome,, the mutations in these genes will probably affect multiple pathways in 
relevant to the cancer phenotype. Consequently, we added layer information connecting 
polymorphism and variance in gene expression. We introduced epigenetic-mediated gene 
regulation as a potential intermediate connecting genotype-phenotype association. The 
high-resolution DNA methylation data was integrated with single nucleotide 
polymorphism resulting in a catalog of genotype-epitype association for identification of 
diagnostic marker in breast cancer. 
  Taken together, the massive integration of Affymetrix SNP array data and 
Illumima 450 DNA methylation data, we identified polymorphic sites potentially 
regulating CpG methylation in breast cancer. Most of these polymorphic alleles (SNPs) 
are predominantly located in a noncoding region depicting their close association with 
epigenetic modification primarily DNA methylation and aids in understanding its 
functional significance in etiology of breast cancer. In our present study, we have mainly 
observed the cis-regulation of CpG site by the genetic variant. The genome-wide study of 
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methylation pattern across 37, 2626 CpG sites showed an extensive range of variability in 
methylation distribution in the order of the chromosome. This increased variability across 
tumor sample was striking feature as it largely distinguished cancer from the normal cells. 
The variable pattern of methylation was analyzed across 740 tumors, and 90 matched 
normal sample obtained from TCGA cohort. Of the total 485, 5512 CpG site, only 37, 
2626 methylated site displayed significance variance across the data set, was considered 
for further analysis. This variance in methylation was explained by associated SNPs in the 
vicinity of CpG site. Thus, allelic polymorphism (SNPs) having significant influence 
DNA methylation is called DNA methylation quantitative trait loci (meQTLs). The 
presence of statistically significant CpG-SNP pair around a given CpG site was 
interrogated at a base interval of 100nt with an overlapping window of 50nt extending to 
5000nt in the upstream and downstream regions. The maximum density of CpG-SNP pair 
hovered around 50-bps upstream and downstream region of each CpG site. Of the total, 
7970 CpG-SNP pairs were significantly associated with CpG site at a base interval of 50-
bps both in upstream and downstream regions. These 7970 CpG sites were further 
evaluated to identify how many of them are associated with differential methylation level 
in tumor with respect to matched normal samples. Out of the total, 997 CpG sites loci 
exhibited remarkable difference in methylation pattern. This differential methylation was 
explained by the variable allelic distribution associated with each SNPs in the vicinity of 
CpG loci. The flipping of major and minor allele frequency in breast cancer and the 
normal population was an incredible feature that explained underlying differential 
methylation in tumor and normal sample. We enlisted the top 3 SNPs; rs9891975, 
rs4421026 and rs17235834, strongly regulated methylation level of CpG sites 
cg02058408, cg05388880, and cg25198340, respectively. However, these differential 
methylated CpG sites did not have significant effect on gene expression. Therefore, in our 
subsequent analysis, we extended our study to see the effect of differential methylation on 
gene expression in tumor and normal samples. Taking SNP, DNA methylation, and gene 
expression together, we identified 16 genes being influenced by difference in the 
methylation level. However, 3 genes showed a strong negative correlation with increase 
in DNA methylation in tumor sample. In particular, we identified 3 major class of allelic 
distribution which could regulate methylation pattern which in turn affected gene 
expression. In the first case, we have the example of SNP rs4929917, where the increase 
in frequency of major allele “C” was associated with increased methylation of CpG site 
cg08710564 in tumor sample. This increase in methylation resulted into the decreased 
expression of ST5 gene. However, the increase in methylation level was associated with 
increased expression of ST5 gene in normal sample. Suppression of tumorigenicity 5 
(ST5) gene is located on chromosome 11 and has the ability to suppress tumor of Hela 
cells in nude mice [360]. This gene encoded a protein such that its C-terminal shares 
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homology with Rab 3 family of small GTP-binding proteins. This protein preferentially 
binds to SH3 domain of the c-Ablkinase and acts as a regulator of the MAPK1/ERK2 
kinase, contributes in reducing the tumorigenic phenotype in cells [361]. From the 
previous studies, it has been reported that aberrant silencing of this gene is of great risk in 
breast, lung and cervical cancer development [360-362]. In the second case, the elevation 
in minor allele frequency has been identified to be of high risk in breast cancer. The high 
frequency of minor allele “A” associated with SNP rs16890134, located in the 
downstream region causes hypermethylation of CpG site cg08306955, subsequently leads 
to down-regulation of CMAH gene in the tumor sample. Cytidine monophosphate-N-
acetylneuraminic acid hydroxylase (CMAH) gene having loci on chromosome 6 encodes 
for the sialic acid which a component of carbohydrate chains of glycol-conjugates and 
actively participates in ligand-receptor and cell to cell interactions [363, 364]. The 
carbohydrate is actively synthesized and secreted by oral and mammary carcinoma cells 
promoting to malignancy [365-368]. Finally we also identified that nearly equal 
distribution of major and minor alele can have signficant effect of differential methylation 
pattern in tumro wiith repsect to normal sampele. SNP rs9387025 having nearly equal 
allele frequency for “A” (57%) and “G” (43%) causes increase methylation level of CpG 
site cg14482998 in tumor sample. The increased methylation level resulted in decreased 
expression of FYN (tyrosine kinase) gene. The gene holds dual property of oncogene and 
tumor suppressor gene. FYN tyrosine kinase gene located on chromosome 6 has been 
reported new candidate tumor suppressor in prostate cancer and gastric cancer [369-371]. 
The SNP mentioned so far have been identified to be germline in comparison to somatic 
mutation.  
The positive correlation between DNA methylation and gene expression in the 
normal sample is condition-specific [342, 372, 373]. Several studies have established the 
concept of negative correlation between DNA methylation and gene expression at 
transcription start sites (TSSs). However, the explained concept cannot be extrapolated 
for CpGs located in the intergenic and intragenic regions. DNA methylation and gene 
transcription follows a non-linear equation. In general the DNA methylation has been 
identified to block the initiation of the transcription but not the elongation. In fact several 
inter/intragenic nucleosomes are associated with histone tri-methylation marks 
H3K36me3 which recruits DNMTs facilitating the methylation of inter/intragenic regions 
[374]. Besides, DNA methylation also regulates gene transcription by incorporating 
molecular mechanism through alternative promoter, enhancer and non-coding RNA. 
More recently, several studies have observed positive correlation between inter/intragenic 
DNA methylation and gene expression in context of cellular development, differentiation 
and in cancer cells [67, 372, 375-378].  
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Our results reveal the new findings based upon genetic variability contribute to 
differential methylation and gene expression in breast cancer. Differential expression of 
ST5, CMAH and FYN gene and the associated CpG-SNP pair will contribute to the major 
finding in the early diagnosis of breast cancer. These results will lead to the discovery of a 
novel mechanism that determine gene-specific DNA methylation and the functional 
effects of polymorphism on disease phenotypes including cancer.  
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Chapter 3 
 
To decipher how single nucleotide polymorphisms 
affect DNA methylation at nearby CpGs and 
impact breast cancer prognosis among individuals 
 
3.1 Introduction 
The variation in the gene expression transforms the cellular programming from normal to 
a diseased state. The multiple genetic circuits within a cell creates a characteristic 
signature profile of gene expression endorsing each cell a unique identity. The gene-
expression-based signatures have been successfully implemented in classifying the breast 
cancer into different subtypes [379, 380]. Similarly, approaches based upon genome-wide 
DNA methylation profiling identified breast-cancer-specific methylation signatures that 
correlate  with specific clinical outcomes [44]. In addition to the diagnostic potential, 
aberrations in DNA methylation profile regulates gene expression dictating tumor 
recurrence and overall survival in breast cancer and their subtypes [229, 381-385]. The 
prognostic potential of genes mainly FLRT2 and SFRP1 have been identified to be 
regulated by DNA methylation and are enriched in ER1/luminal B of breast cancer. 
However, the expression of specific genes linked to immune function such as CD3D, 
CD79B, CD6, HCLS1, HLA-A and lAX1 have been identified to be consistently associated 
with recurrence-free survival (RFS) and overall survival (OS) in ER2/HER22 subtypes of 
breast cancer [386-388]. Further ahead the combination of methylated genes such as 
GSTP1, FOXC1, and ABCB1 has been correlated with respect to the survival of the 
patients [389]. The downregulation of DNA methylation have been significantly 
correlated with the expression of BCAP31 and OGG1 genes and have shown significant 
association with the survival in a large cohort of breast cancer patients [390]. Besides, the 
differential methylation of CpG islands proximal to the genes regulating cell cycle and 
proliferation (HDAC4, KIF2C, Ki-67, and UBE2C), angiogenesis (BTG1, KLF5, VEGF) 
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and cell fate determination (LHX2, LXH2, OLIG2, SPRY1) possess significant prognostic 
values independent of subtypes and clinical features [391]. 
 GWAS have identified a large number of genomic variants associated with 
complex diseases, including breast cancer [356, 392, 393]. However, most of the disease-
associated genomic variants that have been reported in the literature so far are 
predominantly located in the intergenic or intronic regions of the genome [394]. 
Furthermore, numerous studies have noted that GWAS haplotypes are enriched in 
regulatory elements that are concordant with the disease phenotypes [395]. Therefore, it is 
highly likely that most of the disease-causing genomic variations act by altering gene 
regulation, such as transcription factor binding and DNA methylation, rather than directly 
affecting protein function. 
  Despite the advances in sequencing and availability of multi–omics datasets [332, 
396], finding causative and prognostic genetic variants for complex diseases, such as 
breast cancer, remains challenging. Thus, a robust method of associating genomic 
variants, such as SNPs, in regulatory regions, such as CpG islands, with corresponding 
DNA methylation alterations is required [397]. The influence of these genetic variants on 
DNA methylation level was referred to as cis-methylation quantitative trait loci (cis-
meQTLs) [342, 398]. Here, we report the joint effect of meQTLs on clinicopathological 
variables for identification of prognostic biomarkers, their clinical validity and the extent 
to which they capture the pathological difference between breast cancer prognostic groups 
using these external independent studies.  
3.2 Materials and Methods 
Details for Illumina 450K methylation, SNP array and RNAseq TCGA dataset 
incorporated in the present study have been detailed in the previous section of the 
diagnostic analysis.   
3.2.1 Clinical data 
A central premise of cancer treatment resides in deciphering the genotypic information 
into phenotypic expression. The clinicopathological data from TCGA aids in investigating 
the risk associated with polymorphism and associated phenotypic aberration. These 
clinical data have been collected by Biospecimen Core Resource (BRC) with respect to 
the participant sample.  The data are available in XML and flat file biotab format. We 
obtained the biotab file for BRCA that spanned the detail for 1035 tumor patients. The 
clinical data recapitulates; age, gender, menopause status, race and ethnicity, history of 
neoadjuvant treatment, histopathological subtypes and tumor stage corresponding to each 
patient as major details. Length of survival of each patient was measured from the date of 
treatment to the date of last follow-up or death. Vital statistics enumerated the death status 
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of breast cancer patients. Patients alive on the last follow-up date were considered as 
censored. 
3.2.2 Procedure for the identification of CpG-SNP pair associated with 
the prognosis in breast cancer 
Figure 3.1 shows an outline of the procedure for identification of regulatory CpG-SNP 
pair involved in the risk associated with the survival of breast cancer patient. We describe 
the details in the following steps. 
 
Figure 3.1 Detailed outline for identifying significant effect of CpG-SNP pair on the overall 
survival. It also includes in finding the candidate risk SNPs in the breast cancer prognosis.  The 
individual CpG sites and SNPs have also been correlated with the gene expression. This process 
utilizes DNA methylation, SNP-array, RNAseq and clinical data.  
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Step 1: In order to study the synergistic effect of methylation and the associated 
polymorphism in regulating the survival of the breast cancer patients, 660 samples 
sharing the common space between DNA methylation, SNPs and clinical dataset were 
randomly split into training and test model [Figure 3.2 a]. The caret package of R 
(http://caret.r-forge.r-project.org/) was implemented to group the ¾ of the samples (486) 
into training and ¼ (164) as testing based on the vital status of the patients from the 
clinical data [Figure 3.2 b]. 
 
Figure 3.2 (a) Venn diagram details about the DNA methylation, SNP array and clinical samples 
across the tumor patients. (b) The tumor sample overlapping across the three datasets is grouped 
into the 75% training, and 25% test set based on the vital status. 
Step 2: For each of the 7970 CpG-SNP pair located at 50-nt upstream of downstream of 
CpG site (as described in step 1 of diagnostic section), the training model was built across 
486 samples. The beta value associated with each CpG site and the variable genotype 
(AA, AB, BB) with respect to each SNP were selected as the features in the training 
model. The findings in the training model were validated across 164 samples in an 
exclusively independent test model. 
Step 3: The significant association between the beta-values or the proportion of 
methylation at each CpG site and the variable genotype associated with each SNP was 
computed based upon non-parametric one-way analysis of variance (ANOVA). Here the 
β-values were modeled as a linear function with respect to alleles (AA, AB, BB). The 
complete analysis was carried out at R-interface at threshold p-value of 0.05. Each of the 
SNP having a significant association between DNA methylation was labeled as meQTLs. 
The finding of these meQTLs in training model was validated in the test model. 
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Step 4: For each of the significant CpG-SNP pairs from step 3, we analyzed the 
significant association between beta-value with respect to each CpG and the gene 
expression. We extracted the corresponding beta-values with respect to each CpGs and 
log2-tranformed fold change in gene expression (tumor w.r.t normal) for 86 patient 
samples. The association between the DNA methylation and the fold change in gene 
expression was analysed based upon Spearman-correlation test. 
Step 5:  For each of the CpG-SNP pair from step 3, we also studied the significant effect 
of the allelic polymorphism on the gene expression. We extracted the variable genotype 
(AA, AB, BB) associated with each SNP and log2-tranformed fold change in gene 
expression.  We then applied ANOVA to assess the statistical significance between each 
SNP genotype and its neighboring gene expression [399]. Moreover, the mean fold 
change in gene expression was calculated with respect to the genotype associated with 
each SNP.  This association between the differential gene expressions with respect to 
allele was labeled as expression quantitative trait loci (eQTLs).  
Step 6: For each of the significant CpG-SNP pair (test set) from step 3, the differentially 
methylated CpG sites were assessed for the risk associated with the survival of the breast 
cancer patients. The complete analysis was based on the univariate and multivariate Cox 
Proportional Hazard (PH) model [400-402]. It is a regression model which describes the 
relation between the event incidence expressed as hazard function and a set of covariates. 
The hazard parameter is denoted by h (t) or λ (t) and is defined as the risk associated with 
the survival of the diagnosed cancer patient in a given time t. Mathematically the Cox 
Model is represented as;  
 
ℎ (𝑡) =  ℎ0(𝑡)   × exp{𝑏1𝑥1 +  𝑏2𝑥2 + ⋯ 𝑏𝑛𝑥𝑛} 
 
where, the hazard function ℎ (𝑡)  is determined by a set of n covariates (𝑥1, 𝑥2 … . . 𝑥𝑛) and 
the impact of each variable is measured by the respective coefficients (𝑏1, 𝑏1 … . . 𝑏𝑛). 
Here in the equation ℎ0 is the baseline hazard, while, ℎ (𝑡) is the hazard function variable 
over time t. The Kaplan-Meir survival curve was plotted to classify the patients into high 
and low risk, respectively.  
Step 7: Besides, the SNPs were also analysed to study their effect on overall survival. We 
extracted the variable genotype details associated with each SNP and clinical details 
including the vital status (patient alive or dead) and the date of the last follow-up. The 
training model was built for each of the SNP across 486 patients. The findings in the 
training model were validated in the test model. A complete analysis was carried out 
based on the log-rank test [403, 404]. All the significant SNPs identified in the test model 
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were subjected to multivariate Cox regression analysis to visualize their cumulative effect 
on overall survival.  
3.3 Results 
3.3.1 Identification of methylated probes or loci differing in genotypes 
In the previous section of our study, we have described the polymorphism linked to the 
CpG loci results in differential DNA methylation in tumor versus normal cells. However, 
the accumulation of genetic variations on certain chromosome remains dormant and needs 
to be excavated for identification of meQTLs linked to disease progression. In our present 
analysis, we mainly elaborate the pattern of polymorphic allele distribution (AA, AB, and 
BB) and their influence of differential methylation exclusively in breast cancer patients. 
Considering the close proximity between the genetic variability and DNA methylation, 
the comprehensive analysis of the overlapping layers expands our knowledge in 
understanding the association of genetic variability with disease etiology. Realizing the 
fact that a large portion of cancer-related SNPs ispositioned in the noncoding region holds 
substantial functional impact, the coaxial analysis of genotype-epitype interactions will 
facilitate identification of novel prognostic markers.  
 In order to determine the association of genotype-epitype interactions 
comprehensively, we integrated the high-resolution Affymetrix SNP array and Illumina 
450k DNA methylation platforms, analyzing 905,422 SNPs and 485,512 CpG sites. The 
training data set comprising of 486 samples was constructed across the CpG-SNP pairs. 
For each of the benchmark data set, its training and test were used as exclusive subsets. 
The predictive model was built in training data set and validated in the test data set 
bearing 164 samples. Based on the analysis carried out by overlapSelect tool, a total of 
7970 CpG-SNP pairs were identified at a base interval of 50bps upstream and 
downstream across given CpG loci. Of the total 7970 CpG-SNP pairs, 1820 CpG loci 
were identified to be influenced by the variable genotype resulting into differential 
methylation patterns in the predictive training model. These loci are called as methylation 
quantitative trait loci (meQTLs) and have influence the methylation pattern across the 
extended genomic regions. Out of the total 1820 meQTLs in the training model, 489 
polymorphic alleles were identified to be significantly associated with differential 
methylation in the test data set (P < 0.05). However, only 392 and 243 SNPs were 
detected to be significantly associated with differential methylation pattern at astringency 
of 0.01 and 0.001, respectively. The majority of these meQTLs were mapped to the 
intronic regions (50-60%) though a limited number were associated with synonymous 
(1.2-1.7%) or non-synonymous coding SNPs (3-4%). Some of these SNPs being 
associated with one or more CpG loci suggest that they not only influence the methylation 
status to the associated CpG loci but also affect the surroundings at very close distance. 
63 
 
Genome-wide localization of meQTLs identified in test model (p < 0.05) and their loci on 
the respective chromosome have been depicted by Manhattan plot [Figure 3.3].  
 
Figure 3.3 Dots within the Manhattan plot displays the identification of significant SNPs in the 
vicinity of CpG site leading to the meQTLs in the test model; the x-axis represents genomic 
position of SNPs, while the y-axis represents the –log p-value of the association between the 
SNPs and CpG site. The red and the blue line indicates the threshold -log10 (1 × 10
–4
) and –log10 
(0.2), respectively, for genome-wide statistical significance. 
In particular, the association of breast risk alleles, rs1570056 and rs11154883 with 
DNA methylation levels (cg18287222) of MAP3K5 gene (p < 0.001), is an interesting 
case because the gene encodes for mitogen-activated protein kinase protein that activates 
signalling cascade. The downstream protein kinases that are activated include MAPK or 
extracellular signal-regulated kinase (ERK), MAPK kinase (MKK or MEK), and MAPK 
kinase (MAPKKK). These kinases are highly conserved, and the homologs exist in yeast, 
Drosophila, and mammalian cells [405]. While, the differential distribution of major (T) 
and minor allele (C) (SNP: rs1570056) regulates the DNA methylation of the CpG site 
cg18287222 [Figure 3.4 a], the mutation in the allele G -> A associated with SNP 
rs1154883, simultaneously regulates the same CpG loci. These alleles influenced DNA 
methylation at a p-value of 5.8 x 10
-5 
(< 0.001) and 0.0002, respectively [Figure 3.4 a, b]. 
Thus, it presents an interesting fact that the alleles of the respective SNP act in a 
differential manner in regulating DNA methylation. Finally, we examined the overlap in 
regulatory variation affecting both methylation and gene expression based on RNAseq 
data. 
The differentially methylated CpG site was identified to be negatively associated 
(r = -0.53) with the expression of MAP3K5 gene at p-value < 0.01 [Figure 3.5]. We also 
tested the association of these SNPs with the expression level of the gene. The variable 
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allele associated with each SNP regulated the quantitative expression of MAP3K5 gene at 
p-value of 0.028 and 0.012 for rs1570056 and rs11154883 SNP, respectively [Figure 3.6 
a, b]. The polymorphism associated with differential mRNA expression level is referred 
to as expression quantitative trait loci (eQTLs). In summary, our result clearly 
demonstrates that the genetic variants (SNPs) significantly overlay with both meQTLs 
and eQTLs.  
 
Figure 3.4 Breast cancer risk SNP rs1570056 and rs11154883 is associated with differential CpG 
Methylation. Cis-association between the SNPs (a) rs1570056 (b) rs11154883 regulates the 
methylation of CpG site cg18287222. These SNPs have loci as an intron-variant of MAP3K5 
gene. The box plots show the distribution of the methylation levels with respect to each genotype 
category with error bars representing the 25 and 75% quantiles. 
 
Figure 3.5 Spearman Correlation with respect to fold change in gene expression and DNA 
methylation in breast cancer. (a) DNA methylation residuals at loci cg18287222 is negatively 
associated (r = -0.53) with MAP3K5 expression in breast cancer patients at p-value < 0.01. The 
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regression line (red line) depicts the linear association between DNA methylation residuals and 
gene expression residuals.  
 
Figure 3.6 Fold changes in gene expression with respect to variable genotype associated with 
SNPs   was identified to be significant at p-value of 0.028 and 0.012, respectively. (a) Fold change 
in gene expression was evaluated in the presence of SNP rs1570056. Homozygous dominant 
allele “TT” causes comparatively more downregulation in gene expression in comparison to 
heterozygous (TC) and homozygous recessive (CC) allele. (b) Fold change in gene expression is 
evaluated in the presence of SNP rs11154883. Homozygous recessive allele AA causes results in 
more downregulation in comparison to heterozygous (GA) and homozygous dominant (GG) 
allele. 
3.3.2 Prognostic potential of differentially methylated CpG sites on 
survival of breast cancer patients 
Breast cancer has displayed an increasing incidence and more importantly, the steady 
mortality rate in a past decade. While the clinical screening has attributed to the enhanced 
survival of breast cancer patient, still improvised markers are required to assess accurately 
patient prognosis at the time of diagnosis. The disease heterogeneity, limited specificity 
and the clinicopathological variables are being used in prognostication and staging of 
breast cancer. Thus, the development of complementary biomarkers with more specific 
prognostic potential will allow assessing the risk of developing recurrent and/or 
metastatic disease. We report for the first time the association between the differentially 
methylated CpG site and overall survival of breast cancer patients. Univariate and 
multivariate Cox PH regression analysis have been implemented to establish the 
prognostic potential of differentially methylated CpG sites. Of the total 1820 meQTLs, 
489 differentially methylated CpGs were identified to be significantly associated with the 
survival of breast cancer patients in the training model. The prognostic potential of these 
differentially methylated CpGs were validated in test model of 164 patients. 
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 To test the association of risk in 164 breast cancer patients for overall survival, we 
first began our analysis using univariate Cox PH model. On evaluating 489 differentially 
methylated CpGs (training model) based upon the clinicopathological variables of vital 
status and last follow-up days, 18 covariates were found to be significantly associated 
with overall survival of breast cancer patients in the test model. The most significant 
association with overall survival were observed for cg04003327 on chromosome 2q37.3 
(HR= 0.01, p = 0.003), cg14033170 on chromosome 7p15.1 near CREB5 gene (HR = 
158.94, p = 0.004) and cg00902464 on chromosome 1p21.2 (HR = 0.02, p = 0.016) 
[Table 3.1]. The risk allele associated with CpG sites cg11340537, cg00956490, 
cg04586622, and cg14033170 have already been identified in GWAS phenotypes. The 
genotypic variation associated with SNP rs2640785 has been identified to regulate the 
differential methylation of CpG site cg11340537 located in the exonic region of the 
EXPH5 gene. The missense variation (GAG -> GTG) associated with this risk allele is of 
greater significance as it is conjointly associated with differential methylation, gene 
expression and survival of breast cancer patient. A similar explanation can be associated 
with synonymous risk variant rs940453 (ATA -> ATC) that regulates methylation of CpG 
site cg00956490 and simultaneously influences ZNF775 gene expression and overall 
survival. However, the risk allele rs2384061 is an intron variant that is associated with 
CpG site cg0458662 and regulates the expression of ADCY3 gene. The SNP rs2230576 
mapped to the 3̍-UTR variant is correlated with differential methylation of CpG site 
cg05370838 and gene expression of ADMA8 gene. The differentially methylated CpG site 
holds significance in regulating the overall survival of breast cancer patients (HR= 0.008, 
p = 0.049). 
Table 3.1. Univariate analysis of differentially methylated CpGs sites, and theit associations with 
the overall survival in test model:  HR: Hazard Ratio; CI: Confidence Interval for the hazard ratio 
CpG ID  SNP ID GENE HR 95% of CI P-value 
cg04003327 rs1054641 ESPNL; SCLY 0.011948 0.00076 – 0.18 0.0032 
cg14033170 rs177595 CREB5 158.9545 3.10816 – 8129.1 0.0038 
cg00902464 rs17403618 LOC100128787 0.023795 0.00178 -  0.32 0.0167 
cg03383184 rs6988652 Intergenic 52.99806 1.4918 -  1882.7 0.0170 
cg00101629 rs6660333 KIAA1026 0.050101 0.00378 -  0.667 0.0173 
cg03521812 rs4620521 Intergenic 0.023186 0.00107 -  0.498 0.0177 
cg17378966 rs2431663 DUSP1 13.45278 1.2033 -  150.39 0.0262 
cg08937612 rs12409375 VSIG8 0.003215 2.63E-05 -  0.39 0.0270 
cg26901096 rs17444979 LOC254312 13.55016 1.32054 -  139.1 0.0292 
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cg13558682 rs9424283 LRRC47 0.024577 0.001227 -  0.49 0.0366 
cg16774160 rs3088007 HSPA12B 0.000191 2.23E-07 – 0.16 0.0384 
cg06099459 rs10505956 C12orf77 0.002645 1.64E-05 – 0.426 0.0416 
cg05370838 rs2230576 ADAM8 0.008903 0.000201 – 0.395 0.0498 
cg11340537 rs2640785 EXPH5 0.031486 0.00135 -  0.733 0.0528 
cg00956490 rs940453 ZNF775 0.001156 3.58E-06 – 0.373 0.0645 
cg04586622 rs2384061 ADCY3 0.008966 0.000116 – 0.693 0.0648 
cg00889709 rs16923085 FAM110B 0.061646 0.00400 -  0.948 0.0652 
cg14798310 rs738806 SLC2A11 ,MIF  0.000387 2.06E-07 -  0.725 0.0793 
The univariate analysis was followed by the multivariate regression model to assess the 
risk associated with 18 co-variables obtained from the univariate study. This logistic 
regression analysis led to the identification 8 differentially methylated CpGs having a 
significant association with overall survival of the breast cancer patient [Table 3.2]. 
Among these, the most substantial findings were observed for cg04003327 (HR= 0.016; 
95% of CI = 0.0003-0.86; P = 0.04), cg11340537 (HR = 0.28; 95% of CI = 0.005-14.49; 
P = 0.05) and cg00956490 (HR = 0.0005; 95% of CI = 1.36 x 10
-7
-2.44; P = 0.08). These 
8 covariates showed the clear demarcation of the patient into high (84 patients) and low 
risk (84 patients), respectively at a significant p-value of 0.04 [Figure 3.7]. Beside these 
differentially methylated CpGs, the exclusive effects of SNPs were also evaluated for 
both direct and indirect effect on overall survival of breast cancer patients. In the next 
section of our study, we explain the variable allele distribution and its association with 
survival of breast cancer patients. 
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Figure 3.7: Kaplan-Meir plot associated with differnentially methylated CpGs sites. These 
differentially methylated sites could successfully classify 164 tumor patients (test set) into high 
(84 patients) and low risk (84 patients), respectively, at p-value = 0.041. 
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Table 3.2. Summary for univariate and multivariate analysis of differentially methylated CpGs and the associations with overall risk based upon Cox 
proportional hazard model in test dataset. HR: Hazard Ratio; CI: Confidence interval for the hazard ratio. 
SNP ID CpG ID Gene Locus Univariate 
HR            95% of CI      p 
Multivariate 
HR             95% of CI           p 
rs1054641 cg04003327 ESPNL; SCLY 2q37.3 0.012    (0.001-0.18)    0.003 0.016     (0.0003-0.86)       0.04 
rs2640785 cg11340537 EXPH5 11q22.3 0.031     (0.001-0.73)      0.05 0.28       (0.005-14.49)      0.05 
rs940453 cg00956490 ZNF775 7q36.1 0.001    (3.58E-06-0.37)  0.06 0.0005   (1.36E-07-2.44)   0.08 
rs2230576 cg05370838 ADAM8 10q26.3 0.0008   (0.002- 0.39)   0 .049 0.028     (0.0001-4.5)         0.17 
rs6660333 cg00101629 KIAA1026 1p36.21 0.05       (0.003-0.66)     0.17    0.88      (0.02-37.57)          0.95 
rs177595 cg14033170 CREB5 7p15.1 158.94   (3.1-8129.07)   0.003 213       (1.7-25740)        0.028 
rs4620521 cg03521812 Intergenic 1q31.2 0.02       (0.001-0.49)    0.018 0.04     (0.001-1.8)          0.098 
rs9424283 cg13558682 LRRC47 1p36.32 0.024     (0.001-0.49)     0.036 0.336    (0.001- 101.1)      0.71 
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3.3.3 Probing the association SNPs on the survival of breast cancer 
 patients 
Genetic variation characterized by single nucleotide polymorphism offers promising 
surrogate biomarker to predict therapeutic response and prognosis in breast cancer 
patients. In the present study, we investigated the risk associated with the individual SNP 
and in cumulative fashion on the overall survival. We developed a probabilistic 
framework for predicting and prioritizing the candidate SNPs in the training data set and 
validated across test set constituting 164 samples. The complete survival analysis was 
based upon the homozygous dominant and recessive allele and heterozygous allele 
distribution available for each SNP.  
 The univariate survival analysis associated with individual SNP was based upon 
the log-rank test at threshold p-value of 0.05. Of the total 7970 CpG-SNP pair, 492 SNPs 
were significantly associated with the overall survival in the training set of breast cancer 
patient. Each individual SNP were validated in the test model. Of the total significant 
SNPs in the training set, 23 were substantially associated with survival and their 
respective p-value ranged from ≤ 0.0001− ≤ 0.05 [Table 3.3]. These SNPs had a 
variable distribution across the genome. Of the total significant SNPs in the test set, 7 
SNPs (rs2880556, rs17006586, rs876701, rs41470747, rs2967798,rs11804125, 
rs1548373) were present as an intro variant, 6 SNPs (rs12085531,rs12653167, 
rs12591432, rs940482, rs1532272) were present in the intergenic region, 3 SNPs 
(rs16943263, rs9325443,1538146) were localised in the upstream region, each of 2 SNPs 
were associated with non-coding transcript variant (rs7117026, rs10101376) and 
synonymous variant (rs17142291, rs140679) and remaining one SNP  (rs1862372) was 
associated with 5'UTR variant. Moreover, the SNPs highlighted in the table are already 
mentioned in GWAS study in relevance to cancer and other diseases. 
 The Kaplan-Meir plot for the significant SNPs having nearly equal genotypic 
frequency is displayed in Figure 3.8. While the presence of heterozygous allele “GA” 
associated with SNP rs10101376 is detrimental, the homozygous dominant allele “CC” 
and “TT” concomitant with SNP rs140679 and rs1538146 affects the survival of the 
breast cancer patient at threshold p-value of 0.05. The homozygous dominant allele “TT” 
(rs1538146) is located in the upstream of the TRPC4 gene. The transient receptor 
potential cation channel (TRCP4) gene encodes a member of a canonical subfamily of 
transient receptor potential cation channels. This encoded protein forms a non-selective 
calcium-permeable cation channel that is activated by a Gq-coupled receptor and tyrosine 
kinase. The polymorphism  associated with TRCP4 gene is deleterious, as it is conjointly 
linked with gene expression and regulates the overall survival.Similarly, the allele CC 
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associated with SNP rs1538146 regulates the expression of gamma-aminobutyric acid 
(GABA)-A receptor gene and is detrimental to breast cancer patients.  
Table 3.3. Summary of SNPs associated with overall survival of breast cancer patients using         
log-rank in test dataset. AA: Reference allele, AB: Heterozygous allele, BB: Alternate allele.  
CpG_ID SNP_ID P-value GENE A B AA AB BB 
cg11929693 rs2880556 2.29E-24 LOC340073  G T 153 9 2 
cg09939673 rs7117026 2.55E-12 DQ592890   A T 1 10 153 
cg00067528 rs17006586 1.47E-05 ATP6V1B1  C T 140 21 3 
cg01711124 rs12085531 9.05E-05 Intergenic C T 4 24 136 
cg09573435 rs1862372 0.000594 SEMA6A  C T 111 43 10 
cg22675791 rs876701 0.000627 DGKZ  A G 6 36 122 
cg20705812 rs2286218 0.001795 DLGAP2  A G 143 16 5 
cg08980697 rs41470747 0.006462 RASGEF1B  C A 1 12 151 
cg14584565 rs16943263 0.006649 LOC283761  G C 152 8 4 
cg04513214 rs12653167 0.008100 Intergenic T G 162 1 1 
cg22422090 rs2967798 0.008121 KLHL3   T A 102 44 18 
cg24310780 rs11804125 0.008351 LMX1A  G T 122 30 12 
cg03339247 rs1548373 0.013806 ZFHX3  C T 106 38 20 
cg25203310 rs10101376 0.014656 LOC286083 G A 59 47 58 
cg20214734 rs17142291 0.016161 ASB13  G A 4 9 151 
cg15179472 rs12591432 0.018465 Intergenic C T 123 33 8 
cg15461663 rs940482 0.029081 Intergenic C T 99 53 12 
cg22514112 rs1532272 0.031189 Intergenic A G 94 52 18 
cg04966682 rs140679 0.033337 GABRG3  C T 57 67 40 
cg02576753 rs140679 0.033336 GABRG3 C T 57 67 40 
cg20896197 rs9325443 0.037904 KIF20B  A C 91 59 14 
cg24540569 rs574095 0.041499 Intergenic A G 3 26 135 
cg15398976 rs1538146 0.049488 TRPC4  G T 65 54 45 
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Figure 3.8 Kaplan-Meier survival plot for SNPs: (a) rs10101376 (b) rs140679 and (c) rs1538146. 
The survival analysis has been done such that the solid black line represents homozygous 
dominant, red dotted line: heterozygous allele and solid green line for homozygous recessive 
genotype. The findings are based upon test-dataset at threshold p-value of 0.05.  
  
 Beside the log-rank test, these 23 significant SNPs were also subjected to 
univariate Cox PH regression analysis. The most significant association in the univariate 
model for survival was observed for rs7117026 located on chromosome 11p11.2 (HR= 
0.109, p < 0.001) as non-coding transcript variant of DQ582890 gene, rs1548373 at 
chromosome 16q22.3 (HR = 2.35 and p = 0.0096) as an intron variant of  ZFHX3 gene, 
rs140679 on chromosome 15q12 (HR= 0.359, p = 0.016) as non-synonymous variant of 
GABRG3 gene, rs876701 on chromosome 11p11.2 (HR= 0.371, p = 0.038) as a intron 
variant of DGKZ gene and rs41470747 at chromosome 4q21.21 (HR = 0.357, p = 0.039) 
as an intron variant of RASGEF1B gene. Additionally borderline associated risk variants 
included rs574095, rs12653167, rs2286218 and rs1538145 at threshold of p = 0.1. 
Besides SNPs rs16943263 associated with CpG loci cg14584565 (HR = 2.44 and p = 
0.17) is also identified in classifying the patients in high and low risk [Table 3.4]. 
 Finally, we performed conjoint analysis by including 23 SNPs in order to assess 
the cumulative effect of the genetic variant on overall survival. We performed the 
multivariate Cox PH regression analysis between the SNPs and clinical variance 
constituting vital status and last follow-up days. Of the total 23 variables from the log-
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rank test study, 16 SNPs were identified to be significant (test model) in grouping the 
patent into high and low risk based upon the multivariate model at threshold p-value of 
0.05 [Figure 3.9a]. However, top 9 SNPs presents clear demarcation of patients into high 
and low risk at a p-value of 0.005 [Figure 3.9b]. The delineation was such that 84 patients 
(Test sample) survived for a longer duration while the remaining 84 were prone to poor 
prognosis and had survival probability for only 8
1/2
 years. Most of these genetic variants 
are germline and have shown significant association with overall survival. Thus, the Cox 
proportional model conjointly with clinicopathological features suggests the association 
between the genetic variants and the risk in the survival of breast cancer patients which 
may also modulate the cancer prognosis. 
 
 
Figure 3.9 Kaplan-Meir curve associated with (a) top 16 SNPs, (b) top 9 SNPs (listed table 3.4) 
could classify 164 tumor patients into high (84) and low risk (84 patients) at threshold of p < 0.05 
in the test dataset.
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Table 3.4.Summary of univariate and multivariate analysis of SNPs associations with overall risk based upon Cox proportional hazard model in test 
dataset. HR: Hazard Ratio; CI: Confidence interval for the hazard ratio. 
SNP ID CpG ID Gene Locus Univariate 
HR    95% of CI      p  
Multivariate 
HR    95% of CI        p  
rs1862372 cg09573435 SEMA6A 5q23.1 1.66    (0.66-4.15)    0.28 1.15     (0.2-6.3)          0.87 
rs2880556 cg11929693 LOC340073 5q31.3 2.23    (0.5-9.8)       0.29 59.7  (2.52-14.12)    0.011 
rs1548373 cg03339247 ZFHX3 16q22.3 2.35  (1.23-4.17)    0.0096 5.99 (1.84-19.49)   0.0029 
rs12591432 cg15179472 Intergenic 15q23   1.32  (0.48-3.6)    0.59 4.50   (0.67-30.21)      0.12 
rs12653167 cg04513214 Intergenic 5p15.1   2.96  (0.95-9.24)  0.062 4.85  (0.45-52.28)       0.19 
rs16943263 cg14584565 LOC283761 15q26.1    2.44  (0.68-8.6)   0.17 0.06    (0.0007-6.6)     0.25 
rs12085531 cg01711124 Intergenic 1p36.12 0.52   (0.20-1.3)      0.17 1.4     (0.44-4.87)        0.53 
rs1538145 cg15398976 TRPC4 13q13.3 0.558   (0.29-1.07)  0.081 0.58    (0.21-1.54)     0.28 
rs41470747 cg08980697 RASGEF1B 4q21.21 0.35    (0.13-0.94)    0.039 0.38   (0.047-3.07)     0.37 
rs140679 cg04966682 GABRG3 15q12  0.359   (0.15-0.82)  0.016 0.11   (0.018-0.7)      0.019 
rs17142291 cg20214734 ASB13 10p15.1  0.56     (0.15-2.0)     0.38 11.80  (0.47-291.84)  0.13 
rs11804125 cg24310780 LMX1A 1q23.3 1.12     (0.56-2.2)      0.75 1.38     (0.34-5.47)      0.64 
rs7117026 cg09939673 DQ5982890 11p11.2 0.109  (0.03-0.3) 3 .00 X 10-4 0.00198(0.00003-0.12)  0.0034 
rs876701 cg22675791 DGKZ 11p11.2 0.371   (0.14-0.94)   0.038 0.29    (0.07-1.27)   0.1 
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rs574095 cg24540569 Intergenic 1p31.3 0.445   (0.19-1.0)       0.058 0.25   (0.036-1.70)     0.16 
rs2286218 cg20705812 DLGAP2 8p23.3 2.76     (0.88-8.5)    0.08 0.97     (0.05- 19.20)    0.99 
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3.4 Discussions 
Molecular understanding of inter-tumor heterogeneity is key to effective cancer treatment 
and personalized medicine. Analysis of high-throughput molecular profiling data has 
revealed the extent of inter-tumour heterogeneity in breast cancer. The identification of 
diverse levels (sub-types) of tumor heterogeneity and the most-appropriate treatment 
strategies for each sub-type is expected to radically improve the treatment practices for 
the optimal clinical management of breast cancers [406]. 
 Genome-wide association, studies have led to the identification of a large number 
of genetic variants that confer susceptibility to different types of cancers. However, the 
risk conferred by individual variant is not sufficient to uphold the individual risk 
prediction. Assessing the genetic variability by incorporating multiple SNPs into a 
predictive model could achieve improved risk discrimination that may be useful for 
prognostic stratification of breast cancer patients [407, 408]. It is often a challenge to 
assess the functional impact of non-coding genetic variants, for example, the effect of 
SNPs transcriptional activity, and the associated disease risk. It is more likely that such 
variation may indirectly influence the epigenetic regulation located in a nearby position 
(cis) or distant loci (trans). 
 Here, we have investigated the relationship between genetic variation, DNA 
methylation and gene expression, and their potential utility as prognostic biomarkers of 
breast cancer. Numerous studies have discovered the association of genetic variants with 
variation in gene expression [409-411]. To our knowledge, this is the first study where we 
have investigated the relationship between methylation quantitative trait loci (meQTLs) 
and single nucleotide polymorphism (SNPs), and their combined effect on breast cancer 
prognosis. Questions still remain for the prognostic biomarkers identified for cancer. The 
first question is that there is little overlap among numerous prognostic signatures 
generated from different studies. Another question is that most signatures generated do 
not have clear biological meanings as why these prognostic genes may affect patient 
outcome, which lead to the clinical application of such signatures still under debate. In 
this study, we developed a novel method to identify prognostic gene signatures for breast 
cancer by integrating genomic and epigenomic data. This is based on the hypothesis that 
multiple sources of evidence pointing to the same gene or pathway are likely to lead to 
reduced false positives. We also apply random resampling to reduce overfiiting noise by 
dividing samples into training and test datasets. In the current analysis, TCGA breast 
invasive carcinoma (BRCA) overlapping dataset between DNA methylation, Affymetrix 
SNP array, and clinical samples were randomly divided into two subsets based on thevital 
status obtained from clinical data. The Caret module was implemented in the random 
classification of 3/4
th
 (486) of sample into training and 1/4
th
 (164) into test subset at R-
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interface. The predictive model was trained based on certain features mainly the beta 
values and genotype associated with methylation and SNP, respectively. The robustness 
of the features were evaluated statistically in the training subset and were validated in an 
exclusive and independent test subset. The significant association between methylation 
and genotype was calculated based on one-way ANOVA at threshold p-value of 0.05. 
Each SNP encoded for variable homozygous and heterozygous genotypic (allele) 
frequency across the breast cancer samples. Localization of each SNP was interrogated at 
50-bps upstream and downstream of each CpG site. Thus, for a window size of 50-bps we 
investigated CpG-SNP pairs to enlist their statistical significance such that minimum of 
one SNP is associated with one CpG loci. This evidence of a correlation between genetic 
variant at specific loci and DNA methylation led to the identification of meQTLs. Of the 
total distribution of 7970 CpG-SNP pair in the window size of 50-bps, 1820 SNPs were 
significantly associated with differential methylation in the predictive training model. Out 
of these 1820 CpG-SNP pairs, 489 SNP were significantly correlated with differential 
methylation leading to the identification of meQTLs in the test set. These CpG-SNP pairs 
enlighten on the plausible mechanism through which SNPs have an influence on the 
phenotype. In one of the scenario, presence of SNP in the vicinity of CpG loci prevents 
the binding of CpG methyl binding proteins as a consequence of which affects DNA 
methylation [412]. In another scenario, these SNPs may affect the transcriptional 
silencing via differential DNA methylation. Indeed, it has also been reported that DNA 
methylation plays a significant role in the regulation of splicing and aids in distinguishing 
exons from introns [413, 414]. Thus, genetic variant characterized by the presence of 
SNPs in the intronic region, causes differential methylation and leads to a different, set of 
spliceosome [415]. Interestingly, we have identified CpG loci (cg18287222) that constitute 
two SNPs (rs1570056, rs11154883) located in the intronic region and affects the function 
of MAP3K5 gene. These genotypic variation associated with these SNPs regulates the 
methylation pattern in contrary manner. While the homozygous dominant allele TT with 
respect to SNP rs1570056 is responsible for hypermethylation, the homozygous recessive 
allele AA associated with rs11154883 causes increase in methylation level for the same 
CpG loci. These differential distribution landmarks the presence of specific 
meQTL.Beside overlap with meQTL, these SNPs also leads to eQTLs in the cis-
regulatory region. Thus, the meQTLs have been identified to be enriched in eQTLs. 
Moreover, MAP3K5 (Mitogen-activated protein kinase (MAPK) is an essential 
component of MAP kinase signal transduction pathway and plays a crucial role in the 
apoptosis [416, 417]. Characterizing the genetic control of methylation and its association 
with the regulation of MAP3K5 gene expression presents signature marks that can resolve 
in understanding the underlying biology behind the complex phenotype in breast cancer.   
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 The differentially methylated CpG sites obtained from above study was further 
evaluated for their association with overall survival of breast cancer patients. The high 
mortality rate associated with metastasis in breast cancer urge for the development of 
more personalized prognostic algorithms that will complement the general, clinical 
predictors. We have systematically investigated the risk associated with host-related 
breast invasive carcinoma traits that may serve as a biomarker for disease prognosis. In 
this study, we have implemented model selection framework composed of linear 
statistical techniques of univariate analysis based on log-rank test and multivariate Cox 
proportional regression model. Of the total 1820 significant CpG-SNP pair, we identified 
a comprehensive panel of 489 differentially methylated CpGs to be associated with 
overall survival in the training set based upon the the univariate regression model. 
However, 18 differentially methylated CpGs were identified as the landmark risk loci for 
overall survival in the test set. The conjoint multivariate regression analysis of these 
differentially methylated CpG sites led to the identification of 8 differentially methylated 
CpGs as promising candidates having significant prognostic potential. These noteworthy 
biomarkers clearly demarcated 164 breast cancer patients of the test sample into high and 
low risk, respectively. The most interesting fact is that the SNPs (rs2640785, rs940453, 
and rs9424283) associated with the differentially methylated CpG sites (cg11340537, 
cg00956490, and cg04586622) have been already reported in GWAS phenotypes. We 
explored the potential mechanism by which differentially methylation CpG site 
cg11340537 directs overall survival in breast cancer patients. The missense variant (GAG 
-> GTG) associated with SNP rs2640785 dictates differential methylation of CpG site 
cg11340537 and mRNA expression of EXPH5 (Exophilin 5) gene. EXPH5 gene shares 
homology with Rab-GTPase and plays a significant role in vesicle trafficking [418, 419]. 
The active participation of this gene has been reported in colorectal cancer [420]. The 
differential methylation associated with the CpG site cg14033170 also holds greater 
significance. SNP rs177595, an intron variant located in the vicinity of CpG site 
cg14033170 regulates the differential methylation and subsequently deregulates CREB5 
gene expression. CREB5 gene encodes for cAMP responsive element binding protein 5. 
Previous studies have suggested that CREB5 gene play a fundamental role in a metastatic 
signal network in colorectal cancer [421]. Moreover, it has been reported that eQTL 
associated with CREB5 gene causes colorectal, prostate and nasopharyngeal cancer [422-
424]. On a similar account, differentially methylation associated with CpG cg00956490 
holds prognostic significance. The risk variant rs940453 linked to CpG loci regulates the 
mRNA expression of ZNF775 gene. The gene encodes for zinc finger protein 775 [425]. 
It has been identified to be involved in transcriptional regulation. SNP rs2230576 is a 3̍- 
UTR variant that has been mapped to the vicinity of differential methylated CpG site 
cg05370838 and ADAM metallopeptidase domain 8 (ADAM8) gene. The differentially 
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methylated CpG site is associated with high risk in breast cancer patients. ADMA8 gene 
localised in the vicinity of the CpG site encodes for membrane-anchored protein that have 
been implicated in several biological process including cell-cell interactions, cell-matrix 
interactions and neurogenesis [426]. It has been reported that ADMA8 is aberrantly 
expressed in breast tumours, especially in triple-negative breast cancer (TNBCs). The 
aberrant expression of ADAM8 gene has been correlated with poor prognosis in breast 
cancer patients and concomitantly with increased number of circulating tumour cells and 
metastasis [427]. The anomalous expression of the ADAM8 gene is also associated with 
poor survival in colorectal, lung, gastric, pancreatic cancer, hepatocellular, 
gastrointestinal carcinoma and gliomas [428-431].    
 Studies have been done so far correlate the conjoint effect of significant CpG-SNP 
pair regulating the differential methylation and overall survival of breast cancer patients. 
Recent studies have illustrated the upshot of genetic variants in regulating the overall risk 
associated with breast cancer patients. However, the cumulative effect is still to be 
disclosed. In the next section, we detailed about the prognostic potential of individual 
SNPs and their cumulative action. In our study, we have comprehensively analyzed the 
TCGA SNP array data mapped to methylated loci and concomitantly evaluated its 
association with the breast cancer survival. Of the total 7970 CpG-SNP pair, 492 SNPs 
were predicted to be significantly associated with overall survival in the training set. 
However, the univariate analysis based upon log-rank test mapped 23 SNPs to be 
significant across the test data set. Most of these SNPs have been highlighted in GWAS-
studies. In this study, we have mainly displayed Kaplan-Meir plot for the SNP having 
higher and nearly equal allelic distribution in breast cancer population. The heterozygous 
allele “GA” associated with SNP rs10101376 is detrimental and is related to poor 
prognosis. Similarly, the homozygous dominant allele “TT” linked to rs140679 SNP 
disrupts the mRNA expression of gamma-aminobutyric acid A receptor (GABRG3) 
[432], subsequently deteriorates survival probability in breast cancer patients. The 
homozygous genetic variant “TT” of SNP rs1538146 mapped to 1349 bps upstream of 
TRPC4 gene (transient receptor potential cation channel, subfamily C) reduces the overall 
survival and has a significant prognostic determinant. The canonical transient receptor 
potential (TRPC) channels are permeable to Ca
2+
 cationic channels and regulate Ca2+ 
influx in response to G protein-coupled receptor [433].  Overexpression of TRPC4 gene 
resulting in anomalous cell proliferation have been reported in the prostate, ovarian, lung 
cancer and renal cell carcinoma [434-437]. Our findings have demonstrated the potential 
importance of assessing prognosis in breast cancer based upon the univariate model of 
SNP distribution. Finally, we assembled these SNPs to construct logistic regression model 
and evaluated their cumulative effect on overall survival of breast cancer. Of the total 23 
SNPs, 18 SNPs had significant prognostic potential and could classify 164 breast cancer 
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patient into poor prognostic (high risk) and higher prognostic group (low risk). However, 
the conjoint effect of 9 SNPs holds more clear vision on demarcation.   
 In summary, the comprehensive assessment of CpG-SNP pairs has led to the 
identification of loci that holds the risk to the overall survival of breast cancer patients. 
The novel findings are highly promising and strongly support the identification of these 
loci in the clinical visualization of breast cancer progression. Such prognostic scans at the 
genome-wide level will likely be beneficial not only for identification of novel prognostic 
biomarkers, but also will open a new horizon to the novel pathways involved in breast 
cancer progression, directing to the potential targets for more efficient treatment 
strategies. 
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Chapter 4 
To identify novel inhibitor(s) targeting DNA 
methyltransferases for therapeutic intervention of 
breast cancer 
4.1 Introduction 
The intra-tumor heterogeneity in breast cancer characterized by extended molecular 
diversity poses an important impediment [438]. Fuelled by the Darwinian evolutionary 
dynamic governance of the disease, the selective pressure of targeted therapeutics in 
breast cancer inevitably leads to the emergence of resistance in the tumor cell [439].  
Interrogation of molecular mechanisms mediating high resistance rationally guides our 
choice to combinatorial therapeutics. The systemic efforts of interrogation based upon 
synergetic profiling of genetic and epigenetic aberration will provide guidance for 
rationally selecting therapeutic strategies [440]. In the studies done so far, we have 
already predicted the close association of genetic polymorphism and DNA methylation in 
diagnosis and prognosis of breast cancer. The presence of SNPs in the vicinity of CpG 
loci largely influences the distribution of methylation pattern. This differential 
methylation distribution is mainly associated with hypermethylation of tumor suppressor 
genes in breast cancer [129]. However, the reversal of this hypermethylation by small 
molecule or inhibitors may provide novel cancer therapeutic strategies [441].  
Cellular DNA methylation is established and maintained by the complex interplay 
of a family of dedicated enzymes called DNA methyltransferases (DNMTs). Along with 
regional hypermethylation and overall hypomethylation of the genome in many cancers, it 
has been reported that the expression and activity of DNMTs are very high [442]. This 
gives a clue that DNMTs may have oncogenic potential apart from its DNA methylation 
activity thus, it has emerged as a budding anticancer drug development target. Targeting 
inhibitors to the catalytic domain of DNMTs is essential for therapeutic interventions 
[443]. Currently, the available inhibitors of DNMTs are classified into two broad groups, 
known as nucleoside and non-nucleoside analogs. The archetypal nucleoside inhibitors 
are derivatives of the cytidine nucleoside, and they inhibit DNMT activity only after 
getting incorporated into newly synthesized DNA strands and trapping the DNMTs by 
forming DNA-protein adduct [21, 443].  
This chapter is based upon published research article [444].  
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Concomitantly, the cellular levels of DNMTs are rapidly depleted leading to DNA 
demethylation and continued DNA replication. The prototypical nucleoside inhibitor 5-
azacytidine (Vidaza) is an FDA-approved drug largely used in the treatment of cancer 
[445]. 5-azacytidine being a ribose nucleoside is chemically modified to a deoxyribose 
sugar to get incorporated into DNA [446].  
However, a portion of ribose sugar gets incorporated into RNA, affecting diverse 
RNA functions including ribosome biogenesis. 5-aza-2̍-deoxycytidine (i.e., decitabine), 
deoxyribose analog of 5-azacytidine was identified as new potent inhibitor as it directly 
gets incorporated into DNA [447, 448]. It was found to be effective against 
myelodysplastic syndrome, acute myelogenous leukemia, and chronic myelogenous 
leukemia. However, the substantial toxic effect of these nucleoside inhibitors offers 
limitation to their usage in higher dose against the treatment of cancer [449].  
Another class of inhibitor constituting the non-nucleoside group directly blocks 
DNA methyltransferase activity, and it does not possess the inherent toxic property as that 
of the nucleoside inhibitors. One of such DNMT inhibitor is (–)-epigallocatechin-3-
gallate (EGCG), a tea polyphenol. However, the degradation of EGCG produces a 
substantial amount of hydrogen peroxide. H2O2 being strong oxidizing agent causes 
oxidation of DNA methyltransferases and other associated protein [450]. Other group of 
phytochemicals which belong to the category of non-nucleoside inhibitors in the 
treatment of cancer are: mahanine, a carbazole alkaloid [451]; and curcumin, a 
component of the Indian spice turmeric [452]. Many others are effective against non-
cancerous diseases. Some of them are hydralazine, antihypertensive drug [453]; procaine, 
local anesthetic [454] and procainamide, an antiarrhythmic drug [455]. SAH, the end 
product of DNA methylation reaction, and its analogs apparently have also been reported 
as selective inhibitors towards inhibition of DNA methylation [456, 457]. However, these 
inhibitors have some limitations in lieu of their specificity in inhibiting DNMTs.  
In this investigation, we report for the first time a detail view of the elementary 
interactions between non-nucleoside inhibitors and DNMTs in the active site terminal and 
thus, find out the best inhibitors. To explore the interactions between the enlisted non-
nucleoside inhibitors and DNMTs, we performed docking and simulation studies [Figure 
4.1]. Application of docking based on varying algorithms affirms the binding pattern and 
profile of a ligand. The relative binding site for all the compounds/inhibitors is chosen at 
the SAH-binding pocket of DNMT1 and DNMT3A/and of human and mouse. Molecular 
dynamics (MD) simulations analysis of the potential complexes from docking gives the 
final clue about the stability of the DNMT-inhibitor complexes. The dynamic picture of 
the complexes is determined using the time-dependent evolution of the system during the 
simulation.  
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Changes in free energies for binding (-ΔG) were determined and total energy was 
decomposed on the basis of per residue contribution. The non-covalent interactions 
constituting hydrogen bonding, van-der-Waals, and electrostatic occupancies were 
monitored throughout the docking and simulations. Moreover, the efficacy of the best-
found inhibitor is tested by in-vitro studies in invasive breast cancer cell line, MDA-MB-
231.  
 
Figure 4.1 chemical structures of non-nucleoside inhibitors against DNMTs known till date 
4.2 Materials and Methods 
4.2.1 In-silico dataset preparation, molecular docking and simulation 
studies 
4.2.1.1 Preparation of protein structure and ligand 
The X-ray crystallographic structures of human DNMT1 (PDB id: 3PTA) [458] and 
DNMT3a (PDB id: 2QRV) [459] co-crystallized with SAH at resolutions of 3.6 Å and 
2.89 Å, respectively, were retrieved from RCSB Protein Data Bank [460]. Subsequently 
the structure of mouse DNMT1 of 3.25Å (PDB: 3AV5) [461] co-crystallized with DNA 
and SAH was obtained from protein data bank. Mouse DNMT1 was used for the in-silico 
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study because it is used as an experimental model for the in-vivo study. The heteroatoms 
including SAH and zinc ion other than those present in the active site were edited using 
chimera software. The double-stranded DNA attached to human and mouse DNMT1 were 
also clipped off. The energy minimization of protein structures was done using steepest 
descent and conjugate gradient algorithm of 100 steps and step size of 0.02Å. It followed 
the addition of polar hydrogen and Gasteiger charges. The set of non-nucleoside 
inhibitors as described in Figure 4.1 was retrieved from PubChem 
(http://pubchem.ncbi.nlm.nih.gov/) and ChEBI database [462] (www.ebi.ac.uk/chebi). 
The ligand preparation was done using “Prepare ligands” protocol at Discovery Studio 
2.5. The preparation of ligand involved removal of duplicate structure, generation of the 
tautomer, isomers, Lipinski filter, change of ionization state and generating 3D structure.   
4.2.1.2 Multiple sequence alignment of DNMTs nucleotide sequence 
Multiple sequence alignments were carried out for DNMT3A/a DNMT3B/b amino acid 
sequences of human and mouse to determine the conserved amino sequence of the active 
site residues. Amino acid sequences of UniProt accession number Q9Y6K1, Q9UBC3, 
O88508, and O88509 were retrieved from Uniprot database [463] located 
at (http://www.uniprot.org/). The sequence were aligned with a window interface of 
CLUSTALW [464]. The BLOSUM62 substitution matrix [465] was used, with a gap start 
penalty of 10 and a gap extend penalty of 0.2.  
4.2.1.3 Docking protocols 
In order to generalize the ligand and protein conformation on binding accuracy, variable 
docking algorithms were employed. Each algorithm constitutes an alternative way of 
scoring and treating ligand flexibility keeping protein structure in a rigid state in order to 
reduce conformation search space. The various algorithms used for handling ligand 
flexibility constituted “Lamarckian Genetic Algorithm (LGA) (Autodock) [466] , monte-
Carlo conformational search (LigandFit) [467], descriptor matching (Glide_XP) [468] 
and molecular dynamics simulated annealing (CDOCKER) [469]. 
 Autodock 
AutoDock 3.05 is freely available software availed from Scripps Research 
Institute. Here, the inhibitors are treated as flexible ligands by modifying their rotatable 
torsions while the protein template is considered to be a rigid receptor. The minimised 
protein structures 3PTA, 2QRV and 3AV5 were used as target structures. Grid maps were 
prepared using auto grid to fix the active site of protein having specific co-ordinates and 
dimension of 40 × 40 × 40 and a resolution of 0.375 Å. Docking parameters were set as: 
number of individuals in the population (set to 150), maximum number of energy 
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evaluations (set to 2500000), maximum number of generations (set to 27000), and 
number of hybrid GA-LS runs (set to 100). 
 Glide_XP 
The protein structure was prepared using the protein preparation module of 
Schrödinger software. The co-crystallized water molecules were removed. All the 
selected ligands were assigned an appropriate bond order using the LigPrep 2.4.107 script 
and converted to .mae format (Maestro, Schrödinger, Inc.) and optimization was carried 
out by means of the OPLS_2005 force field. The Protein ligand docking studies were 
performed using Maestro 9.1.107. Parameters having default values were selected and 
docking was carried out using Glide Extra Precision (XP Glide), version 4.5.19. After the 
complete preparation of protein and ligand for docking, receptor-grid files were 
generated. Here van-der Waal radii were scaled of receptor atoms by 1Å with partial 
atomic charge of 0.25 for running the grid generation module.  
 CDOCKER 
CDOCKER is an in-house docking protocol of “Accelyrs Discovery studio”. For 
initial stage MD a softcore potential is used. Each of the structures from the MD run are 
then located and fully minimized. The solutions are then clustered according to position 
and conformation and ranked by energy. CHARMm charges are used for the protein 
structure, i.e., the param19/toph19 parameter set38 using only polar hydrogens. 
CDOCKER only allows for flexible ligand treatment. Here the docking model constitutes 
receptor in its rigid state and static protein conformation of biding site is described using 
1.0 Å grid and for every point grid, interaction energies of 20 types of probe atoms are 
calculated. The three dimensional grid is calculated such that radius of 8Å extend in all 
directions from any atom in the ligand. Subsequent to simulated annealing conformational 
search of the flexible ligand, the grid is removed minimization of all atoms of protein-
ligand is performed by fixing the coordinates of the protein using the standard all atom 
potential function with a distance dependent dielectric (RDIE). This interaction energy is 
taken as the score for the final ligand pose.  
 LigandFit 
LigandFit is another docking programme of Accelyrs Discovery Studio. It is based 
on protein minimization using steepest descent (gradient <0.1) and conjugate gradient 
algorithms (gradient <0.01) of CHARMm force field. The active site determination 
includes within 10Å radius from the centre of the bound ligand. Docking was performed 
with monte-carlo simulations using the CFF95 force field. The grid resolution was set to 
0.5Å (default), and the ligand accessible grid was defined such that the minimum distance 
between a grid point and the protein is 2.0Å for hydrogen and 2.5Å for heavy atoms. The 
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grid extends from the defined active site to a distance of 5Å in all directions. The top 10 
conformations were saved after rigid body minimizations of 1,000 steps. The scoring was 
performed using set of scoring functions (including Dock_score, -PMF, -PLP1 and –
PLP2) implemented in LigandFit module. The combination of consensus scoring 
functions was employed to obtain the most preferable output conformation. 
4.2.1.4 Molecular dynamics simulation analysis 
The molecular dynamics of the protein–inhibitor complex provides understanding to the 
flexibility associated with ligand conformational change and thus provides an insight into 
the molecular basis for the inhibition. All of the simulations were carried out using the 
GROMACS 4.5.5 package with an identical protocol [470]. The best orientation obtained 
out of docking of protein-ligand complex was used for simulation. We performed the 
simulation for ligands SAH, EGCG and procyanidin B2 and their respective binding with 
human DNMT1, DNMT3a and mouse DNMT1. Here we separated the ligands from 
protein in order to prepare protein and ligand topology file separately. We used the 
GROMOS96 43a1 force field to generate topology file for protein. The ligand topology 
file was generated using PRODRG server employing GROMOS96.1 force field [471]. 
The protein was solvated in a dodecahedron box with edges 1 nm in length using the 
explicit solvent–simple point charge model (SPC216 water molecules), which generated 
the water box. The next step followed the 5000 steps of steepest descent minimization and 
position restrained dynamics to distribute water molecule throughout in 100 ps. The 
simulation was carried out at 300 k of constant temperature and pressure of 5000 steps for 
100 ps using Nose–Hoover method (nvt) and the Parrinello–Rahman method respectively. 
Once the system was equilibrated with desired temperature and pressure, the final step 
was to release the position restraints and run production of 500000 steps for 1000ps for 
data collection.  
4.2.1.4 Evaluation of free binding energy by MM-PBSA method 
Free energy of binding was calculated using the molecular mechanics-Poisson-Boltzmann 
surface area (MM-PBSA) method implemented in Amber12 [472]. For each complex, a 
total number of 40 snapshots were taken from an interval of 50 ps from the final 5000 ps 
of the MD simulation. The MM-PBSA method and nmode module of Amber 12 were 
implemented to calculate the binding free energy of the inhibitor and the detail is 
summarized as: 
                                          ΔGb = ΔEMM + ΔGsol – TΔS,              (1) 
where, ΔGb is the binding free energy in solution consisting of the molecular mechanics 
free energy (ΔEMM) and the conformational entropy effect to binding (−TΔS) in the gas 
phase, and the solvation free energy (ΔGsol). ΔEMM was evaluated as:  
                                             ΔEMM = ΔEvdw+ ΔEele,                (2) 
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where, ΔEvdw and ΔEelestand for van der Waals and electrostatic interactions in the gas 
phase, respectively. The solvation free energy (ΔGsol) was calculated in two steps:  
                                             ΔGsol = ΔGpol + ΔGnonpol                                                (3) 
where, ΔGpol and ΔGnonpol are polar and nonpolar components of the salvation free energy, 
respectively. The ΔGsol was calculated with the PBSA module of Amber 12 suite. The 
nonpolar contribution of the solvation free energy is calculated as a function of the 
solvent-accessible surface area (SAS), as follows: 
                                             ΔGnonpol = γ (SAS) + β,                (4) 
where, the values of empirical constants γ and β were set to 0.00542 kcal, (molÅ2) and 
0.92 kcal, mol, respectively. The contributions of entropy (TΔS) to binding free energy 
can be evaluated as the sum of change in the translational, rotational, and vibrational 
degrees of freedom, as follows: 
                             ΔS = ΔStranslational + ΔSrotational + ΔSvibrational                        (5) 
TΔS was calculated using classical statistical thermodynamics and normal-mode analysis. 
4.2.1.5 Residue-inhibitor interaction decomposition  
The interaction between inhibitors and each residue of hDNMT1, DNMT3A, and 
mDNMT1 was calculated using molecular mechanics of Generalized Born Surface Area 
(MM-GBSA) decomposition process module of Amber 12 [473, 474]. The binding 
interaction of each inhibitor-residue pair was evaluated in terms of electrostatic (ΔEele) 
contribution, van der Waals (ΔEvdw) contribution in the gas phase, polar solvation (ΔGpol) 
and nonpolar solvation (ΔGnopol) contributions. 
           ΔG inhibitor-residue=ΔEele+ΔEvdw+ΔGpol+ΔGnopol    (6) 
The polar contribution (ΔGpol) to solvation energy was calculated by using the 
GB (Generalized Born) module.  
4.2.2 In-vitro analysis of gene expression, DNMT activity, and toxicity 
4.2.2.1 Reagents 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT), dimethylsulfoxide (DMSO),  
epigallocathechin-3-gallate (EGCG), procyanidin B2-3, 3'-di-O-gallate (procyanidin B2), 
S-Adenosyl-L-homocysteine (SAH)  and trypsin were purchased from Sigma-Aldrich (St 
Louis, MO, USA). Dulbecco’s modified Eagle medium (DMEM), Fetal bovine serum   
(FBS) (sterile-filtered, South American origin) were purchased from Invitrogen 
(Carlsbad, CA, USA).  
4.2.2.2  Cell culture 
Human invasive breast cancer cell line MDA-MB-231 and the immortalized human 
keratinocyte cells HaCaT were obtained from National Centre for Cell Science, Pune. 
MDA-MB-231 and HaCaT cells were maintained in DMEM supplemented with 10% 
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FBS and 100 U Penicillin and 0.1 mg Streptomycin at 37 °C in a humidified incubator 
(5% CO2). 
4.2.2.3 DNMT inhibition assay  
Cultured MDA-MB 231 cells were harvested to prepare nuclear extract according to 
standard protocol [475]. After quantification of protein by Bradford method, nuclear 
extract having 7.5 µg of protein was used to measure total DNMT activity using the 
EpiQuik DNA Methyltransferase Activity Assay Kit (Epigentek, Inc.) according to the 
manufacturer’s protocol. As per protocol, the nuclear extracts were added to the pre-
coated substrate and then AdoMet was added followed by inhibitors (EGCG and 
procyanidin B2) at varying concentrations and incubated for 2 h at 37°C. The above 
incubated nuclear extracts were exposed to capture antibody against 5-methyl cytosine for 
1 h and the detection antibody for 30 min at room temperature. Finally, developer 
solution was added, and absorbance was recorded using microplate reader 
spectrophotometer (Perkin-Elmer, Waltham, MA, USA) at 450 nm with an optional 
reference wavelength of 655 nm. The assay was conducted to identify the IC50 for the 
inhibitors against DNMT activity. The log dose response curve was plotted, and IC50 was 
calculated using the following equation.  
𝑦 = 𝐴1+
𝐴2−𝐴1
1+10(𝐿𝑂𝐺𝑥0−𝑥)𝑝
 
                   IC50 = 10
𝐿𝑂𝐺𝑥0 
Here A1 and A2 are bottom and top asymptote, p is the hill slope, and LOGx0 is the 
center of the curve. The graph for log dose response was plotted using GraphPad Prism 
software. 
4.2.2.4 Quantitative reverse transcription PCR (qRT-PCR) of DNMT target genes 
MDA-MB-231 cells were treated with EGCG and procyanidin B2 for 24 h at their 
respective sub-lethal concentration. Total cellular RNA was isolated with Tri Reagent 
(Sigma) according to the manufacturer’s instructions. Reverse transcriptase reactions 
were performed using Revert-Aid First Strand cDNA Synthesis Kit (Thermo Scientific) 
with 1 μg of RNA.  qRT-PCR was performed using SYBR® Green JumpStart™ Taq 
Readymix in the Realplex4Eppendorf system. The primer sequences of DNMT target and 
the three DNMT genes are enlisted in Table 4.1. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) gene was used as an internal control.  
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Table 4.1 Primer sequences of DNMT target and DNMT genes. 
Gene name Primers sequence 
Amplicon 
size (bp) 
E-cadherin F 5’-CGAGAGCTACACGTTCACGG-3’ 
R 5’-GGGTGTCGAGGGAAAAATAGG-3’ 
119 
Maspin F 5’-GGAATGTCAGAGACCAAGGGA-3’ 
R 5’-GGTCAGCATTCAATTCATCCCTT-3’ 
139 
BRCA1 F 5’-ACAGCTGTGTGGTGCTTCTGTG-3’ 
R 5’-CATTGTCCTCTGTCCAGGCATC-3’ 
107 
DNMT1 
 
F 5′-GGCTGAGATGAGGCAAAAAG-3′ 
R 5′-ACCAACTCGGTACAGGATGC-3′ 
112 
DNMT3A 
 
F  5′-TATTGATGAGCGCACAAGAGAGC-3′ 
R 5′-GGGTGTTCCAGGGTAACATTGAG-3′ 
111 
DNMT3B F 5′-AATGTGAATCCAGCCAGGAAAGGC-3′ 
R  5′-ACTGGATTACACTCCAGGAACCGT-3′ 
191 
GAPDH F 5′-GGAGCGAGATCCCTCCAAAAT-3′ 
R 5′-GGCTGTTGTCATACTTCTCATGG-3′ 
197 
4.2.2.5 Evaluation of cytotoxicity of SAH, EGCG and procyanidin B2 
The cytotoxicity of SAH, EGCG and procyanidin B2 was evaluated in both MDA-MB-
231 and HaCaT cells by colorimetric MTT assay. In brief, the cells in the logarithmic 
phase were plated in 96-well flat-bottom culture plates at a density of 4000 cells/well and 
treated with SAH, EGCG and procyanidin B2 at six different concentrations for 24 h. The 
cytotoxic effect of SAH, EGCG and procyanidin B2 was determined by measuring the 
absorbance intensity of formed formazan solution at 595 nm by using microplate reader 
spectrophotometer (Perkin-Elmer, Waltham, MA, USA).  Water in case of SAH and 
DMSO (0.01%) in case of EGCG and procyanidin B2 was used in the control treatment. 
All the experiments were done in triplicate, and the cell viability was determined by 
percentage at varying concentration of drugs. 
4.2.2.6 Statistical analysis 
The statistical significance of the above result was analyzed using Student’s t-test by 
SPSS software. Data are expressed as a mean ± standard deviation. The significant 
difference in IC50, LC50 and gene expression between two groups (EGCG and procyanidin 
B2 treatment) was computed using one-way ANOVA, and the p-value was evaluated at 
the threshold of 0.05. 
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4.3 Results 
Till date, many non-nucleoside inhibitors of DNMTs have been identified. We have 
enlisted some of them through a literature survey and taken into consideration for this 
study [Figure 4.1]. Several experimental analyzes depict the interaction of specific non-
nucleoside inhibitor of the target DNMT enzyme; however, the comparative analysis of 
the known non-nucleoside inhibitors was not done prior to our present work. We 
investigated to identify which among these inhibitors is best in inhibiting DNMTs 
activity, including both DNMT1 and DNMT3a. Our results obtained byanalyzing the 
existing inhibitors and their analogsare supporting procyanidin B2, a novel phytochemical 
to be the best effective in reducing DNMT activity. The efficiency of ligands has been 
analyzed by in-silico and in-vitro experiments. In-silico analyzes involve the ligand 
interaction with DNMTs at both static and dynamic conditions. The in-vitro study 
includes cell viability assay, relative gene expression study on the application of different 
drugs of varying concentration and identification of drug concentration at which it 
reduces DNMT activity to 50%. A detailed report is presented below. 
4.3.1 Comparison of active site loop of DNMT3A/a and DNMT3B/b 
Figure 4.2a shows the sequence alignment of the catalytic domain of human DNMT3A, 
DNMT3B and mouse DNMT3a, and DNMT3b. It is apparent that the catalytic domains 
superimpose well due to their high sequence similarity. The active-site loop of human 
DNMT3A (2QRV) (residues 708–729) superimposes well with the mouse DNMT3a 
(residues 704-725). These DNMT3A/a active site residues also depict significant 
overlapping with human DNMT3B (residues 649-670) and mouse DNMT3b (residues 
655-976) with an exception of amino acid Ile (isoleucine) residue substituted by Asn 
(aspargine) (marked yellow). The key amino acid residues for the catalysis and cofactor 
binding are found to be conserved. Thus, it may be assumed that the inhibitors will have a 
similar effect on both DNMT3A/a and DNMT3B/b. So, for our further studies we have 
focused on the detailed analysis of the interaction of non-nucleoside inhibitors on 
hDNMT1 (3PTA), mDNMT1 (3AV5) and DNMT3A (2QRV). The non-nucleoside 
inhibitors were docked at the SAH-binding pocket present in the active site of 3PTA, 
2QRV and 3AV5 [Figure 4.2, b-d]. 
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Figure 4.2 (a) Depiction of conserved active site regions of DNMT3A/a and DNMT3B/b in 
human and mouse. The numberingof the sequences corresponds to the mouse orthologs. Grey 
highlighted regions were conserved sites along DNMT3a and DNMT3b while red highlighted 
regions depict amino acid Cysteine (C), a nucleophilic group. Positions highlighted in yellow 
exhibit unconserved residues and pink highlighted regions exhibit common interacting regions 
between DNMT3A/a-DNMT3L and DNMT3B/b-DNMT3L. Neighbour sites of the active site 
with differences in amino acids are marked as green. Binding of SAH to active site of pocket of 
(b) hDNMT1 (3PTA), (c) DNMT3A (2QRV), (d) mouse DNMT1 (3AV5) as obtained by 
modelling using Maestro 9.1.107 of Schrodinger. 
4.3.2 Interactions of DNMTs with non-nucleoside inhibitors 
The enlisted non-nucleoside inhibitors in Figure 4.1 constituting both synthetic 
(hydralazine, RG108, procaine, procainamide) and natural compounds (curcumin, EGCG, 
parthenolide, mahanine) are identified to inhibit DNMT activity through different 
mechanisms. The binding affinity of non-nucleoside phytochemicals were analyzed with 
respect to synthetic inhibitors. These inhibitors were docked at SAH-binding pocket of 
DNMTs, and their binding affinity was analyzed by different algorithms of glide_XP, 
autodock, cdocker and LigandFit [Figure 4.3].  
 Among all non-nucleoside inhibitors, EGCG binds with the highest efficacy 
exhibiting glide score of -10.56, -10.13 and -11.0 kcal/mol, when bound to catalytic 
domain of 3PTA, 2QRV and 3AV5, respectively [Figure 4.3 a]. However, curcumin binds 
only to 3PTA showing glide score of -10.52 kcal/mol. The binding energy analysis was 
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further confirmed with other algorithms [Figure 4.3 b-d]. The more negative binding 
energy (ΔG) reflects the stability of a complex and is a consequence of non-covalent 
interactions, mainly hydrogen bonding, van der Waals and electrostatic forces by the 
residues of the binding pocket. EGCG interacts with 3PTA via 5 hydrogen bonds. Six 
hydrogen bonds are formed on an interaction with 2QRV and 3AV5 active site residues, 
respectively. The binding residues and hydrogen bond donor and acceptor groups and 
their respective bond length have been depicted in Figure 4.4 (a-c).  
 Thus, among the enlisted non-nucleoside inhibitors, EGCG have been identified 
as the most potent inhibitor to diminish DNMTs activity. Thereafter, we examined a 
novel set of other phytochemicals which would be better than EGCG to reduce DNA 
methylation density and cellular toxicity. 
4.3.3  Interaction of DNMTs with novel set of phytochemicals/compounds 
In quest of identification of novel inhibitors, thirty-two EGCG analogs were retrieved 
from PubChem database (http://pubchem.ncbi.nlm.nih.gov/). It mainly constituted the 
polyphenolic groups of phytochemicals. Some of them are eryvarinol A, mangiferin, 
isomagniferin, 3, 4'- 5-trihydroxystilbene, theaflavin-di-gallate, procyanidin B2-3, 3'-di-
O-gallate and others. Extensive chemoinformatic analyzes of these compounds were done 
to expand the medicinally relevant chemical space. Compounds selected were docked into 
the active site pocket of the crystallographic structure of DNMTs using Glide_XP 
protocol. According to the Glide score, procyanidin B2-3,3̍-di-O-gallate (Prc) ranked, 
first of all, the analogs, indicating that it may possess higher inhibition potential against 
DNMTs. The score obtained was as high as -13.95, -11.53 and -14.9 kcal/mol when 
docked to 3PTA, 2QRV, and 3AV5, respectively. The comparative analysis of binding 
energy, hydrogen bond donor-acceptor groups and the bond length for SAH, EGCG and 
procyanidin B2 with respective DNMTs is depicted in Table 4.2. The binding energy of 
procyanidin B2 was comparatively higher than EGCG and SAH. The increased binding 
energy is characterized by increased non-covalent interactions, mainly, involving 
hydrogen bonding, van der Waals, and electrostatic forces. Procyanidin B2 on an 
interaction with 3PTA exhibit -7.54, -6.25 and -1.85 kcal/mol of hydrogen bonding, 
hydrophobic and electrostatic interactions, respectively. Similarly, the respective non-
covalent interactions are identified to be -5.73, -3.59 and -1.65 kcal/mol on interaction 
with 2QRV, while -8.04, -5.42 and -1.37 kcal/mol with 3AV5. 
 The detailed binding residues of procyanidin B2 with DNMTs (3PTA, 2QRV and 
3AV5), hydrogen bond donor and acceptor groups, their respective bond lengths and pi 
(π)-cation interactions have been depicted in Figure 4.5 (a-c). The principle pi (π)-cation 
interaction is identified between the phenolic ring of procyanidin B2 and NH1, NH2 
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group at R1312 of 3PTA. Similarly, it also forms pi (π)-cation interaction with NH1 and 
NH2 group at R684 and R887 of 2QRV.  
Finally, DNMT-inhibitor (SAH, EGCG, and procyanidin B2) complexes 
exhibiting higher binding score were selected and subjected to molecular dynamics 
simulations in explicit aqueous solution.  
 
Figure 4.3 Docking of non-nucleoside inhibitors with 3PTA (blue), 2QRV (orange) and 3AV5 
(green) with (a) Glide_XP, (b) Autodock, (c) CDOCKER and (d) LigandFit. The binding energy 
was determined in terms of kcal/mol. Among all known non-nucleoside inhibitors, EGCG was 
identified to have higher binding energy at SAH-binding pocket of DNMT. 
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Figure 4.4: Depiction of the interaction of EGCG with (a) 3PTA, (b) 2QRV and (c) 3AV5 via 
hydrogen bonds of specific length. The hydrogen bonds and their respective bond lengths in Å 
have been shown. The π-cation interactions have been displayed by a solid orange line. The figure 
is produced by Accelrys discovery studio. 
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Figure 4.5 Depiction of interaction of Procyanidin B2 with (a) 3PTA), (b) 2QRV, (c) 3AV5 via 
hydrogen bonds defining specific length. The hydrogen bonds and their respective bond lengths in 
Å have been shown. The π-cation interactions have been shown by a solid orange line. The figure 
is produced by Accelrys discovery studio. 
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Table 4.2. Detailed study of interaction of SAH, EGCG and Procyanidin B2 with DNMTs 
Protein (PDB) Ligand Glide Score 
(kcal/mol) 
 
Residues at binding 
site 
H-bond donor-acceptor 
groups 
H-bond 
distance 
(Å) 
Human_DNMT1 
(3PTA) 
SAH 
 
 
 
 
 
 
 
EGCG 
 
 
 
 
 
 
 
 
Procyanidin 
B2 
(Prc) 
-9.44 
 
 
 
 
 
 
 
-10.56 
 
 
 
 
 
 
 
 
-13.95 
G1223,S1146,G1222, 
L1151,E1266,G1147, 
E1168,M1169,I1167 
D1190,E1189,C1191, 
P1225,F1145 
 
 
 
E1168,L1247,C1191,M
1169,D1190,T1170,Q1
227,M696,P1225, 
E698,F1145,G1147, 
L1247,R650,E1168, 
T1170,F1146,V1144, 
I1167,M1169,C1191, 
D1190,L1247, 
 
P1225,M696,Q1227 
E698,A699,P1224, 
T1528,N1578,G1223,D
700,V1268,E1266, 
G1577,R1310,D701, 
R1312, G1147 
L1151:H->SAH: O 
E1168: HE2->SAH:O3 
E1168: HE2->SAH:O2 
C1191: H->SAH:N1 
SAH: HN3->E1266:OE1 
SAH: HN3>E1266:OE2 
SAH: HN1>D1190:OD2 
 
C1191: H->EGCG:O7 
Q1227: HE22>EGCG:O3 
EGCG: H6->M696:SD 
EGCG: H14>D1190:OD2 
EGCG: H16->F1145:O 
 
 
 
 
E1168:HE2->Prc:O5 
C1191:H->Prc:O11 
R1310:HH22->Prc:O11 
T1528:HG1->Prc:O14 
Prc:H16->E698:OE1 
Prc:H23->D1190:OD2 
Prc:H31->G1577:O 
1.8 
2.1 
2.1 
2.3 
1.9 
2.1 
1.8 
 
1.9 
2 
2.4 
2.3 
2.1 
 
 
 
 
2.9 
1.9 
2.2 
2.2 
2.1 
2.2 
1.7 
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Prc:H32->D701:OD1 
Prc:H33->D701:OD1 
1.8 
1.6 
Human 
DNMT3a(2QRV) 
SAH 
 
 
 
 
 
 
EGCG 
 
 
 
 
 
 
 
Procyanidin 
B2 
(Prc) 
-9.69 
 
 
 
 
 
 
-10.13 
 
 
 
 
 
 
 
-11.53 
E660,F636,D637, 
W889, T641, S888, 
S659, R887, P705, 
V683, D682,V661, 
L726 
 
 
E660,S665,G638, 
R887,L884,G703,  
E752,F636,P705, 
V683,L726,S704, V661 
 
 
 
 
N707,P705,V683, 
V661,S659,F636, 
G681,R887, R684, 
D682,R883,G722, 
L726,T723 
T641:HG1->SAH:OXT 
V863:H->SAH:N1 
W889:H->SAH:OXT 
SAH:HO->E660:OE1 
SAH:H1->E660:OE2 
SAH:H3->D682:OD1 
 
S665:HG->EGCG:O8 
R887:HH22>EGCG:O8 
EGCG:H5->E752:OE1 
EGCG:H5->E660:OE2 
EGCG: H13->L884:O 
EGCG:H15->E660:OE1 
V683:H>Prcd:O20 
 
N707:HD22->Prc:O12 
N707:HD22>Prc:O14 
R887:HH21->Prc:O7 
Prc:H23->D682:OD1 
Prc:H30->G722:O 
Prc:H31->G722:O 
Prc:H33->S659:OG 
Prc:H34->D682:OD2 
2A 
2.4 
1.9 
2A 
2.1 
2.4 
 
2.1 
2.1 
2 
2.2 
2 
2.2 
1.8 
 
2.1 
2.1 
2.3 
1.7 
2.3 
2.4 
2.3 
2.2 
Mouse_DNMT1 
(3AV5) 
SAH 
 
 
-10.35 
 
 
E1171,N1580,G1225,G
1150,F1148,S1149,A15
81,D1146,V1582,L115
G1152:H->SAH:O 
G1153:H->SAH:O 
L1154:H->SAH:OXT 
2.1 
2 
2.1 
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EGCG 
 
 
 
 
 
 
Procyanidin 
(Prc) 
 
 
 
 
 
 
 
 
 
 
 
-11.0 
 
 
 
 
 
 
-14.9 
4,E1269,G1153,G1152,
C1151,V1147,I1170,P1
228,C1194,N1195,E119
2,D1193,L1250, M1172 
 
 
 
 
 
 
C1194,P1228,W1173,F
1148,E1192,A621,N12
48,D1193,N1195,L125
0,M1172 
 
 
 
 
C1194,W1173,L1250,
D1174,N1196,Q123, 
P1228,N1580,G1579, 
C1229,G1150,G1226, 
S1149,E1171,F1148 
C1194:H->SAH:N1 
N1580:HD21->SAH:O3 
V1582:H->SAH:OXT 
SAH:HN2->S1149:O 
SAH:HO->N1171:OE1 
SAH:HO->N1171:OE2 
SAH:HN1->D1143:OD1 
SAH:HN1->D1193:OD1 
SAH:H1->F1148:O 
 
M1172: H->EGCG:O6 
C1194: H->EGCG:O8 
EGCG: H15>D1193:OD1 
EGCG: H17->N1248:O 
EGCG: H17- N1248: OD1 
EGCG:H18>D1193:OD2 
 
C1194:H->Prc:O17 
Q1230:HE11->Prc:O4 
Q1230:HE22->Prc:O13 
Prc:H16->Q1230: OE1 
Prc:H24->E1171:OE1 
Prc:H27->F1149:O 
Prc:H33->G1579:O 
2.2 
2.1 
2.1 
2.2 
2.1 
2.1 
3.6 
1.8 
2.4 
 
2.1 
1.9 
2 
2.1 
2.5 
1.6 
 
2.1 
2.3 
2.5 
1.7 
2.1 
2 
1.9 
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4.3.4 Molecular dynamics simulation of DNMT-inhibitor complexes   
The molecular dynamics simulations were implemented to authenticate the docking 
results and decipher efficacy inhibiting DNMTs activity. In order to maintain proper 
orientation of ligand distance, restraints were applied to inhibitors in the initial few 
picoseconds (ps) and then whole complexes were allowed to move freely. The docked 
conformations were analysed by examining their relative total energy scores, protein 
backbone root mean square deviation (RMSD), total hydrogen bonds, van-der-Waals 
interaction, electrostatic interaction and root mean square fluctuation (RMSF) of active 
site residues. 
Here, the stability of DNMT-inhibitor complex was determined in terms of total 
energy (kinetic Ek+ potential Ep) at the given temperature of 310K and pressure of 1atm. 
We plotted the fluctuation in total energy as a function of constant time gaps. The average 
total energy (kJ/mol) for EGCG and procyanidin B2 was very high at SAH-binding 
pocket of 3PTA, 2QRV, and 3AV5. In Figure 4.6 it is evident that both the inhibitors 
oscillated with a nearly same frequency of -1.718 x 10
6
, -6.868 x 10
5
 and -4.071 x 10
6
 
kJ/mol. 
 The RMSD of each protein relative to binding of respective inhibitors (SAH, 
EGCG, and procyanidin B2) was calculated to monitor the stability of each trajectory. 
Here, we mainly focussed on the active site residues of DNMTs. The stability of protein- 
inhibitor complex was analyzed by aligning heavy atoms of the complex to the crystal 
structures of proteins using the mass-weighted least square fitting method. The RMSD 
plot exhibited the structures which are stable during the course of MD simulations. The 
RMSD plot unveiled an increase in deviation at first 200ps of the production phase. This 
is because the equilibration phase was performed with restraints on complex, while the 
restraints in production phase were released. From Figure 4.7 one can easily watch that 
the inhibitor procyanidin B2 attains equilibrium after 500ps and on average comparatively 
lesser RMSD of 3.0 Å, 1.6 Å, and 2.4 Å is attained on interaction with 3PTA, 2QRV, and 
3AV5 respectively. Thus from this observation it's evident that procyanidin B2 forms 
more stable complex than SAH and EGCG with DNMTs. The stability of an enzyme-
ligand complex is characterized by ligand binding mode inside the active site pocket of 
the enzyme, and the binding force includes strong hydrogen bonds, electrostatic and van 
der Waals interactions. The intermolecular hydrogen bond plots between enzyme and 
inhibitor are shown in Figure 4.8. 
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Figure 4.6 Total energy at each ps on interaction of SAH (red), EGCG (blue) and Procyanidin B2 
(green) with (a) 3PTA, (b) 2QRV, (c) 3AV5 in kJ/mol. Total energy has been identified to be 
elevated for EGCG and procyanidin B2 on interaction with DNMT1 in human and mouse and 
DNMT3A human. 
 
Figure 4.7 RMSD plot with respect to time in ps on binding of SAH (red), EGCG (blue) and 
Procyanidin B2 (green) with (a) 3PTA, (b) 2QRV and (c) 3AV5 in Å. RMSD is calculated for 
heavy atoms with reference to their respective orientation in the crystal structures. Procyanidin B2 
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exhibits the least deviation on interaction with DNMT and forms most stable complex as 
compared to SAH and EGCG. 
 On an average procyanidin B2 forms a higher number of hydrogen bonds than 
SAH and EGCG with the cognate donor/receptor in the vicinity of the binding pocket of 
DNMTs. It forms an average of 6.5 on interaction with 3PTA while 5.2 hydrogen bonds 
are formed when ligated to 2QRV and 3AV5. Further, non-bonding interaction 
constituting Columbic function and Lennard–Jones potential function were employed to 
calculate electrostatic and van-der-Waals interactions, respectively with a cut-off distance 
of 9Å. On the evaluation of both the parameters, it has been identified that van-der-Waals 
interaction take over the electrostatic interaction, thus favoring the interaction of 
inhibitors mainly to procyanidin B2 at the active site pocket. The average van-der-Waals 
energy (ΔEvdw) is identified to -367.743, -296.80 and -330.101 kJ/mol on interaction 
with 3PTA, 2QRV, and 3AV5. Thus from the above findings it can be inferred that 
hydrogen bonds and van der Waals energy dominates in the total binding energy profile 
for stabilizing the protein-inhibitor complex. 
 
Figure 4.8 Observation of intermolecular hydrogen bond in Å between SAH (red), EGCG (blue), 
Procyanidin B2 (green) with active site residues of (a) 3PTA, (b) 2QRV and (c) 3AV5. On an 
average Procyanidin B2 forms a higher number of hydrogen bonds with the respective enzymes. 
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 The residue flexibility of bound DNMT-inhibitor complexes was examined by 
analyzing the RMSF of the Cα atoms of each residue. The RMSF plot for different 
protein complexes has shown the flexible regions of the systems; however plot clearly 
displayed minimum fluctuation around the active site residues [Figure 4.9 a-c]. The 
amino acid residues exhibit an average fluctuation of 0.98, 0.69, and 1.1 Å in case of 
procyanidin B2 while 1.2, 0.8 and 1.13 Å in case of EGCG, on interaction with 3PTA, 
2QRV, and 3AV5, respectively. The average fluctuation of amino acid residues in the 
interaction of SAH with these proteins has been found to be 1.3, 1.0 and 1.5 Å, 
respectively. From the above findings, we can infer that procyanidin B2 forms more 
stable complex because the residues fluctuation is comparatively lesser than others. Thus, 
stability of procyanidin B2-DNMT complexes has been established by total energy, 
RMSD of the protein backbone, non-covalent interactions and RMSF of active site 
residues measurements.  
 
 
Figure 4.9 Root-mean-squared fluctuations (RMSF) of backbone atoms (Å) of (a) 3PTA, (b) 
2QRV and (c) 3AV5 on binding to SAH (red), EGCG (blue) and Procyanidin B2. Active site 
residues for all protein-ligand complexes exhibit the least fluctuation, exhibiting the stability of 
the complexes. 
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4.3.5  Thermodynamic evaluation of DNMT-inhibitor complexes  
Absolute free energies of binding were evaluated using MM-PBSA method in order to 
gain insight into the continuous spectrum of binding energy of hDNMT1, DNMT3A, and 
mDNMT1 with respect to SAH, EGCG and procyanidin B2. In this method the 
interaction and solvation energy is computed for complex, receptor and ligand in order to 
investigate average binding free energy. The detailed binding energy of protein-inhibitor 
complexes have been depicted in Figure 4.10 (a-c). The free energy of binding has been 
evaluated with respect to SAH at active site pocket of DNMTs. It is evident from Figure 
10 that procyanidin B2 has highest binding efficiency for DNMTs (3PTA, 2QRV, and 
3AV5). The binding energies of the 3PTA, 2QRV and 3AV5 with respect to procyanidin 
B2 are -16.64, -15.06 and -17.29 kcal/mol respectively. The binding efficiency of EGCG 
for the respective proteins has also been identified to be greater than SAH. The 
discrepancy in binding energy of protein-inhibitor complexes implicates that there are 
various mode of interactions  From Figure 4.10, it is evident that the highest binding 
energy for procyanidin B2-DNMT complexes are consequence of gaseous phase 
electrostatic and van der Waals interactions. The nonpolar solvation energy (ΔGnp) also 
favors binding affinity in active site pockets of the enzyme. The relatively lower value of 
non-polar solvation energies indicates the closeness and integrity of packing of cavity 
regions. Moreover, the parameters like entropy (−TΔS) and polar solvation energy which 
is unfavorable for binding of inhibitors is identified to comparatively less for procyanidin 
B2 as compared to SAH and EGCG.  Thus, the calculations of the free energy of binding 
of DNMT-inhibitor complexes elucidate that procyanidin B2 may be a novel inhibitor 
against DNMTs. Thereafter, the detailed mechanism of interaction was decomposed into 
inhibitor-residue pairs in order create a spectrum of inhibitor-residue interaction. 
104 
 
 
Figure 4.10 Energy components (kcal/mol) for the binding of SAH (blue), EGCG (brown) and 
procyanidin B2 (green) at binding pocket of (a) 3PTA (b) 2QRV and (c) 3AV5. ΔEele, 
electrostatic energy in the gas phase; ΔEvdw, van der Waals energy; ΔGnp, nonpolar solvation 
energy; ΔGpb, polar solvation energy, TΔS, total entropy contribution; ΔGtotal = ΔEele + ΔEvdw + 
ΔEint + ΔGpb; ΔG = ΔGtotal−TΔS. Error bars in indicates the difference. 
4.3.6 Binding spectrum of residues at active site pocket of DNMTs 
In order to obtain the detailed thermodynamic description of contribution from amino 
acid residue to the free energy of binding, the interaction energies were further 
decomposed to contributions of individual residues through MM-GBSA script in the 
AMBER 12 suite. The method of residue decomposition aids in understanding the 
atomistic detail of the mechanism of residue-inhibitor interactions. The detailed study of 
the contribution of residues to the binding energy for SAH, EGCG, and procyanidin B2 
with respect to 3PTA, 2QRV and 3AV5 has been depicted in Figure 4.11 (a-c). Overall 
the major interaction at the active site of the pocket of 3PTA is the contribution of F1145, 
E1168, M1169, E1189, and C1191. The average binding energy of these residues is 
greater than -1 kcal/mol. Similarly, in case of mouse DNMT1 (3AV5), the residues 
F1148, E1171, M1172, C1194, and C1248 contributes to the elevation of binding energy. 
From the Figures 4.11a and 4.11c, it is evident that procyanidin B2 has higher interaction 
with these residues as compared to SAH and EGCG. Moreover, among all, the cysteine 
residue offers highest binding energy on interaction with procyanidin B2. C1191 and 
C1194 contribute to the binding energy of -5.10 and -4.21 kcal/mol to the interaction of 
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procyanidin B2 with 3PTA and 3AV5 respectively. In case of DNMT3A, the residues 
F636, D637, E660, D684, and W889 imparts to the elevation in the binding of inhibitors 
in the catalytic pocket of the enzyme. The D684 residue has a higher contribution to the 
interaction with procyanidin B2, and the average binding energy is identified to be -4.01 
kcal/mol.  This decomposition of free binding energy (ΔG) per residue is a consequence 
of van der Waals (ΔEvdw) energy, the sum of electrostatic and the polar solvation energy 
and the non-polar solvation (ΔGnp) energy. The change of entropy parameter is not 
included. Further ahead, the in-vitro studies were carried out to affirm the role of 
procyanidin B2 as a potent DNMT inhibitor. 
 
 
Figure 4.11 Decomposition of ΔG on a per-residue basis for the SAH (blue), EGCG (brown) and 
procyanidin B2 (green) at the binding pocket of (a) 3PTA (b) 2QRV and (c) 3AV5.   
4.3.7  Effect of EGCG and procyanidin B2 on DNMTs activity 
The inhibitors, EGCG and procyanidin B2, were used to construct a dose-response curve 
in terms of IC50 value at varying concentration of drugs. The nuclear extracts from 
MDA-MB-231 cells were incubated with increasing concentrations of EGCG and 
procyanidin B2 (1, 2.5, 5, 10 and 15 µM). We observed dose-dependent growth inhibition 
of DNMTs on incubation with various concentration EGCG and procyanidin B2. The IC50 
was determined under identical assay conditions. The IC50 of EGCG is identified to be 
9.36±1.02 µM while, that of procyanidin B2 is 6.88±0.64 µM [Figure 4.12]. Thus, from 
above analysis it can be concluded that procyanidin B2 is effective successfully inhibiting 
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DNMTs at a lower dose of drug concentration as compared to EGCG. The difference in 
IC50 between EGCG and procyanidin B2 was identified to be significant (n=3, mean ± 
S.D.). The p-value was found to be significant at 0.05 (p=0.023). 
 
 
Figure 4.12 Depiction of the log of dose-response plot in terms of percentage decrease in DNMT 
activity against increasing log of the concentration of procyanidin B2 and EGCG.  The IC50 of 
procyanidin B2 and EGCG are found to be 6.88±0.647 µM and 9.36±1.02, respectively. This 
clearly demonstrates that procyanidin B2 is more active in inhibiting DNMTs. Data are expressed 
as mean ± S.D., n=3, p < 0.05. 
4.3.8 Upregulation of DNMT target and DNMTs genes by EGCG and 
 Procyanidin B2 
To further validate the DNMT inhibitory activity, we examined the effect of 
procyanidinB2 and EGCG on the expression of DNMT target genes (E-cadherin, Maspin, 
and BRCA1) in MDA-MB-231 cells. Our result indicates that the procyanidin B2 
treatment more efficiently upregulates the expression of E-cadherin, Maspin, and BRCA1 
as compared to EGCG. This apparently reveals that procyanidin B2 inhibition of DNMTs 
causes upregulation of these genes [Figure 4.13a]. Moreover, the expression of the 
DNMT genes; DNMT1, DNMT3A, and DNMT3B were also enhanced by treatment with 
these polyphenols (Figure 4.13a). The mRNA levels of these genes were identified to be 
significant (n=3, mean ± S.D.) between EGCG and procyanidin B2 treated groups. The p-
value was significant at 0.05.  
 
107 
 
 
Figure 4.13 Real-time RT-PCR analyses: (a) E-cadherin, Maspin, BRCA1, and (b) DNMT1, 
DNMT3A, DNMT3B gene expression after treatment with EGCG and procyanidin B2. The 
mRNA level of both DNMT target and DNMT genes are upregulated more in case of procyanidin 
B2 than EGCG.  Data are expressed as mean ± S.D., n=3, p < 0.05. 
4.3.9  EGCG and procyanidin B2 are non-toxic for normal cells 
The cytotoxicity analysis examined the toxic nature of EGCG and ProcyanidineB2 
towards normal keratinocytes (HaCaT) and triple negative breast cancer cells (MDA-
MB231) in terms of percentage of cell viability. From the figure 4.14, it is evident that a 
significant decrease in cell viability was seen with an increasing concentration of EGCG 
and procyanidin B2 in MDA-MB231 cells. However, these inhibitors did not elicit any 
lethal effect on normal cells. The sub-lethal concentration (LC50) of EGCG and 
procyanidin B2 was determined to be 200 and 150µM, respectively, in MDA-MB-231 
cells. In contrast, at LC50 of EGCG and procyanidin B2, the HaCaT cells were found to 
induce no such cytotoxic phenomena. SAH, being an endogenous biochemical product of 
the methylation reaction has a minimal cytotoxic effect on MDA-MB 231 cells. The 
difference in LC50 between EGCG and procyanidin B2 was identified to be significant 
(n=3, mean ± S.D.). The p-value was found to be significant at 0.05 (p=0.01). 
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Figure 4.14 Effect of (a) SAH, (b) EGCG and (c) Procyanidin B2 on cell viability and growth. 
MDA-MB231 and HaCaT cells were treated with indicated concentrations of (a) SAH, (b) EGCG 
and (c) Procyanidin B2 in µM for 24 h. Cell viability was determined by MTT assay. Data are 
represented as the mean±SD of three different observations. EGCG and Procyanidin B2 exhibits 
LC50 of 200 µM and 150 µM, respectively, while SAH has been identified having the almost 
negligible cell growth inhibitory effect of MDA MB 231. However, ECGC and Procyanidin B2 
show no cytotoxic effect on HaCaT cells. Data are expressed as mean ± S.D., n=3, p < 0.05. 
4.4 Discussion 
Several studies have documented the apoptosis-inducing effect of polyphenols like 
catechins and procyanidins indicating their anti-cancer potential and chemotherapeutic 
application [476, 477]. However, the mystery behind the molecular targets of cell killing 
effect of these polyphenolic groups or their effect on epigenetic molecular marks, like 
DNA methylation and manipulators, like DNMTs was not resolved prior to this work. We 
are acquainted with the fact that DNMTs are responsible for hypermethylation of various 
genes, imposing a genotoxic effect including tumor suppressor gene during tumor 
development and cancer progression [478]. Thus, we sought to explore the factors 
dictating the selectivity of inhibitors binding to DNMT1 and DNMT3A/a. Docking, 
molecular dynamics simulation, and free energy analyzes were carried out in order to 
unravel the potential of non-nucleoside inhibitors known till date. We found that the 
binding affinity of EGCG was highest among all, successfully inhibiting DNMTs in both 
human and mouse. The docking and simulation analysis illustrate that EGCG-DNMT 
complex is energetically favored, and the finding is apparently consistent with an in-vitro 
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analysis. Further ahead, EGCG analogs, mainly polyphenolic groups were screened in 
quest of identification of novel inhibitors. In this second category, procyanidin B2-3, 3-di-
O-gallate moiety presented itself valid, and the most promising inhibitor is having a 
strong correlation with the active site residues of DNMTs. The selection of procyanidin 
B2 is of higher negative binding energy and greater selectivity towards DNMTs. Our 
results demonstrate that binding geometry, driven by hydrogen bond and van-der-Waals 
energy dominates in the enhancement of total binding energy. Electrostatic interaction 
occupancy is comparatively feeble along the interface of protein-inhibitor complex. 
Molecular dynamics simulation of protein-ligand complexes fortified the docking 
analysis. The stability of the inhibitor inside the binding pocket has been substantiated by 
total energy, RMSD and RMSF data. Furthermore, the analysis of free energy of binding 
by MM-PBSA for SAH, EGCG, and procyanidin B2 with DNMTs established that 
procyanidin B2 has the highest efficacy for the catalytic pocket. Moreover, the detailed 
thermodynamic description of residue contribution to the free energy of binding affirms 
the intimate interaction with active site residues.  
 In addition to the results rationalizing in-silico observed selectivity, in vitro 
experimental analyzes also revealed the potential of procyanidin B2 as an effective 
inhibitor for diminishing DNMTs activity. The effect of procyanidin B2 in inhibiting 
DNMTs was evaluated following direct as well as an indirect approach. The indirect 
approach, procyanidin B2 was directly used as an inhibitor against DNMTs in the nuclear 
extract of the cells and DNMT activity was noted to be declined with respect to control. 
Moreover, procyanidin B2 elicits a greater reduction of DNMT activity at a concentration 
of 6.88±0.647 µM as compared to EGCG. The indirect approach deals with reactivation 
of DNMT target genes on the application of procyanidin B2. Previously, it has been 
documented that E-cadherin [479], Maspin [480] and BRCA1 [481] are epigenetically 
inactivated in breast cancer due to aberrant cytosine methylation in their promoter 
regions. Evidence also report that inhibition of DNA methylation by 5-Aza-2-
deoxycytidine (AZA), could restore the expression the E-cadherin and Maspin (gene) in 
this cell line [482]. Moreover, in prostate cancer cells it has been reported that BRCA1 
can be reactivated by treatment with AZA. Based on this fact, we sought to examine 
whether EGCG and procyanidin B2 could be able to restore the expression of these 
DNMT target genes as that of AZA. Corroborating our in silico analysis and in vitro 
DNMT activity inhibition measurement, we found that both EGCG and procyanidin B2 
lead to reactivation of E-cadherin, Maspin and BRCA1 gene at the transcription level. Of 
note, procyanidin B2 could more efficiently upregulate the DNMT target gene expression 
relative to EGCG. This might be due to more affinity of procyanidin B2 for DNMTs, thus 
inhibiting DNMTs to a greater extent than EGCG. However, this enzymatic inhibition 
impels the elevated expression of DNMTs. Consequently, among the non-nucleoside 
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inhibitors procyanidin B2 can be considered to be more effective in reducing the DNMT 
activity and hence can be used to decrease the methylation level.  
 One of the foremost concerns for clinical application of any anticancer drug 
relies on its clinical toxicity. So, after searching a potential DNMT inhibitor as 
procyanidin B2, our next attempt was to examine its cytotoxic nature towards normal 
cells in contrast to breast cancer cells. Both EGCG and procyanidinB2 were found to 
elicit extensive cytotoxic effect in highly invasive triple-negative MDA-MB-231 breast 
cancer cells. While EGCG reduced 50% cell viability at 200 µM concentration, 
procyanidin B2 was effective at a comparatively lower concentration of 150 µM for 24 h. 
Conversely, the same LC50 of EGCG and procyanidin B2 treatment exhibited no 
cytotoxic activity to normal keratinocytes (HaCaT).   
 In contrast to conventional chemotherapeutic drugs, procyanidin B2 is non-
toxic in nature. Additionally, it is natural and a dietary component with substantial 
anticancer effects on breast cancer cells. In conclusion, we have unraveled the role of 
procyanidin B2 as an epigenetic modulator which precisely targets DNMTs and reverses 
the silencing of tumor suppressor genes. The outcome of this investigation holds 
procyanidin B2 as a promising inhibitor against cancer targeting the enzyme DNMTs. 
Further, by executing experiments in animal models and clinical settings, it may be 
recommended for incorporation in the list of compounds in chemoprevention of breast 
cancer.
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Chapter 5 
Conclusions 
The occurrence of inter/intra-tumor heterogeneity and clonal evolution in breast cancer 
requires accurate elucidation of geographical and chronological variations in patient 
samples. Despite the success of GWAS in identifying loci associated with tumor 
initiation, there is still a substantial proportion of the causality to be explored. 
Interestingly, EWAS have the potential to capture disease-associated epigenetic 
variations, primarily differential methylation. In this thesis, we have integrated genotype-
epitype dataset to identify haplotype-specific DNA methylation in breast cancer, 
subsequently excavated locus specific diagnostic and prognostic marker. The biomarker 
identification was conjointly associated with sequential therapeutic strategies for 
identifying novel drugs, to achieve low dose, the customized and high-impact treatment 
we seek.  
 Considering the conjoint study based on genotype-epitype interactions, 
chapter 2, details about the comparative and comprehensive study of risk alleles in breast 
cancer and matched normal tissues. The identification of risk allele supports the potential 
implementation of meQTLs as a risk factor in cancer, wherein DNA methylation 
functions as a mediator for the respective risk allele. Likewise, risk associated with a 
polymorphism display germline variant in the cancer tissue and the matched normal 
counterparts. Mutated genes are inherited in breast cancer and are a well-defined example 
of breast cancer susceptibility. The increased predisposition of germline mutations in 
breast cancer tissues is more susceptible for inheritance. The conjoint study of genotype-
epitype association has enlightened a novel approach to elucidate the genome-wide 
distribution of differentially methylated loci. Based on the integrated study, three 
significant CpG-SNP pairs have been identified that clearly demonstrates variability in 
the distribution of polymorphic allele is linked to differential methylation pattern which in 
turn is associated with the gene expression. The fluctuation in major and minor allele 
distribution associated with SNPs rs9891975, rs4421026 and rs17235834 regulates the 
methylation level of CpG sites SNP cg02058408, cg05388880 and cg25198340, 
respectively in tumor and normal samples. These CpG sites lead to differential gene 
expression of ST5, CMAH and FYN genes, respectively in breast cancer patients in 
comparison to normal population. Thus, findings based upon novel mechanism 
constituting genetic variation, DNA methylation and gene expression may serve as novel 
biomarkers for early diagnosis.   
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 Owing to the identification of diagnostic marker, the next step was to detect 
the prognostic potential of the biomarkers in determining the overall risk associated with 
the survival. In chapter 3, the detailed analysis based upon meQTLs is integrated with 
clinicopathological factors to detect the risk related to overall survival of breast cancer 
patients. Unlike GWAS, environmental factors directly confound on EWAS, affecting 
both epigenotype and phenotype and exaggerating the risk associated with the progression 
of breast cancer. Indeed, when DNA methylation is integrated with SNP array data, it 
gives a more appropriate clue in understanding principle coordinates of both genetic and 
epigenetic states in dissecting the risk associated with overall survival. In our study, we 
have investigated the genome-wide distribution of meQTLs and their cumulative effect on 
risk stratification of breast cancer patients. The Cox proportional hazard model based on 
multiple covariates provides an empirical estimate of overall risk. The comprehensive 
assessment based on meQTLs depicts that variable genotype associated with particular 
SNP results in differential methylation distribution. These differentially methylated CpG 
sites have been identified in delaminate the breast cancer patients into the high and low-
risk group. In particular, the quantification in methylation level was observed at CpG 
sites, cg05370838, cg00956490 and cg11340537. These differentially methylated regions 
were the consequence of discrepancy in allelic distribution associated rs2230576, 
rs940453, and rs2640785 SNPs, respectively. Furthermore the differentially methylated 
CpGs were strongly associated with the expression of ADAM8, CREB5, and EXPH5 gene, 
respectively. These differentially methylated CpGs were identified to have a promising 
association with tumor progression and overall survival of breast cancer patients. Besides, 
the exclusive effects of SNPs were also interrogated to assess the risk of cancer 
progression. In summary, conjoint analysis based upon differential methylated CpG sites 
and SNPs have resulted in the identification of novel susceptible loci that holds 
prognostic relevance in breast cancer. Further ahead, the functional studies on the 
candidate genes are required to explicate their potential relevance to the pathophysiology 
and treatment efficacy of breast cancer.  
 Tumors displaying global differential methylation hold the benefit of the 
restoration of these global patterns. Considering their dynamic and reversible nature, the 
modifying enzymes need to be targeted by small molecules or inhibitors, adding to the 
drug arsenal to improve their specificity and reduce their toxicity. In chapter 4, we 
elucidate combinatorial approach of in-silico and in-vitro analysis in the development of 
personalized medicine therapies. DNMT, the key epigenetic manipulator, was targeted for 
pharmacological inhibition and cancer reprogramming. DNMT inhibitors known till date 
were excavated and examined in-lieu of identification of novel and potent inhibitor. 
EGCG, being efficient of all had its own limitations. However, on analysis of 32 EGCG 
analogues, procyanidin B2-3, 3'-di-O-gallate (procyanidin B2) emerged as potent 
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inhibitor attenuating DNMT activity at IC50 of 6.88±0.647 µM and successfully restoring 
the expression of E-cadherin, Maspin and BRCA1 tumor suppressor genes. Moreover, the 
toxic property of procyanidin B2 has the ability to discern the triple negative breast 
cancer (MDA-MB231) cells to normal cells. In summary, the identified epigenetic 
modulator will have considerable clinical effect in remodeling the malignant cells, and 
will hold a prime position in breast cancer therapy.  
 Finally we would like to conclude by saying that the conjoint analysis based 
upon genetic and epigenetic marker will enlighten the researcher and clinicians to design 
new strategy in resolving the complexity associated with diagnosis, prognosis and 
therapeutic implications of breast cancer treatment.  
Scope for further research 
Integrative studies of genotype-epitype interactions have provided tantalizing insight into 
the global distribution of meQTLs; however, the significant details need to be evaluated. 
For instance, there are many questions that need to be answered regarding the genomic 
architecture of meQTLs (e.g. exact number of loci having differentially methylated 
regions, how far are the DMRs extended across the functional loci or have positional 
biasness). The distal or the trans effect of these meQTLs on gene expression needs to be 
evaluated. Moreover, these DMRs are closely linked to another epigenetic process such as 
histone modifications and non-coding RNA, needs to be interrogated conjointly. 
Genetically and stochastically driven DMRs holds functional significance and requires 
systematic investigation across tissues and cell types. Moreover, beside the significant 
influence of SNP, other genetic variants such as insertion, deletion, duplication and copy 
number variations need to be incorporated to resolve the complexity associated with 
disease etiology. 
 High-throughput technology is characterized by next generation sequencing aids 
in genome-wide methylome-profiling. Nowadays, it is feasible to map allelic 
polymorphism associated with DNA methylation at a single base-pair resolution as it 
provides detailed information about the extent and location of meQTLs. However, 
technical limitation related to bisulphite sequencing to determine epialleles and epi-
haplotypes in the genome is still constrained. It has been identified that sequencing based 
upon single molecule resolution is required for high epi-allelic and quantitative 
information. The establishment of the repository and electronic access to samples and 
associated data will enable to dissect the specific sequence polymorphism, specifically in 
cancer patients. Finally, appropriate designing of EWAS database needs to developed and 
conducted, to enable the tools for analysis and interpretation of EWAS data. To achieve 
clear insight into the exact mechanism of initiation and propagation of tumors condition, 
cooperation between scientist, clinicians and resource provider is required to pioneer the 
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conjoint study of GWAS and EWAS. The recognition of the epigenome-wide study of 
differential methylation has opened new avenues for drug discovery and therapeutics. 
Therapeutic implications could be combined with conventional therapies to develop 
personalized treatment and render unresponsive tumors susceptible to treatment at 
reduced dose. Such advancement may restrict the side effects of treatment and will 
improve the compliance associated with dose regimens and overall quality of life 
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